---
title: "Cretostimogene grenadenorepvec (CG0070) in BCG-unresponsive high-risk non-muscle-invasive bladder cancer: Product information and disease description"
description: "Formulary evidence on Cretostimogene grenadenorepvec (CG0070) in BCG-unresponsive high-risk non-muscle-invasive bladder cancer: Product information and disease description. Covers Product description and Place of product in therapy. 273 evidence topics quoted from 114 sources."
canonical: "https://www.evicenter.com/drugs/cretostimogene-grenadenorepvec--bcg-unresponsive-high-risk-non-muscle-invasive-bladder-cancer/product-information-and-disease-description"
published: "2026-11-18T10:43:03-05:00"
modified: "2026-11-18T10:43:03-05:00"
---

# Cretostimogene grenadenorepvec (CG0070) in BCG-unresponsive high-risk non-muscle-invasive bladder cancer: Product information and disease description

<a id="product-information-and-disease-description"></a>

## 2 Product Information and Disease Description

<a id="heading-2.1"></a>

### 2.1 Product Description

<a id="heading-2.1.1"></a>

#### 2.1.1 Phase of Product Development

<a id="topic-2.1.1-1"></a>

##### Regulatory status: Under review; rolling BLA initiated November 2025, completion anticipated by March 2027

> “Based on FDA feedback, initial BLA submission in BCG-unresponsive NMIBC to be broadened to include both CIS and high-grade papillary-only disease; completion anticipated in March 2027”
> “To incorporate the additional data, we now expect to complete the submission before the end of March 2027.”

Source: [CG Oncology PIVOT-006 topline press release (2026)](https://ir.cgoncology.com/news-releases/news-release-details/pivot-006-phase-3-registrational-trial-demonstrates)

> “Initiated rolling Biologics License Application (BLA) submission to U.S. FDA for cretostimogene monotherapy in high-risk (HR) BCG-unresponsive non-muscle invasive bladder cancer (NMIBC)”

Source: [CG Oncology third-quarter 2025 results press release (2025)](https://ir.cgoncology.com/news-releases/news-release-details/cg-oncology-reports-third-quarter-2025-financial-results-and)

> “This trial served as the basis for our Biologics License Application (BLA) submission for our initial indication to the U.S. Food and Drug Administration (FDA), which we initiated in the fourth quarter of 2025”

Source: [CG Oncology Form 10-K (2026)](https://www.sec.gov/Archives/edgar/data/1991792/000119312526079498/ck0001991792-20251231.htm)

> “CG社は、2025年11月に米国で本剤のローリング申請を開始しました。”

Source: [Kissei Pharmaceutical Lancet Oncology publication press release (2026)](https://www.kissei.co.jp/news/uploaded/ac0d28038b8ced3e28ffd15df1f1d731.pdf)

<a id="topic-2.1.1-2"></a>

##### Launch

No evidence found.

<a id="topic-2.1.1-3"></a>

##### BLA completion expected in the fourth quarter of 2026 for CIS-containing disease, May 2026, superseded in November 2026

> “Following alignment discussions with FDA, BLA completion for HR BCG-unresponsive NMIBC is expected fourth quarter 2026”
> “We have successfully completed non-clinical and clinical modules for our first BLA submission. The remaining CMC module is progressing as planned, and we are on track to finalize our submission in the fourth quarter 2026.”

Source: [CG Oncology first-quarter 2026 results press release (2026)](https://ir.cgoncology.com/news-releases/news-release-details/cg-oncology-reports-first-quarter-2026-financial-results-and)

> “This trial served as the basis for our Biologics License Application (BLA) submission for our initial indication to the U.S. Food and Drug Administration (FDA), which we expect to complete in the fourth quarter of 2026.”

Source: [CG Oncology Form 10-Q (2026)](https://www.sec.gov/Archives/edgar/data/1991792/000199179226000012/ck0001991792-20260930.htm)

> “BLA completion for BCG-unresponsive NMIBC anticipated Q4 2026”
> “Completion of BLA submission in initial indication of BCG-unresponsive NMIBC with CIS with or without papillary disease Q4 2026”

Source: [CG Oncology third-quarter 2026 results press release (2026)](https://ir.cgoncology.com/news-releases/news-release-details/cg-oncology-reports-third-quarter-2026-financial-results-and)

<a id="topic-2.1.1-4"></a>

##### BLA completion expected in 2026, November 2025, superseded in May 2026

> “The Company initiated its rolling BLA submission for cretostimogene with complete submission expected in 2026.”

Source: [CG Oncology third-quarter 2025 results press release (2025)](https://ir.cgoncology.com/news-releases/news-release-details/cg-oncology-reports-third-quarter-2025-financial-results-and)

> “This trial served as the basis for our Biologics License Application (BLA) submission for our initial indication to the U.S. Food and Drug Administration (FDA), which we initiated in the fourth quarter of 2025 and expect to complete in 2026.”

Source: [CG Oncology Form 10-K (2026)](https://www.sec.gov/Archives/edgar/data/1991792/000119312526079498/ck0001991792-20251231.htm)

<a id="topic-2.1.1-5"></a>

##### Investigational status

> “Cretostimogene is an investigational candidate, and its safety and efficacy have not been established by the FDA or any other health authority.”

Source: [CG Oncology PIVOT-006 topline press release (2026)](https://ir.cgoncology.com/news-releases/news-release-details/pivot-006-phase-3-registrational-trial-demonstrates)

> “We do not have any products approved for sale and have not generated any revenue from product sales.”

Source: [CG Oncology Form 10-Q (2026)](https://www.sec.gov/Archives/edgar/data/1991792/000199179226000012/ck0001991792-20260930.htm)

<a id="topic-2.1.1-6"></a>

##### Development phase: phase 3 trial supporting the BLA

> “We are evaluating the safety and efficacy of cretostimogene monotherapy in BOND-003 Cohort C, our ongoing Phase 3 clinical trial in Bacillus Calmette-Guérin (BCG)-unresponsive NMIBC with carcinoma in situ (CIS), with or without papillary disease.”
> “Additionally, in April 2024, we initiated BOND-003 Cohort P, an exploratory study evaluating cretostimogene monotherapy in BCG-unresponsive papillary only NMIBC.”

Source: [CG Oncology Form 10-Q (2026)](https://www.sec.gov/Archives/edgar/data/1991792/000199179226000012/ck0001991792-20260930.htm)

> “BOND-003 Cohort P (BCG-unresponsive papillary only NMIBC) 12-month data December 2026”

Source: [CG Oncology third-quarter 2026 results press release (2026)](https://ir.cgoncology.com/news-releases/news-release-details/cg-oncology-reports-third-quarter-2026-financial-results-and)

<a id="topic-2.1.1-7"></a>

##### FDA Fast Track and Breakthrough Therapy designations

> “today announced that the U.S. Food and Drug Administration (FDA) has granted both Fast Track Designation and Breakthrough Therapy Designation for cretostimogene grenadenorepvec in high-risk Bacillus Calmette-Guérin (BCG)-unresponsive Non-Muscle Invasive Bladder Cancer (NMIBC) with carcinoma in situ with or without Ta or T1 (papillary) tumors.”

Source: [CG Oncology Fast Track and Breakthrough Therapy press release (2023)](https://ir.cgoncology.com/news-releases/news-release-details/cg-oncology-receives-both-fda-fast-track-and-breakthrough)

> “Cretostimogene has received both Fast Track and Breakthrough Therapy designations from the FDA for the treatment of BCG-unresponsive NMIBC with CIS with or without papillary disease.”

Source: [CG Oncology Form 10-Q (2026)](https://www.sec.gov/Archives/edgar/data/1991792/000199179226000012/ck0001991792-20260930.htm)

<a id="topic-2.1.1-8"></a>

##### Breakthrough Therapy designation for the combination with pembrolizumab

> “We have obtained Breakthrough Therapy designation from the FDA for cretostimogene for the treatment of BCG-unresponsive, high-risk NMIBC with carcinoma in-situ with or without Ta or T1 tumors to improve CR and for cretostimogene in combination with pembrolizumab for the treatment of NMIBC unresponsive to BCG”

Source: [CG Oncology Form 10-K (2026)](https://www.sec.gov/Archives/edgar/data/1991792/000119312526079498/ck0001991792-20251231.htm)

<a id="topic-2.1.1-9"></a>

##### Manufacturing readiness for the BLA

> “All BLA-enabling manufacturing activities supporting both regulatory filings have been completed.”

Source: [CG Oncology PIVOT-006 topline press release (2026)](https://ir.cgoncology.com/news-releases/news-release-details/pivot-006-phase-3-registrational-trial-demonstrates)

<a id="topic-2.1.1-10"></a>

##### Second BLA planned for intermediate-risk and high-grade Ta disease

> “PIVOT-006 data will support a second BLA submission in intermediate-risk and high-grade Ta NMIBC anticipated in Q2 2027”

Source: [CG Oncology PIVOT-006 topline press release (2026)](https://ir.cgoncology.com/news-releases/news-release-details/pivot-006-phase-3-registrational-trial-demonstrates)

<a id="topic-2.1.1-11"></a>

##### Japan: filing planned after the U.S. submission is complete

> “当社は、米国での申請完了後、”
> “必要な資料を整え、国内で申請する予定です。”

Source: [Kissei Pharmaceutical Lancet Oncology publication press release (2026)](https://www.kissei.co.jp/news/uploaded/ac0d28038b8ced3e28ffd15df1f1d731.pdf)

<a id="topic-2.1.1-12"></a>

##### China: phase 2 study sponsored by the licensee

> “A Single-arm, Open-label, Multicenter Phase II Clinical Study to Evaluate the Efficacy and Safety of Cretostimogene Grenadenorepvec in Patients With BCG-unresponsive High-risk Non-Muscle Invasive Bladder Cancer”

Source: [ClinicalTrials.gov NCT07283835](https://clinicaltrials.gov/study/NCT07283835)

Additional sources: [MHLW orphan regenerative medical product designation (2025)](https://www.pref.nara.jp/secure/307355/06314.pdf)

<a id="heading-2.1.2"></a>

#### 2.1.2 Product Information

<a id="heading-2.1.2.1"></a>

##### 2.1.2.1 Generic, Brand Name and Therapeutic Class of Product

<a id="topic-2.1.2.1-1"></a>

###### Manufacturer: CG Oncology

> “We are a late-stage clinical biopharmaceutical company focused on developing and commercializing cretostimogene grenadenorepvec (cretostimogene), an investigational oncolytic immunotherapy with a dual mechanism of action designed both to eliminate cancer cells directly by selective replication and indirectly by activating an anti-tumor immune response, as a potential backbone therapy in a broad range of patients afflicted with bladder cancer.”
> “Other than Biovire, which manufactures and conducts release testing of our cretostimogene drug product, we do not own or operate any manufacturing facilities.”

Source: [CG Oncology Form 10-Q (2026)](https://www.sec.gov/Archives/edgar/data/1991792/000199179226000012/ck0001991792-20260930.htm)

<a id="topic-2.1.2.1-2"></a>

###### International nonproprietary name

> “cretostimogene grenadenorepvec”
> “recombinant conditionally replication-competent”
> “oncolytic adenovirus type 5 (Ad5)”

Source: [WHO recommended INN List 89 (2023)](https://cdn.who.int/media/docs/default-source/international-nonproprietary-names-(inn)/rl89.pdf)

<a id="topic-2.1.2.1-3"></a>

###### Development code and registry intervention names

| Registry field | Quoted record |
| --- | --- |
| Intervention name | “Cretostimogene Grenadenorepvec” |
| Other name | “CG0070” |
| Intervention description | “Engineered Oncolytic Adenovirus” |
| Co-administered agent | “n-dodecyl-B-D-maltoside” |
| Co-administered agent description | “Transduction-enhancing agent” |

Source: [ClinicalTrials.gov NCT06443944](https://clinicaltrials.gov/study/NCT06443944)

<a id="topic-2.1.2.1-4"></a>

###### Therapeutic class as described in the pivotal publication and by the company

> “Cretostimogene grenadenorepvec (hereafter, cretostimogene) is an oncolytic immunotherapy with dual mechanisms of action”

Source: [Tyson et al. (2026)](https://pubmed.ncbi.nlm.nih.gov/42508433/)

> “Cretostimogene is an investigational, intravesically delivered oncolytic immunotherapy that has been studied in a clinical development program, which includes more than 700 patients with Non-Muscle Invasive Bladder Cancer (NMIBC).”

Source: [CG Oncology PIVOT-006 topline press release (2026)](https://ir.cgoncology.com/news-releases/news-release-details/pivot-006-phase-3-registrational-trial-demonstrates)

<a id="topic-2.1.2.1-5"></a>

###### Brand name

No evidence found.

<a id="heading-2.1.2.2"></a>

##### 2.1.2.2 Dosage Forms and Strengths

<a id="topic-2.1.2.2-1"></a>

###### Viral particle dose per instillation: two reported volumes

> “intravesical cretostimogene (1 × 1012 viral particles per 0·8 mL per week)”

Source: [Tyson et al. (2026)](https://pubmed.ncbi.nlm.nih.gov/42508433/)

> “The initial induction course of therapy is six weekly doses of cretostimogene containing 1x1012 VPs per milliliter.”

Source: [CG Oncology Form 10-K (2026)](https://www.sec.gov/Archives/edgar/data/1991792/000119312526079498/ck0001991792-20251231.htm)

<a id="topic-2.1.2.2-2"></a>

###### Frozen supply of cretostimogene and DDM

> “Ensure DDM (excipient) and creto are completely thawed before use”

Source: [Donahue et al. (2025)](https://cgoncology.com/wp-content/uploads/2025/11/SUNA_Cretostimogene-Nursing-Logisitics_Final-1.pdf)

> “We also rely on a third party to store and transport cretostimogene at temperatures within a certain range, which is known as”
> “storage and transportation. Any failure by this third party to store or transport cretostimogene at the appropriate temperature could impair the quality of cretostimogene”

Source: [CG Oncology Form 10-K (2026)](https://www.sec.gov/Archives/edgar/data/1991792/000119312526079498/ck0001991792-20251231.htm)

<a id="topic-2.1.2.2-3"></a>

###### Vial presentation and closed-system transfer

> “enables direct vial>syringe>bladder delivery”

Source: [CG Oncology investor presentation (2026)](https://ir.cgoncology.com/static-files/16380a7a-42d9-40fc-a2a5-03e0b5235ed3)

<a id="topic-2.1.2.2-4"></a>

###### Transduction-enhancing agent given before cretostimogene: 5% DDM

> “Cretostimogene will be administered intravesically following a series of bladder washes with 5% DDM and normal saline.”

Source: [ClinicalTrials.gov NCT04452591](https://clinicaltrials.gov/study/NCT04452591)

<a id="topic-2.1.2.2-5"></a>

###### Commercial vial strength, fill volume, and storage conditions

No evidence found.

<a id="heading-2.1.2.3"></a>

##### 2.1.2.3 Average Sales Price and Wholesale Acquisition Cost

Not applicable.

<a id="heading-2.1.2.4"></a>

##### 2.1.2.4 American Hospital Formulary Service (AHFS), or Other Drug Classification

<a id="topic-2.1.2.4-1"></a>

###### WHO INN class

> “virus-based gene therapy (antineoplastic)”

Source: [WHO proposed INN List 127 (2022)](https://cdn.who.int/media/docs/default-source/international-nonproprietary-names-(inn)/pl127.pdf)

<a id="topic-2.1.2.4-2"></a>

###### Registry intervention class in the pivotal trial

> “Engineered Oncolytic Adenovirus”

Source: [ClinicalTrials.gov NCT04452591](https://clinicaltrials.gov/study/NCT04452591)

<a id="topic-2.1.2.4-3"></a>

###### AHFS classification

No evidence found.

<a id="heading-2.1.2.5"></a>

##### 2.1.2.5 Indication

<a id="topic-2.1.2.5-1"></a>

###### Indication sought in the initial BLA after FDA feedback

> “Based on FDA feedback, we plan to broaden our initial BLA submission in BCG-unresponsive NMIBC, which was focused on patients with CIS with or without papillary tumors, to also include patients with high-grade papillary-only disease.”
> “Together, these populations represent the full range of BCG-unresponsive patients, and our goal is a label that reflects that.”

Source: [CG Oncology PIVOT-006 topline press release (2026)](https://ir.cgoncology.com/news-releases/news-release-details/pivot-006-phase-3-registrational-trial-demonstrates)

<a id="topic-2.1.2.5-2"></a>

###### Initial BLA indication limited to CIS-containing disease, November 2025, superseded in November 2026

> “the initiation of our BLA submission of cretostimogene for our lead indication of HR BCG-unresponsive NMIBC with CIS with or without Ta/T1 disease”

Source: [CG Oncology third-quarter 2025 results press release (2025)](https://ir.cgoncology.com/news-releases/news-release-details/cg-oncology-reports-third-quarter-2025-financial-results-and)

<a id="topic-2.1.2.5-3"></a>

###### Populations of the Breakthrough Therapy designations

> “Cretostimogene has received both Fast Track and Breakthrough Therapy designations from the FDA for the treatment of high-risk BCG-unresponsive NMIBC with CIS with or without Ta or T1 papillary tumors.”

Source: [CG Oncology Form 10-K (2026)](https://www.sec.gov/Archives/edgar/data/1991792/000119312526079498/ck0001991792-20251231.htm)

<a id="topic-2.1.2.5-4"></a>

###### Definition of BCG failure in the pivotal trial

> “Patients will have had to fail prior BCG therapy which is defined as having persistent or recurrent disease within 12 months (Cohort C) or 6 months (Cohort P) following the completion of adequate BCG therapy for HGUC”

Source: [ClinicalTrials.gov NCT04452591](https://clinicaltrials.gov/study/NCT04452591)

<a id="heading-2.1.2.6"></a>

##### 2.1.2.6 Pharmacology

<a id="heading-2.1.2.6.1"></a>

###### 2.1.2.6.1 Mechanism of Action

<a id="topic-2.1.2.6.1-1"></a>

###### Oncolytic immunotherapy with dual mechanisms of action

> “Cretostimogene grenadenorepvec (hereafter, cretostimogene) is an oncolytic immunotherapy with dual mechanisms of action”
> “it replicates in and lyses cancer cells with retinoblastoma-E2F pathway alterations and amplifies the immune response”

Source: [Tyson et al. (2026)](https://pubmed.ncbi.nlm.nih.gov/42508433/)

<a id="topic-2.1.2.6.1-2"></a>

###### Serotype-5 adenovirus designed for selective replication in cells with retinoblastoma pathway alterations

> “Cretostimogene grenadenorepvec is a serotype-5 oncolytic adenovirus designed to selectively replicate in cancer cells with retinoblastoma pathway alterations”

Source: [Li et al. (2024a)](https://www.nature.com/articles/s41591-024-03025-3)

<a id="topic-2.1.2.6.1-3"></a>

###### Cell entry through coxsackievirus and adenovirus receptors

> “Cretostimogene is an investigational oncolytic immunotherapy that has been designed to selectively replicate in retinoblastoma (Rb)-E2F gene pathway-altered cells present in the majority of UCs and trigger an anti-tumor immune response.”
> “Cretostimogene enters the tumor by binding to Coxsackievirus and Adenovirus Receptors (CAR) present in specialized intracellular junctions and tight junctions of polarized epithelial cells.”

Source: [CG Oncology Form 10-K (2026)](https://www.sec.gov/Archives/edgar/data/1991792/000119312526079498/ck0001991792-20251231.htm)

<a id="topic-2.1.2.6.1-4"></a>

###### Tumor selectivity and the GM-CSF transgene as described by the manufacturer

> “There are two modifications made to cretostimogene for tumor selectivity and potency.”
> “The first modification is the insertion of an E2F-1 promoter in cretostimogene which acts as a safety mechanism to selectively replicate and lyse Rb-E2F altered tumor cells rather than healthy cells which have intact Rb pathways.”
> “The second modification is the insertion of the gene for the cytokine granulocyte-macrophage colony stimulation factor (GM-CSF).”
> “GM-CSF is widely recognized as a potent stimulator of longer-term anti-tumor activity, and we believe its addition to the viral construct may both prime the immune system and induce tumor-specific immunity.”
> “Replication and lysis of Rb-E2F altered tumor cells by cretostimogene may trigger an immunogenic cell death that stimulates an anti-tumor immune response.”

Source: [CG Oncology Form 10-K (2026)](https://www.sec.gov/Archives/edgar/data/1991792/000119312526079498/ck0001991792-20251231.htm)

<a id="topic-2.1.2.6.1-5"></a>

###### Functions attributed to the elements of the construct

| Element | Stated function |
| --- | --- |
| E2F | “Leads to selective viral replication in tumor cells, but not normal cells” |
| E1A / E3 | “Viral gene retains wild-type adenovirus lytic ability” |
| GM-CSF | “GM-CSF activates and matures antigen-presenting cells” |

Source: [Li et al. (2023)](https://cgoncology.com/wp-content/uploads/2025/11/AUA-2023-CORE-001-Presentation.pdf)

<a id="topic-2.1.2.6.1-6"></a>

###### Direct lysis combined with immune-mediated cell death

> “The CG0070 mechanism of action includes direct cell lysis in conjunction with immune mediated cell death which is enhanced in the presence of GM-CSF.”
> “In CG0070, the human E2F-1 promoter drives expression of the essential viral genes and restricts viral replication to retinoblastoma (Rb) gene pathway defective tumor cells, selectively killing these cells with minimal damage to normal tissues.”

Source: [Li et al. (2021)](https://cgoncology.com/wp-content/uploads/2025/11/2021_sitc_core-001_poster-1.pdf)

<a id="heading-2.1.2.6.2"></a>

###### 2.1.2.6.2 Pharmacodynamics

<a id="topic-2.1.2.6.2-1"></a>

###### Viral replication and GM-CSF expression in urine during induction, BOND-003 Cohort C

> “Cretostimogene replication and GM-CSF expression are linked”
> “Levels peak immediately after instillation”
> “Sustained local dosing”
> “Drop to BLOD within a week”
> “Effective payload delivery”

Source: [Bivalacqua (2025)](https://cgoncology.com/wp-content/uploads/2025/11/Updated_Clinical_and_Translational_Results_from_BOND-003_Cohort_C.pdf)

<a id="topic-2.1.2.6.2-2"></a>

###### Replication and transgene expression during maintenance dosing, BOND-003 Cohort C

> “Similar pharmacokinetic peak and trough pattern, that mirrors replication kinetics”
> “Titers present through maintenance”
> “Supports oncolytic immunotherapy MOA”

Source: [Bivalacqua (2025)](https://cgoncology.com/wp-content/uploads/2025/11/Updated_Clinical_and_Translational_Results_from_BOND-003_Cohort_C.pdf)

<a id="topic-2.1.2.6.2-3"></a>

###### Adenovirus serotype 5 antibodies and antibody response over time, BOND-003 Cohort C

> “Pre-existing Ad5 antibodies”
> “Stable antibody and anti-tumor response over time”
> “Antibody response correlates with clinical outcomes”
> “Intravesical delivery reduces ADA neutralization, preserving therapeutic efficacy”

Source: [Bivalacqua (2025)](https://cgoncology.com/wp-content/uploads/2025/11/Updated_Clinical_and_Translational_Results_from_BOND-003_Cohort_C.pdf)

<a id="topic-2.1.2.6.2-4"></a>

###### Urinary cytokine profiling as a measure of the local immune response, BOND-003 Cohort C

> “Urinary cytokines (a surrogate of local immune milieu) were profiled post-treatment to characterize the immune-mediated MOA”
> “Serial urine collected pre-dose (−2 hr) and post-dose (+2 hr) across treatment phases from BOND-003 Cohort C biomarker consented participants (n=60)”
> “Tested with Olink Target 48 Cytokine panel”

Source: [Dinney et al. (2026a)](https://cgoncology.com/wp-content/uploads/2026/09/NSAUA_2026_BOND-003_CohortC_and_Cytokines_Poster.pdf)

<a id="topic-2.1.2.6.2-5"></a>

###### Magnitude and direction of the urinary cytokine changes during induction

> “GM-CSF (CSF2) shows the largest induction (~300-fold peak at W1 D4).”
> “Coordinated induction of Th1, Th17, M1, DC-priming, and TNF-superfamily analytes is evident at post-dose timepoints.”
> “Th2 and immunoregulatory cytokines remained largely below the limit of detection and were not induced.”
> “Post-dose induction with return toward baseline before subsequent dosing indicates repeated acute, self-limiting immune activation.”

Source: [Dinney et al. (2026a)](https://cgoncology.com/wp-content/uploads/2026/09/NSAUA_2026_BOND-003_CohortC_and_Cytokines_Poster.pdf)

<a id="topic-2.1.2.6.2-6"></a>

###### GM-CSF transgene expression and replication in the phase 1 study

> “High levels of granulocyte-monocyte colony-stimulating factor were detected in urine after administration in all patients.”
> “Virus replication was suggested based on an increase in urine CG0070 genomes between days 2 and 5 in 58.3% of tested patients (7 of 12).”
> “Granulocyte-monocyte colony-stimulating factor transgene expression and CG0070 replication were also suggested.”

Source: [Burke et al. (2012)](https://pubmed.ncbi.nlm.nih.gov/23088985/)

<a id="topic-2.1.2.6.2-7"></a>

###### Retinoblastoma phosphorylation status and response in the phase 1 study

> “A subset of 18 patients was assessed for retinoblastoma phosphorylation status.”
> “In an exploratory, retrospective assessment patients with borderline or high retinoblastoma phosphorylation who received the multidose schedules had an 81.8% complete response rate (9 of 11).”

Source: [Burke et al. (2012)](https://pubmed.ncbi.nlm.nih.gov/23088985/)

<a id="topic-2.1.2.6.2-8"></a>

###### Urinary tumor DNA minimal residual disease in BOND-003 and CORE-001

> “UroAmp is Convergent Genomics’s genetic platform which quantifies mutations and DNA alterations from urine tumor DNA (utDNA).”
> “Quantifies minimal residual disease (MRD) by the genomic disease burden (GDB) which is a percentile ranking of the variant allele frequency (VAF) from a sample relative to its percentile ranking within the established training set.”
> “VAF and MRD prognostic for recurrence.”
> “UroAmp stratified patients treated with Cretostimogene as MRD positive or negative and was associated with durable 12 mo. RFS.”

Source: [Mokkapati (2025)](https://cgoncology.com/wp-content/uploads/2025/11/A0793_Mokkapati_EAU-2025_BOND-003-and-CORE-001-Convergent_Final-V7-1.pdf)

<a id="topic-2.1.2.6.2-9"></a>

###### Pretreatment PD-L1 expression and response in muscle-invasive disease, CORE-002

> “Importantly, investigators found that treatment response was not correlated with pre-treatment PD-L1 levels, and that the majority of PD-L1 negative patients had CRs.”
> “Additionally, the formation and maturation of tertiary lymphoid structure (TLS) in responders were observed, suggesting the mechanistic onset of anti-tumor humoral memory.”

Source: [CG Oncology Form 10-K (2026)](https://www.sec.gov/Archives/edgar/data/1991792/000119312526079498/ck0001991792-20251231.htm)

<a id="heading-2.1.2.6.3"></a>

###### 2.1.2.6.3 Pharmacokinetics

<a id="topic-2.1.2.6.3-1"></a>

###### Local persistence in the bladder and absence of systemic exposure, BOND-003 Cohort C

> “Translational data shared at the EAU Congress showed the level of cretostimogene peaked immediately after instillation, which was sustained locally for 4-5 days.”
> “There was no systemic exposure, with cretostimogene levels remaining below the limit of detection, providing evidence that post cretostimogene treatment close contact precautions are not needed.”
> “This information supports the current dosing schedule.”

Source: [CG Oncology Form 10-K (2026)](https://www.sec.gov/Archives/edgar/data/1991792/000119312526079498/ck0001991792-20251231.htm)

<a id="topic-2.1.2.6.3-2"></a>

###### Serum measurements with repeat dosing, BOND-003 Cohort C

> “No systemic exposure”
> “Creto levels remain below the limit of detection”
> “Concentrated within the bladder, even with repeat dosing”

Source: [Bivalacqua (2025)](https://cgoncology.com/wp-content/uploads/2025/11/Updated_Clinical_and_Translational_Results_from_BOND-003_Cohort_C.pdf)

<a id="topic-2.1.2.6.3-3"></a>

###### Urine measurement of the drug and the transgene in the phase 1 study

> “Urine and plasma CG0070, and granulocyte-monocyte colony-stimulating factor were measured in all patients.”

Source: [Burke et al. (2012)](https://pubmed.ncbi.nlm.nih.gov/23088985/)

<a id="topic-2.1.2.6.3-4"></a>

###### Urinary replication and clearance in high-risk BCG-naive disease, CORE-008 Cohort A

> “Transient increase in cretostimogene levels during induction, declining below the limit of detection after induction and maintenance dosing, with no evidence of latent or extended replication”
> “Effective viral clearance supports relaxed close-contact precautions”
> “GM-CSF levels increased robustly after first induction dose; declined to near-baseline levels within a week, indicating successful transgene expression”
> “Maintenance GM-CSF remain near baseline, consistent with transient expression and pre-dose sampling”

Source: [Dinney et al. (2026b)](https://cgoncology.com/wp-content/uploads/2026/09/NSAUA_2026_CORE-008_CohortA_and_PK_PD_Poster.pdf)

<a id="heading-2.1.2.7"></a>

##### 2.1.2.7 Contraindications/Warnings/Precautions/Adverse Effects

<a id="heading-2.1.2.7.1"></a>

###### 2.1.2.7.1 Warnings and Precautions

Not applicable.

<a id="heading-2.1.2.8"></a>

##### 2.1.2.8 Special Populations

<a id="topic-2.1.2.8-1"></a>

###### Performance status and cystectomy eligibility in the pivotal trial population

> “Have Eastern Cooperative Oncology Group (ECOG) performance status of 0 to 2.”
> “Ineligible to receive radical cystectomy (medically unfit) or refusal of radical cystectomy according to Investigator assessment.”

Source: [ClinicalTrials.gov NCT04452591](https://clinicaltrials.gov/study/NCT04452591)

<a id="topic-2.1.2.8-2"></a>

###### Older participants in BOND-003 Cohort C

> “median age was 74·0 years (IQR 68·5-79·5)”

Source: [Tyson et al. (2026)](https://pubmed.ncbi.nlm.nih.gov/42508433/)

<a id="topic-2.1.2.8-3"></a>

###### Precautions for household contacts and sexual activity after each instillation

> “For 7 days after every treatment, patients should follow these precautions:”
> “Minimize/avoid direct contact with urine”
> “Highly effective birth control and barrier methods must be used during sexual activity”
> “Close contact (kissing, hugging) is fine if symptom-free”
> “Avoid contact with others up to 2 weeks if febrile illness, respiratory symptoms, or diarrhea are present”

Source: [Cohen (2026)](https://cgoncology.com/wp-content/uploads/2026/10/SUNA_2026_Cretostimogene_Optimized_Administration_Podium.pdf)

<a id="topic-2.1.2.8-4"></a>

###### Biosafety handling in the clinic

> “Follow universal biosafety protocols- cretostimogene is BSL-2 like BCG”
> “Use appropriate protective equipment (e.g., gloves, gown, eye protection) during preparation and administration”

Source: [Donahue et al. (2025)](https://cgoncology.com/wp-content/uploads/2025/11/SUNA_Cretostimogene-Nursing-Logisitics_Final-1.pdf)

<a id="topic-2.1.2.8-5"></a>

###### Use in pregnancy and lactation, in children, and in renal or hepatic impairment

No evidence found.

<a id="heading-2.1.2.9"></a>

##### 2.1.2.9 Drug/Drug, Drug/disease Interactions

<a id="heading-2.1.2.9.1"></a>

###### 2.1.2.9.1 Effects of Other Drugs on Cretostimogene grenadenorepvec

<a id="topic-2.1.2.9.1-1"></a>

###### Transduction-enhancing excipient given before each instillation

> “DDM is an excipient used to attenuate the GAG lining of the transitional epithelium and enhance transduction efficiency of adenovirus by urothelial cells.”

Source: [CG Oncology Form 10-K (2026)](https://www.sec.gov/Archives/edgar/data/1991792/000119312526079498/ck0001991792-20251231.htm)

<a id="topic-2.1.2.9.1-2"></a>

###### Combination with systemic pembrolizumab in CORE-001

> “In this phase 2 study, we assessed the potential synergistic efficacy between intravesical cretostimogene and systemic pembrolizumab in patients with BCG-unresponsive non-muscle-invasive bladder cancer with carcinoma in situ (CIS).”
> “There was no evidence of overlapping or synergistic toxicities.”

Source: [Li et al. (2024a)](https://www.nature.com/articles/s41591-024-03025-3)

<a id="topic-2.1.2.9.1-3"></a>

###### Concomitant anticancer therapy excluded in the pivotal trial

> “Has received systemic anti-cancer therapy, including investigational agents, within 4 weeks of Day 1.”
> “Has had prior systemic treatment (with the exception of checkpoint inhibitor therapy), radiation therapy, or surgery for bladder cancer other than TURBT or bladder biopsies.”

Source: [ClinicalTrials.gov NCT04452591](https://clinicaltrials.gov/study/NCT04452591)

<a id="topic-2.1.2.9.1-4"></a>

###### Supportive medication before or after instillation

> “No Pretreatment or ancillary medications are required per protocol”

Source: [Donahue et al. (2025)](https://cgoncology.com/wp-content/uploads/2025/11/SUNA_Cretostimogene-Nursing-Logisitics_Final-1.pdf)

<a id="heading-2.1.2.9.2"></a>

###### 2.1.2.9.2 Effects of Cretostimogene grenadenorepvec on Other Drugs

No evidence found.

<a id="heading-2.1.2.10"></a>

##### 2.1.2.10 Dosing and Administration

<a id="heading-2.1.2.10.1"></a>

###### 2.1.2.10.1 Dosage

<a id="topic-2.1.2.10.1-1"></a>

###### BOND-003 induction, second induction, and maintenance schedule

> “Patients received intravesical cretostimogene (1 × 1012 viral particles per 0·8 mL per week) as 6-week induction followed by maintenance; re-induction was permitted for persistent disease at 3 months.”

Source: [Tyson et al. (2026)](https://pubmed.ncbi.nlm.nih.gov/42508433/)

> “Patients who achieve a CR at month three receive maintenance treatments, involving three weekly cretostimogene doses administered at the same concentration every three months for the first 12 months and every six months for the next 24 months.”
> “Patients who do not achieve a CR after the first induction course may receive a second induction course of six weekly cretostimogene treatments at month 3, rather than the maintenance course involving three weekly treatments.”

Source: [CG Oncology Form 10-K (2026)](https://www.sec.gov/Archives/edgar/data/1991792/000119312526079498/ck0001991792-20251231.htm)

<a id="topic-2.1.2.10.1-2"></a>

###### Treatment duration in BOND-003 Cohort C and its extension

> “Cohort C(All Countries):Beginning at Week 25, patients will receive weekly x 3 treatments every 12 weeks through week 51 then every 6 months and then a last treatment at Weeks 73, 74, and 75 until the tumor returns or study treatment is completed at Week 97.”
> “Cohort C Extension( Japan and the US) At Week 25, patients will receive weekly x 3 treatments every 12 weeks through week 51 then every 6 months starting at Weeks 73, 74, and 75 through Weeks 157, 158, and 159 until the tumor returns or study treatment is completed at Week 159.”

Source: [ClinicalTrials.gov NCT04452591](https://clinicaltrials.gov/study/NCT04452591)

<a id="topic-2.1.2.10.1-3"></a>

###### Expanded access program schedule

> “Participants will receive an induction course of 6 weekly treatments, and, if there is no disease recurrence at Week 13, participants will receive a cycle of 3 weekly treatments up to Week 15.”
> “After Month 12, participants will receive a cycle of 3 weekly treatments every 6 months through the last treatment cycle at Month 24, or until discontinuation from the study treatment.”

Source: [ClinicalTrials.gov NCT06443944](https://clinicaltrials.gov/study/NCT06443944)

<a id="topic-2.1.2.10.1-4"></a>

###### Dose modification

No evidence found.

<a id="heading-2.1.2.10.2"></a>

###### 2.1.2.10.2 Administration

<a id="topic-2.1.2.10.2-1"></a>

###### Intravesical catheter instillation after DDM pretreatment, without anesthesia

> “Prior to the administration of cretostimogene, patients undergo a saline wash and are then pretreated with n-Dodecyl-ß-D-maltoside (DDM) through IVE delivery.”
> “Following DDM wash/dwell and GAG layer attenuation, cretostimogene is IVE-delivered via a catheter. We have now streamlined this process and eliminated the saline and DDM wash steps. This administration process does not require operating room time nor placement of the patient under anesthesia.”

Source: [CG Oncology Form 10-K (2026)](https://www.sec.gov/Archives/edgar/data/1991792/000119312526079498/ck0001991792-20251231.htm)

<a id="topic-2.1.2.10.2-2"></a>

###### Optimized two-step instillation, dwell times, and staff

> “~15 minutes”
> “~45 to 60 minutes”
> “Medical Assistant, Nurse, Nurse Practitioner, Physician Assistant, or Urologist”
> “Administered via soft catheter by medical assistant, a urologist or MD does not have to be involved in process”
> “optimized instillation protocol”

Source: [CG Oncology investor presentation (2026)](https://ir.cgoncology.com/static-files/16380a7a-42d9-40fc-a2a5-03e0b5235ed3)

<a id="topic-2.1.2.10.2-3"></a>

###### Preparation, biosafety handling, and premedication

> “No Pretreatment or ancillary medications are required per protocol”
> “Follow universal biosafety protocols- cretostimogene is BSL-2 like BCG”
> “Use appropriate protective equipment (e.g., gloves, gown, eye protection) during preparation and administration”
> “Administered with foley (indwelling with balloon)”
> “Close contact with loved ones is acceptable if patient is free from cold- or flu-like symptoms”

Source: [Donahue et al. (2025)](https://cgoncology.com/wp-content/uploads/2025/11/SUNA_Cretostimogene-Nursing-Logisitics_Final-1.pdf)

<a id="heading-2.1.2.11"></a>

##### 2.1.2.11 Access and Distribution

<a id="topic-2.1.2.11-1"></a>

###### Expanded access program for BCG-unresponsive NMIBC

> “today announced that it has initiated an Expanded Access Program (EAP) for cretostimogene grenadenorepvec in the U.S. for patients with Non-Muscle Invasive Bladder Cancer (NMIBC) who are unresponsive to Bacillus Calmette-Guerin (BCG) and meet certain program eligibility criteria.”

Source: [CG Oncology expanded access program press release (2024)](https://ir.cgoncology.com/news-releases/news-release-details/cg-oncology-initiates-expanded-access-program-cretostimogene)

> “This is an open-label, expanded access trial designed to provide access to cretostimogene in patients with NMIBC (specifically CIS with or without HG Ta/T1) unresponsive to BCG.”
> “Ineligible to receive radical cystectomy (medically unfit) or refusal of radical cystectomy according to Investigator assessment.”

Source: [ClinicalTrials.gov NCT06443944](https://clinicaltrials.gov/study/NCT06443944)

> “Additionally, we have initiated an Expanded Access Program for cretostimogene in North America for patients who are unresponsive to BCG and meet”

Source: [CG Oncology PIVOT-006 topline press release (2026)](https://ir.cgoncology.com/news-releases/news-release-details/pivot-006-phase-3-registrational-trial-demonstrates)

<a id="topic-2.1.2.11-2"></a>

###### Manufacturing, storage, and distribution through third parties

> “We rely, and expect to continue to rely, on Biovire and third parties for the manufacture of cretostimogene for clinical testing, as well as for commercial manufacture if we obtain marketing approval. In addition, we rely on third parties to package, label, store, and distribute cretostimogene, and we intend to rely on third parties for our commercial products if marketing approval is obtained.”

Source: [CG Oncology Form 10-Q (2026)](https://www.sec.gov/Archives/edgar/data/1991792/000199179226000012/ck0001991792-20260930.htm)

<a id="topic-2.1.2.11-3"></a>

###### Commercial preparation

> “As we prepare for potential FDA approval of cretostimogene for high-risk NMIBC patients unresponsive to BCG, we believe we have established a seasoned executive leadership team and commercial leadership organization with a proven track record for successfully bringing urology and bladder cancer products to market. Additionally, we continue to build our commercial capabilities and commercial infrastructure to ensure market development and commercial launch readiness.”

Source: [CG Oncology Form 10-K (2026)](https://www.sec.gov/Archives/edgar/data/1991792/000119312526079498/ck0001991792-20251231.htm)

> “Commercial prep activities ongoing”
> “MSLs/HSDs, site / payor engagement”

Source: [CG Oncology investor presentation (2026)](https://ir.cgoncology.com/static-files/16380a7a-42d9-40fc-a2a5-03e0b5235ed3)

> “In October, the Company appointed Isabel Kalofonos as Chief Commercial Officer.”

Source: [CG Oncology third-quarter 2026 results press release (2026)](https://ir.cgoncology.com/news-releases/news-release-details/cg-oncology-reports-third-quarter-2026-financial-results-and)

<a id="topic-2.1.2.11-4"></a>

###### Development and commercialization rights outside the United States

> “In March 2019, we entered into a development and license agreement (the Lepu License Agreement) with Lepu Biotech Co., Ltd. (Lepu), under which we granted an exclusive license to Lepu to develop, manufacture and commercialize cretostimogene and/or DDM to treat and/or prevent cancer in the Lepu Territory.”
> “In March 2020, and as amended September 2022, we entered into a license and collaboration agreement (the Kissei License Agreement) with Kissei Pharmaceutical Co., Ltd. (Kissei), under which we granted to Kissei an exclusive license to certain intellectual property rights in Bangladesh, Bhutan, Brunei, Cambodia, India, Indonesia, Japan, South Korea, Laos, Malaysia, Myanmar, Nepal, Pakistan, Palau, Philippines, Singapore, Sri Lanka, Taiwan, Thailand and Vietnam (the Kissei Territory), for Kissei to develop and commercialize, but not manufacture, cretostimogene in combination with DDM”

Source: [CG Oncology Form 10-Q (2026)](https://www.sec.gov/Archives/edgar/data/1991792/000199179226000012/ck0001991792-20260930.htm)

<a id="heading-2.1.2.12"></a>

##### 2.1.2.12 Co-prescribed/Concomitant Therapies

<a id="topic-2.1.2.12-1"></a>

###### Intravesical n-dodecyl-β-D-maltoside pretreatment before each instillation

> “Prior to the administration of cretostimogene, patients undergo a saline wash and are then pretreated with n-Dodecyl-ß-D-maltoside (DDM) through IVE delivery.”
> “DDM is an excipient used to attenuate the GAG lining of the transitional epithelium and enhance transduction efficiency of adenovirus by urothelial cells.”
> “Following DDM wash/dwell and GAG layer attenuation, cretostimogene is IVE-delivered via a catheter.”
> “We have now streamlined this process and eliminated the saline and DDM wash steps.”

Source: [CG Oncology Form 10-K (2026)](https://www.sec.gov/Archives/edgar/data/1991792/000119312526079498/ck0001991792-20251231.htm)

<a id="topic-2.1.2.12-2"></a>

###### Transduction-enhancing agent listed as a study intervention in BOND-003

> “Transduction-enhancing agent.”
> “Cretostimogene will be administered intravesically following a series of bladder washes with 5% DDM and normal saline.”

Source: [ClinicalTrials.gov NCT04452591](https://clinicaltrials.gov/study/NCT04452591)

<a id="topic-2.1.2.12-3"></a>

###### Original five-step and optimized two-step instillation processes

> “Original instillation included 5-step instillation with series of bladder saline washes followed by DDM and cretostimogene instillations.”
> “Optimized instillation streamlined the process to 2-steps inclusive of DDM followed by cretostimogene instillations.”
> “All studies beyond BOND-003 Cohort C use optimized instillation protocol”

Source: [CG Oncology investor presentation (2026)](https://ir.cgoncology.com/static-files/16380a7a-42d9-40fc-a2a5-03e0b5235ed3)

<a id="topic-2.1.2.12-4"></a>

###### Dwell times of the pretreatment agent and cretostimogene

| Instillation step | Duration |
| --- | --- |
| DDM | “~15 minutes” |
| Cretostimogene | “~45 to 60 minutes” |

Source: [CG Oncology investor presentation (2026)](https://ir.cgoncology.com/static-files/16380a7a-42d9-40fc-a2a5-03e0b5235ed3)

<a id="topic-2.1.2.12-5"></a>

###### Premedication and ancillary medications in BOND-003

> “No Pretreatment or ancillary medications are required per protocol”
> “Ensure DDM (excipient) and creto are completely thawed before use”

Source: [Donahue et al. (2025)](https://cgoncology.com/wp-content/uploads/2025/11/SUNA_Cretostimogene-Nursing-Logisitics_Final-1.pdf)

<a id="topic-2.1.2.12-6"></a>

###### Combination with pembrolizumab and gemcitabine under study

> “Cretostimogene, in combination with the CPI pembrolizumab produced an 82.9% CR at any time in our completed Phase 2 CORE-001 clinical trial, with no Grade 3 or higher TRAEs attributable to cretostimogene, demonstrating the potential benefits of using cretostimogene in a combination therapy.”
> “Cretostimogene’s combination potential is being further assessed in a Phase 2 CORE-008 Cohort CX clinical trial evaluating cretostimogene in combination with gemcitabine in high-risk BCG-exposed and BCG-unresponsive NMIBC patients.”
> “for cretostimogene in combination with pembrolizumab for the treatment of NMIBC unresponsive to BCG”

Source: [CG Oncology Form 10-K (2026)](https://www.sec.gov/Archives/edgar/data/1991792/000119312526079498/ck0001991792-20251231.htm)

<a id="topic-2.1.2.12-7"></a>

###### Prior and concurrent anticancer therapy excluded from BOND-003

> “Has received systemic anti-cancer therapy, including investigational agents, within 4 weeks of Day 1.”
> “Has had prior systemic treatment (with the exception of checkpoint inhibitor therapy), radiation therapy, or surgery for bladder cancer other than TURBT or bladder biopsies.”

Source: [ClinicalTrials.gov NCT04452591](https://clinicaltrials.gov/study/NCT04452591)

<a id="heading-2.1.2.13"></a>

##### 2.1.2.13 Effect of Cretostimogene grenadenorepvec on Quality Measures

<a id="topic-2.1.2.13-1"></a>

###### Quality measure for intravesical BCG in newly diagnosed non-muscle-invasive bladder cancer

| Field | Quoted record |
| --- | --- |
| Title | “Intravesical Bacillus-Calmette-Guerin for Non-Muscle Invasive Bladder Cancer” |
| MIPS Quality ID | “481” |
| Measure steward | “Oregon Urology” |
| Description | “Percentage of patients initially diagnosed with non-muscle invasive bladder cancer and who received intravesical Bacillus-Calmette-Guerin (BCG) within 6 months of bladder cancer staging” |
| Measure type | “Process” |
| Denominator exclusion | “Patients who undergo cystectomy, chemotherapy or radiation within 6 months of Bladder Cancer Staging” |
| Denominator exception | “Unavailability of BCG within 6 months after Bladder Cancer Staging” |

Source: [eCQI CMS646v6 Intravesical BCG for NMIBC (2026)](https://ecqi.healthit.gov/ecqm/ec/2026/cms0646v6)

<a id="topic-2.1.2.13-2"></a>

###### Product-specific effect on quality measures

No evidence found.

<a id="heading-2.1.2.14"></a>

##### 2.1.2.14 Product comparison

<a id="topic-2.1.2.14-1"></a>

###### Company cross-trial comparison with approved agents in CIS-containing BCG-unresponsive disease

| Feature | Cretostimogene | TAR-200 | N-803 + BCG | Nadofaragene | Pembrolizumab |
| --- | --- | --- | --- | --- | --- |
| Mechanism | “Oncolytic Immunotherapy” | “Gemcitabine via In-Dwelling Device” | “IL-15 Superagonist + BCG combo” | “Gene Therapy Secreting IFN” | “Checkpoint Inhibitor” |
| Route of administration | “Intravesical” | “Transurethral Procedure” | “Intravesical” | “Intravesical” | “Intravenous” |
| CR at any time | “75.5% (83/110)” | “82.4% (70/83)” | “62.3% (48/77)” | “51.0% (50/98)” | “40.6% (39/96)” |
| CR at 12 months | “46.4% (51/110)” | “K-M: 45.9% (39/83)” | “36.4% (28/77)” | “24.3% (25/103)” | “18.8% (18/96)” |
| CR at 24 months | “41.8% (46/110)” | “Not Reported” | “24.7% (19/77)” | “19.4% (20/103)” | “9.4% (9/96)” |
| Grade 3 or higher treatment-related adverse events | “0%” | “13%” | “Not reported; 16% SAE” | “4%” | “13%” |
| Treatment-related discontinuation | “0%” | “3.5%” | “7%” | “3%” | “11%” |

Source: [CG Oncology investor presentation (2026)](https://ir.cgoncology.com/static-files/16380a7a-42d9-40fc-a2a5-03e0b5235ed3)

<a id="topic-2.1.2.14-2"></a>

###### Company caveat on cross-trial comparisons

> “These data are not based on head-to-head or comparator studies. Differences exist between study designs and subject characteristics, and caution should be exercised when comparing data across studies.”

Source: [CG Oncology investor presentation (2026)](https://ir.cgoncology.com/static-files/16380a7a-42d9-40fc-a2a5-03e0b5235ed3)

<a id="topic-2.1.2.14-3"></a>

###### Guideline table of bladder-sparing options for carcinoma in situ with or without papillary disease

| Compound | Study design | n | Follow-up (months) | CR at 3 months (%) | CR at 6 months (%) | CR at 12 months (%) | Adverse events |
| --- | --- | --- | --- | --- | --- | --- | --- |
| Nadofaragene firadenovec | “Phase III Cis Cohort” | “103” | “19.7” | “53.4” | “40.8” | “24.3” | “G3 4%” |
| Cretostimogene grenadenorepvec (CG0070) | “Phase II” | “45” | Not reported | Not reported | “58 CIS”; “50 CIS+P” | Not reported | “G1-2 82.5% G ≥ 3 4.5%” |
| Nogapendekin alfa inbakicept plus BCG | “Phase II/III QUILT 3032 CA” | “82” | “23.9” | “55.0” | “56.0” | “45.0” | “G1-2 86% G ≥ 3 23%” |
| TAR-200 | “Phase II b SunRISe-1 C2” | “81” | “20.2” | “78.8” | “58.8” | “45.9” | “Any G 83.5% G ≥ 3 12.9%” |
| Pembrolizumab | “Phase II Cohort A KEYNOTE-057” | “96” | “36.4” | “41.0” | Not reported | “18.7” | “G1-2 53.0% G ≥ 3 13%” |

Source: [European Association of Urology NMIBC Guidelines (2026)](https://d56bochluxqnz.cloudfront.net/documents/full-guideline/EAU-Guidelines-on-Non-muscle-invasive-Bladder-Cancer-2026.pdf)

<a id="topic-2.1.2.14-4"></a>

###### Re-induction at 3 months as a difference in trial design

> “Recently, a CR rate of 75% was reported for the investigational agent cretostimogene grenadenorepvec in patients with BCG-unresponsive CIS, although this CR rate included patients with persistent disease who underwent repeat induction treatment, which was not permitted in SunRISe-1.”
> “Acknowledging the limitations of indirect cross-study comparisons, TAR-200 was associated with a higher CR rate than both conventional gemcitabine instillation and FDA-approved novel agents (pembrolizumab, nadofaragene firadenovec, and NAI + BCG), ranging from 41% to 62%.”

Source: [Daneshmand et al. (2025)](https://pmc.ncbi.nlm.nih.gov/articles/PMC12622271/)

<a id="topic-2.1.2.14-5"></a>

###### Nadofaragene firadenovec: indication, dosing, and efficacy in prescribing information

| Feature | Quoted label text |
| --- | --- |
| Indication | “(BCG)-unresponsive non-Muscle Invasive Bladder Cancer (NMIBC) with carcinoma in situ (CIS) with or without papillary tumors” |
| Dosing interval | “instilled once every three (3) months into the bladder via a urinary catheter” |
| Premedication | “Premedication with an anticholinergic is recommended before each instillation of ADSTILADRIN.” |
| Complete response rate | “51%” |
| Median duration of response, months (range) | “9.7 (3, 52+)” |
| Responders with duration of 12 months or longer | “46%” |

Source: [Adstiladrin prescribing information (2026)](https://www.fda.gov/media/164029/download)

<a id="topic-2.1.2.14-6"></a>

###### Nogapendekin alfa inbakicept: indication, dosing, and efficacy in prescribing information

| Feature | Quoted label text |
| --- | --- |
| Indication | “ANKTIVA, in combination with Bacillus Calmette-Guérin (BCG) is indicated for the treatment of adult patients with BCG-unresponsive nonmuscle invasive bladder cancer (NMIBC).” |
| Induction | “400 mcg administered intravesically with BCG once a week for 6 weeks.” |
| Maintenance | “400 mcg administered intravesically with BCG once a week for 3 weeks at months 4, 7, 10, 13 and 19.” |
| Bladder retention | “ANKTIVA in combination with BCG admixture should be retained in the bladder for 2 hours and then voided.” |
| Complete response rate (95% CI) | “62% (51, 73)” |
| Responders with duration of 12 months or longer | “58% (28)” |
| Responders with duration of 24 months or longer | “40% (19)” |

Source: [Anktiva prescribing information (2026)](https://www.accessdata.fda.gov/drugsatfda_docs/label/2026/761336s002lbl.pdf)

<a id="topic-2.1.2.14-7"></a>

###### Gemcitabine intravesical system: indication, dosing, and efficacy in prescribing information

| Feature | Quoted label text |
| --- | --- |
| Indication | “INLEXZO is indicated for the treatment of adult patients with Bacillus Calmette-Guérin (BCG)-unresponsive, non-muscle invasive bladder cancer (NMIBC) with carcinoma in situ (CIS), with or without papillary tumors.” |
| Dosing | “Insert INLEXZO (225 mg of gemcitabine) into the bladder once every 3 weeks up to 6 months (8 doses), followed by once every 12 weeks (6 doses).” |
| Insertion | “Insert into the bladder using the co-packaged urinary catheter and stylet only.” |
| Complete response rate (95% CI) | “82% (72, 90)” |
| Responders with duration of 12 months or longer | “51% (35)” |

Source: [Inlexzo prescribing information (2025)](https://www.accessdata.fda.gov/drugsatfda_docs/label/2025/219683s000lbl.pdf)

<a id="topic-2.1.2.14-8"></a>

###### Pembrolizumab: indication, dosing, and efficacy in prescribing information

| Feature | Quoted label text |
| --- | --- |
| Indication | “KEYTRUDA, as a single agent, is indicated for the treatment of patients with Bacillus Calmette-Guerin (BCG)-unresponsive, high-risk, non-muscle invasive bladder cancer (NMIBC) with carcinoma in situ (CIS) with or without papillary tumors who are ineligible for or have elected not to undergo cystectomy.” |
| Dosing | “200 mg every 3 weeks”; “400 mg every 6 weeks” |
| Duration of therapy | “Until persistent or recurrent high-risk NMIBC, disease progression, unacceptable toxicity, or up to 24 months” |
| Administration | “Administer KEYTRUDA as a 30-minute intravenous infusion.” |
| Complete response rate (95% CI) | “41% (31, 51)” |
| Median duration of response, months (range) | “16.2 (0.0+, 30.4+)” |
| Responders with duration of 12 months or longer | “46% (18)” |

Source: [Merck KEYTRUDA prescribing information (2026)](https://www.accessdata.fda.gov/drugsatfda_docs/label/2026/125514s191lblCorrected.pdf)

Additional sources: [Colbert et al. (2025)](https://pmc.ncbi.nlm.nih.gov/articles/PMC11961324/); [Heiss et al. (2025)](https://pmc.ncbi.nlm.nih.gov/articles/PMC12363661/)

<a id="heading-2.2"></a>

### 2.2 Place of Product in Therapy

<a id="heading-2.2.1"></a>

#### 2.2.1 Disease Description

<a id="heading-2.2.1.1"></a>

##### 2.2.1.1 Definition and Etiology

<a id="topic-2.2.1.1-1"></a>

###### Definition of non-muscle-invasive bladder cancer

> “Urothelial tumours confined to the mucosa and invading the lamina propria are classified as stage Ta and T1, respectively, according to the Tumour, Node, Metastasis (TNM) classification system”
> “Intra-epithelial, high-grade (HG) tumours confined to the mucosa are classified as CIS (Tis).”
> “All of these tumours can be treated by transurethral resection of the bladder tumour (TURBT), eventually in combination with intravesical instillations, and are therefore grouped under the heading of NMIBC for therapeutic purposes.”

Source: [European Association of Urology NMIBC Guidelines (2026)](https://d56bochluxqnz.cloudfront.net/documents/full-guideline/EAU-Guidelines-on-Non-muscle-invasive-Bladder-Cancer-2026.pdf)

<a id="topic-2.2.1.1-2"></a>

###### Definition and clinical classification of carcinoma in situ

> “Carcinoma in situ is an intra-epithelial, HG, non-invasive UC.”
> “Primary: isolated CIS with no previous or concurrent papillary tumours and no previous CIS.”
> “Secondary: CIS detected during follow-up of patients with a previous tumour that was not CIS.”
> “Concurrent: CIS in the presence of any other urothelial tumour in the bladder.”

Source: [European Association of Urology NMIBC Guidelines (2026)](https://d56bochluxqnz.cloudfront.net/documents/full-guideline/EAU-Guidelines-on-Non-muscle-invasive-Bladder-Cancer-2026.pdf)

<a id="topic-2.2.1.1-3"></a>

###### High-risk and very high-risk NMIBC: EAU prognostic factor risk groups

> “All T1 HG/G3 without CIS, EXCEPT those included in the very high-risk group”
> “All CIS patients, EXCEPT those included in the very high-risk group”
> “Additional clinical risk factors are age > 70; multiple papillary tumours; and tumour diameter > 3 cm.”
> “T1 HG/G3 and CIS with at least one risk factor”
> “Patients with primary (pure) CIS should be considered in the high-risk group.”

Source: [European Association of Urology NMIBC Guidelines (2026)](https://d56bochluxqnz.cloudfront.net/documents/full-guideline/EAU-Guidelines-on-Non-muscle-invasive-Bladder-Cancer-2026.pdf)

<a id="topic-2.2.1.1-4"></a>

###### Definition of BCG-unresponsive disease: FDA guidance

> “For the purposes of this guidance, BCG-unresponsive disease is defined as being at least one of”
> “Persistent or recurrent Carcinoma in Situ (CIS) alone or with recurrent”
> “(noninvasive papillary disease/tumor invades the subepithelial connective tissue) disease”
> “within 12 months of completion of adequate BCG therapy”
> “disease within 6 months of completion of adequate BCG”
> “T1 high-grade disease at the first evaluation following an induction BCG”
> “At least five of six doses of an initial induction course plus at least two of three doses of”
> “At least five of six doses of an initial induction course plus at least two of six doses of a”
> “Patients with BCG-unresponsive NMIBC are unlikely to benefit from further therapy with BCG”
> “Patients with BCG-unresponsive NMIBC include those who experienced recurrence with either”
> “papillary disease or CIS or both and who have completely resected disease, resected disease with”
> “CIS, or CIS alone at trial entry.”

Source: [FDA BCG-unresponsive NMIBC draft guidance (2024)](https://www.fda.gov/media/101468/download)

<a id="topic-2.2.1.1-5"></a>

###### Categories of BCG failure: EAU definitions

> “Several categories of BCG failures, broadly defined as any HG disease occurring during or after BCG therapy, have been proposed (see Table 7.2).”
> “To be able to specify the subgroup of patients where additional BCG is unlikely to provide benefit, the category of BCG-unresponsive tumour was defined. Further BCG instillations in these patients are associated with an increased risk of progression”
> “The category of BCG-unresponsive tumours comprises BCG-refractory and early BCG-relapsing tumours (see Table 7.2)”
> “BCG-unresponsive tumours include all BCG refractory tumours and those who develop T1/Ta HG recurrence within six months of completion of adequate BCG exposure”
> “or develop CIS within 12 months of completion of adequate BCG exposure”
> “Adequate BCG is defined as the completion of at least five of six doses of an initial induction course plus at least two out of six doses of a second induction course or two out of three doses of maintenance therapy.”
> “Non-HG recurrence after BCG is not considered as BCG failure.”

Source: [European Association of Urology NMIBC Guidelines (2026)](https://d56bochluxqnz.cloudfront.net/documents/full-guideline/EAU-Guidelines-on-Non-muscle-invasive-Bladder-Cancer-2026.pdf)

<a id="topic-2.2.1.1-6"></a>

###### BCG-exposed disease: high-grade recurrence outside the BCG-unresponsive criteria

> “Patients who experience recurrence with HG NMIBC after BCG without meeting BCG-unresponsive criteria may benefit from additional BCG therapy. This category of high-risk patients that lies between BCG-naïve and BCG-unresponsive NMIBC is termed BCG-exposed”
> “Delayed relapse after adequate BCG: to indicate patients that are disease free after adequate BCG but subsequently experience a HG recurrence outside of the BCG-unresponsive window (> 6 months for Ta/T1 and > 12 months for CIS), up to 24 months.”

Source: [European Association of Urology NMIBC Guidelines (2026)](https://d56bochluxqnz.cloudfront.net/documents/full-guideline/EAU-Guidelines-on-Non-muscle-invasive-Bladder-Cancer-2026.pdf)

<a id="topic-2.2.1.1-7"></a>

###### International Bladder Cancer Group classification of BCG failures

> “Table 5 summarizes our classification of BCG failures, dividing them into the following four types: BCG refractory, BCG relapsing, BCG intolerant, and BCG unresponsive.”
> “Persistent high-grade disease at 6 months despite adequate BCG”
> “The term BCG unresponsive, which essentially includes BCG refractory and BCG relapsing (within 6 months of last BCG exposure), is meant to denote a subgroup of patients at highest risk of recurrence and progression for whom additional BCG therapy is not a feasible option.”
> “For clinical trials, adequate BCG therapy is when a patient has received at least five of six induction instillations and at least one maintenance (two of three instillations) in a 6-month period.”

Source: [Kamat et al. (2016)](https://pmc.ncbi.nlm.nih.gov/articles/PMC5321095/)

<a id="topic-2.2.1.1-8"></a>

###### Origin of the term BCG-unresponsive: 2015 Genitourinary Cancers Symposium task force

> “identifies those patients with high grade (HG) NMIBC who have been treated with adequate BCG (see below) and are unlikely to benefit from and should not receive further intravesical BCG.”
> “Have received at least 2 courses of intravesical BCG – defined as at least 5 of 6 induction instillations of BCG and at least 2 of 3 instillations of maintenance BCG.”
> “Exception: those who have T1HG disease at first evaluation following induction BCG alone (at least 5 of 6 doses) would qualify.”
> “We also recommend including CIS of the prostatic urethra within the definition of BCG unresponsive”

Source: [Lerner et al. (2015)](https://pmc.ncbi.nlm.nih.gov/articles/PMC4720147/)

<a id="topic-2.2.1.1-9"></a>

###### Data-driven definition of BCG-unresponsive disease

> “Those with CIS recurrence at 6–12 months did not differ from those recurring within 6 months (HR = 0.88, p = 0.71).”
> “Patients who fail two courses of BCG with either persistent or recurrent multifocal papillary disease within 6 months or CIS within 12 months of their prior BCG should be considered BCG unresponsive.”

Source: [Steinberg et al. (2016)](https://pmc.ncbi.nlm.nih.gov/articles/PMC4927860/)

<a id="topic-2.2.1.1-10"></a>

###### Etiology of bladder cancer: tobacco smoking

> “Tobacco smoking is the most important risk factor for BC, accounting for approximately 50% of cases”
> “The risk of BC increases with smoking duration and intensity”
> “Passive exposure to tobacco smoke is also associated with an increased risk of BC”

Source: [European Association of Urology NMIBC Guidelines (2026)](https://d56bochluxqnz.cloudfront.net/documents/full-guideline/EAU-Guidelines-on-Non-muscle-invasive-Bladder-Cancer-2026.pdf)

> “It is estimated that cigarette smoking causes up to one-half of all bladder cancers and that smoking increases a person’s risk of bladder cancer two to four times above baseline risk.”

Source: [National Cancer Institute PDQ Bladder Cancer Treatment (2025)](https://www.cancer.gov/types/bladder/hp/bladder-treatment-pdq)

> “Advanced age, male sex, and cigarette smoking contribute to the development of bladder cancer.”

Source: [Lenis et al. (2020)](https://pubmed.ncbi.nlm.nih.gov/33201207/)

<a id="topic-2.2.1.1-11"></a>

###### Etiology of bladder cancer: occupational, environmental, and treatment-related exposures

> “Occupational exposure to aromatic amines, polycyclic aromatic hydrocarbons and chlorinated hydrocarbons is the second most important risk factor for BC, accounting for approximately 10% of all cases.”
> “Exposure to pelvic ionising radiation is associated with an increased risk of BC”
> “Schistosomiasis, an infection caused by a parasitic trematode, can lead to BC”
> “A weak association was also suggested for cyclophosphamide and pioglitazone”

Source: [European Association of Urology NMIBC Guidelines (2026)](https://d56bochluxqnz.cloudfront.net/documents/full-guideline/EAU-Guidelines-on-Non-muscle-invasive-Bladder-Cancer-2026.pdf)

> “Specific chemicals linked to bladder carcinogenesis include beta-naphthylamine, 4-aminobiphenyl, and benzidine.”
> “Exposure to the chemotherapy drug cyclophosphamide has also been associated with an increased risk of bladder cancer.”

Source: [National Cancer Institute PDQ Bladder Cancer Treatment (2025)](https://www.cancer.gov/types/bladder/hp/bladder-treatment-pdq)

<a id="topic-2.2.1.1-12"></a>

###### Etiology of bladder cancer: genetic factors

> “Family history appears to have little impact”
> “Lynch syndrome carriers appear to have a higher relative risk of developing BC”
> “Currently, there is insufficient evidence to support genetic screening for BC.”

Source: [European Association of Urology NMIBC Guidelines (2026)](https://d56bochluxqnz.cloudfront.net/documents/full-guideline/EAU-Guidelines-on-Non-muscle-invasive-Bladder-Cancer-2026.pdf)

<a id="heading-2.2.1.2"></a>

##### 2.2.1.2 Epidemiology

<a id="heading-2.2.1.2.1"></a>

###### 2.2.1.2.1 Incidence of BCG-unresponsive high-risk non-muscle-invasive bladder cancer

<a id="topic-2.2.1.2.1-1"></a>

###### Bladder cancer new cases in the United States, 2026 estimate

> “In 2026, an estimated 84,530 new cases of bladder cancer will be diagnosed in the US and 17,870 people will die from the disease”
> “Bladder is the only cancer for which in situ disease (diagnosed before it has spread beyond the layer of cells where it developed) is included in the case estimate because of its high likelihood of progression and recurrence.”
> “The incidence of bladder cancer is 4 times higher in men than in women.”
> “Bladder cancer incidence decreased by about 1% per year in both men and women from 2013 through 2022.”

Source: [American Cancer Society Cancer Facts and Figures (2026)](https://www.cancer.org/content/dam/cancer-org/research/cancer-facts-and-statistics/annual-cancer-facts-and-figures/2026/2026-cancer-facts-and-figures.pdf)

<a id="topic-2.2.1.2.1-2"></a>

###### Bladder cancer incidence rate, lifetime risk, and age at diagnosis

> “In 2026, it is estimated that there will be 84,530 new cases of bladder cancer and an estimated 17,870 people will die of this disease.”
> “The rate of new cases of bladder cancer was 17.9 per 100,000 men and women per year.”
> “Approximately 2.1 percent of men and women will be diagnosed with bladder cancer at some point during their lifetime, based on 2021–2023 data.”
> “Bladder cancer is most frequently diagnosed among people aged 65–74.”
> “Median Age At Diagnosis 73”

Source: [SEER Cancer Stat Facts Bladder Cancer (2026)](https://seer.cancer.gov/statfacts/html/urinb.html)

<a id="topic-2.2.1.2.1-3"></a>

###### Share of bladder cancer diagnosed as non-muscle-invasive disease

> “Most patients (74%) are diagnosed with non–muscle-invasive bladder cancer (NMIBC),”

Source: [Gore et al. (2026)](https://pmc.ncbi.nlm.nih.gov/articles/PMC12707586/)

> “At diagnosis, approximately three-quarters of bladder cancer cases present as non–muscle-invasive bladder cancer (NMIBC)”

Source: [Williams et al. (2026)](https://www.tandfonline.com/doi/full/10.1080/13696998.2026.2651037)

<a id="topic-2.2.1.2.1-4"></a>

###### Population funnel from bladder cancer to BCG-unresponsive high-risk NMIBC, SEER and SEER-Medicare inputs

> “Specifically, the prevalence of bladder cancer was 0.0634% and the incidence was 0.0244%, based on US Surveillance, Epidemiology, and End Results Program (SEER) registry data”
> “a real-world study of treatment patterns and clinical outcomes of US patients with bladder cancer based on the SEER-Medicare claims data, 73.1% of all patients with bladder cancer had NMIBC and, among them, 42.3% were classified as high-risk; 16.5% of patients with high-risk NMIBC had CIS ± Ta/T1 while 83.5% had high-grade Ta/T1 only”
> “Among patients with high-risk NMIBC, 56.5% were treated with BCG”
> “and 30% of those were unresponsive to BCG”

Source: [Yang et al. (2026)](https://www.tandfonline.com/doi/full/10.1080/13696998.2026.2630599)

<a id="topic-2.2.1.2.1-5"></a>

###### Population funnel assumptions in the ICER review: NMIBC stage mix and BCG non-response

> “Kirkali et al. estimated that approximately 70% of bladder cancers present as NMIBC, with approximately 70% classified as Ta, 20% as T1, and 10% as CIS”
> “we assumed that approximately 38% will be classified as BCG non-responders”

Source: [ICER Bladder Cancer Final Evidence Report (2020)](https://icer.org/wp-content/uploads/2020/08/ICER_Bladder_Cancer_Final_Report_07292022.pdf)

<a id="topic-2.2.1.2.1-6"></a>

###### Proportion of high-risk NMIBC that fails BCG

> “However, more than 40% of patients with high-risk NMIBC do not respond to initial BCG treatment, and many experience loss of response over time”

Source: [Yang et al. (2026)](https://www.tandfonline.com/doi/full/10.1080/13696998.2026.2630599)

> “Unfortunately, initial BCG therapy fails in approximately 40% of patients over a 2-year span”

Source: [Steinberg et al. (2016)](https://pmc.ncbi.nlm.nih.gov/articles/PMC4927860/)

> “High‐risk non‐muscle‐invasive bladder cancer (NMIBC) recurs after adequate intravesical BCG therapy in ~40% of patients”

Source: [Taylor et al. (2025a)](https://pmc.ncbi.nlm.nih.gov/articles/PMC11745998/)

<a id="topic-2.2.1.2.1-7"></a>

###### BCG-unresponsive share among recurrences after BCG, US electronic health record and claims cohort

> “The study included 26 876 patients with NMIBC (median [IQR] age at BCG initiation, 73 [65-77] years; 79.5% male), including 9639 patients with carcinoma in situ”
> “Of 5271 patients with carcinoma in situ–containing tumors and sufficient follow-up, 3134 (59.3%) experienced recurrence within 24 months, of whom 2604 (83.1%) were BCG exposed and 530 (16.9%) were BCG unresponsive.”

Source: [Giatsoglou et al. (2026)](https://pmc.ncbi.nlm.nih.gov/articles/PMC13087816/)

<a id="topic-2.2.1.2.1-8"></a>

###### BCG-unresponsive share among classifiable BCG-treated high-grade NMIBC, single-center cohort

> “We conducted a retrospective cohort study for adults with histologically confirmed high-grade NMIBC treated with intravesical BCG at Moffitt Cancer Center between 1988 and 2024.”
> “Of 1076 NMIBC patients treated with BCG, 470 were classifiable: 245 (52.1%) were BCG-E, of whom 173 (70.6%) were resistant and 72 (29.4%) experienced delayed relapse, and 225 (47.9%) were BCG-UR.”

Source: [Jazayeri et al. (2026)](https://pubmed.ncbi.nlm.nih.gov/41421932/)

<a id="heading-2.2.1.2.2"></a>

###### 2.2.1.2.2 Prevalence of BCG-unresponsive high-risk non-muscle-invasive bladder cancer

<a id="topic-2.2.1.2.2-1"></a>

###### Bladder cancer prevalence in the United States

> “In 2023, there were an estimated 763,031 people living with bladder cancer in the United States.”

Source: [SEER Cancer Stat Facts Bladder Cancer (2026)](https://seer.cancer.gov/statfacts/html/urinb.html)

> “Bladder cancer (BC) is a malignancy commonly affecting elderly people, with a prevalence of 744,039 individuals in the United States (US) in 2022”

Source: [Williams et al. (2026)](https://www.tandfonline.com/doi/full/10.1080/13696998.2026.2651037)

<a id="topic-2.2.1.2.2-2"></a>

###### Prevalent population eligible for treatment of BCG-unresponsive high-risk NMIBC, ICER estimate

> “The National Cancer Institute’s Surveillance, Epidemiology and End Results Program (SEER) estimates that prevalence of bladder cancer was 712,614 people in the US in 2017”
> “Applying these proportions to the estimated prevalent NMIBC population (712,614), we arrived at an estimate of 70,135 individuals as the eligible population for these treatments, with 73% (51,180) being Ta and T1 patients and 27% (18,956) being CIS patients.”

Source: [ICER Bladder Cancer Final Evidence Report (2020)](https://icer.org/wp-content/uploads/2020/08/ICER_Bladder_Cancer_Final_Report_07292022.pdf)

<a id="topic-2.2.1.2.2-3"></a>

###### Eligible population per 1 million health plan members, budget impact model estimate

> “In a hypothetical health plan with one million lives, the number of adults with high-risk, BCG-unresponsive NMIBC with CIS ± Ta/T1 who were eligible for nadofaragene firadenovec was estimated to be 5.5 in Year 1, 4.9 in Year 2, and 4.5 in Year 3”
> “when considering the broader population eligible for nadofaragene firadenovec to the pooled population of CIS ± Ta/T1 plus Ta/T1 only, the size of the target population was estimated to be 33.2 patients in Year 1, 29.7 in Year 2, and 27.5 in Year 3.”

Source: [Yang et al. (2026)](https://www.tandfonline.com/doi/full/10.1080/13696998.2026.2630599)

<a id="topic-2.2.1.2.2-4"></a>

###### Limits of classifying BCG-unresponsive disease in real-world data

> “As a result, a substantial proportion of patients cannot be classified under existing criteria because the exposure-based and time-dependent conditions required by regulatory definitions are not met in routine practice.”
> “Maintenance BCG is infrequently delivered, surveillance intervals vary widely, early radical cystectomy is limited by system-level and institutional factors, and key tumour-level variables required for classification are often missing in large-scale datasets.”

Source: [Pinton et al. (2026)](https://pmc.ncbi.nlm.nih.gov/articles/PMC13464600/)

> “Adequate BCG maintenance therapy was uncommon; only 24.9% (4951 of 19 889) of patients across all risk groups received maintenance therapy.”

Source: [Giatsoglou et al. (2026)](https://pmc.ncbi.nlm.nih.gov/articles/PMC13087816/)

<a id="heading-2.2.1.3"></a>

##### 2.2.1.3 Natural History, Survival, and Mortality

<a id="topic-2.2.1.3-1"></a>

###### Bladder cancer mortality in the United States

> “Bladder cancer mortality rates were stable from the 1990s until 2016 but have since declined by 1.4% per year.”

Source: [American Cancer Society Cancer Facts and Figures (2026)](https://www.cancer.org/content/dam/cancer-org/research/cancer-facts-and-statistics/annual-cancer-facts-and-figures/2026/2026-cancer-facts-and-figures.pdf)

> “Bladder cancer is the tenth leading cause of cancer death in the United States.”
> “The death rate was 4.1 per 100,000 men and women per year.”
> “The percent of bladder cancer deaths is highest among people aged 75–84.”

Source: [SEER Cancer Stat Facts Bladder Cancer (2026)](https://seer.cancer.gov/statfacts/html/urinb.html)

<a id="topic-2.2.1.3-2"></a>

###### Five-year relative survival overall and for in situ disease

> “The 5-year relative survival rate for bladder cancer is 79%, largely because half of cases are diagnosed in situ (still within the layer of cells where it originated), for which 5-year survival is 98%”

Source: [American Cancer Society Cancer Facts and Figures (2026)](https://www.cancer.org/content/dam/cancer-org/research/cancer-facts-and-statistics/annual-cancer-facts-and-figures/2026/2026-cancer-facts-and-figures.pdf)

<a id="topic-2.2.1.3-3"></a>

###### Stage at diagnosis and five-year relative survival by stage, SEER 21, 2016 to 2022

| Stage at diagnosis | Percent of cases | 5-year relative survival |
| --- | --- | --- |
| In situ | “50%” | “98.0%” |
| Localized | “34%” | “73.0%” |
| Regional | “7%” | “41.8%” |
| Distant | “6%” | “9.6%” |
| Unknown | “3%” | “50.8%” |

Source: [SEER Cancer Stat Facts Bladder Cancer (2026)](https://seer.cancer.gov/statfacts/html/urinb.html)

<a id="topic-2.2.1.3-4"></a>

###### Recurrence, progression, and bladder cancer mortality after high-grade NMIBC, SEER-Medicare

> “Of 7,410 subjects, 2,897 (39.1%) experienced a recurrence without progression, 2,449 (33.0%) experienced disease progression, of whom 981 succumbed to bladder cancer.”
> “Using competing-risks regression analysis, we found the 10-year recurrence, progression, and bladder cancer-related mortality rates to be 74.3%, 33.3%, and 12.3%, respectively.”
> “Nearly three-fourths of patients diagnosed with high-risk bladder cancer will recur, progress, or die within ten years of their diagnosis.”

Source: [Chamie et al. (2013)](https://pmc.ncbi.nlm.nih.gov/articles/PMC3773281/)

<a id="topic-2.2.1.3-5"></a>

###### Probability of progression at five years by prognostic risk group

> “From the multivariable analyses, tumor stage, WHO 1973/2004-2016 grade, concomitant carcinoma in situ, number of tumors, tumor size, and age were used to form four risk groups for which the probability of progression at 5 yr varied from <1% to >40%.”

Source: [Sylvester et al. (2021)](https://pubmed.ncbi.nlm.nih.gov/33419683/)

> “At five years, the probabilities of recurrence and progression ranged from 31% to 78% and from less than 1% to 45%.”

Source: [Sylvester et al. (2006)](https://pubmed.ncbi.nlm.nih.gov/16442208/)

<a id="topic-2.2.1.3-6"></a>

###### Risk of progression and metastasis after BCG failure

> “Patients who are BCG-unresponsive are at high risk of progression to muscle-invasive bladder cancer (MIBC) and development of metastatic disease”

Source: [Yang et al. (2026)](https://www.tandfonline.com/doi/full/10.1080/13696998.2026.2630599)

> “Major guidelines recommend radical cystectomy (RC) with urinary diversion as the standard‐of‐care for BCG‐unresponsive NMIBC due to higher propensity for disease recurrence and progression”

Source: [Taylor et al. (2025a)](https://pmc.ncbi.nlm.nih.gov/articles/PMC11745998/)

<a id="topic-2.2.1.3-7"></a>

###### Survival with BCG-unresponsive high-risk NMIBC, SEER-Medicare model input

> “Among adults with high-risk, BCG-unresponsive NMIBC, 92.6% and 81.2% remained alive at Years 2 and 3, respectively, based on an analysis of SEER Medicare claims data”

Source: [Yang et al. (2026)](https://www.tandfonline.com/doi/full/10.1080/13696998.2026.2630599)

<a id="topic-2.2.1.3-8"></a>

###### BCG-refractory compared with BCG-relapsing disease, prospective cohort

> “Seventeen patients were classified as BCG refractory and 15 patients defined BCG relapsing.”
> “Progression-free survival time was 18 months for BCG-refractory vs. 52 months for BCG-relapsing patients (P = 0.001). Of the 17 BCG-refractory patients, 8 (47%) have died vs. 3 (20%) of the 15 BCG-relapsing patients.”

Source: [Herr et al. (2015)](https://pubmed.ncbi.nlm.nih.gov/25813144/)

<a id="topic-2.2.1.3-9"></a>

###### Progression and disease-specific death after T1 recurrence following BCG

> “In the historical cohort the 85 patients with documented T1 recurrence were initially treated with repeat transurethral resection and intravesical bacillus Calmette-Guerin.”
> “At 5 years after T1 recurrence, the cumulative incidence of progression to T2 disease was 71% (95% CI 61%, 81%) and the cumulative incidence of death from disease was 48% (95% CI 39%, 60%).”
> “In this cohort 65 of the 129 patients with recurrent T1 underwent immediate radical cystectomy.”
> “At 5 years after T1 recurrence, the cumulative incidence of progression to muscle invasive disease was 28% (95% CI 20%, 38%) and the cumulative incidence of death from disease was 31% (95% CI 22%, 42%).”

Source: [Raj et al. (2007)](https://pubmed.ncbi.nlm.nih.gov/17382713/)

<a id="topic-2.2.1.3-10"></a>

###### Recurrence and progression with bladder-sparing therapy in BCG-unresponsive NMIBC, international multicenter cohort

> “Among 578 patients, 28% underwent upfront RC and 72% received BST. The median (interquartile range) follow‐up was 50 (20–69) months.”
> “There were no statistically significant differences in metastasis‐free survival, cancer‐specific survival, or overall survival between treatment groups. In the BST group, high‐grade recurrence rates were 37% and 52% at 12 and 24 months and progression to MIBC was observed in 7% and 13% at 12 and 24 months, respectively.”
> “Cancer‐specific survival (CSS) is >80% after RC is performed for NMIBC”

Source: [Taylor et al. (2025a)](https://pmc.ncbi.nlm.nih.gov/articles/PMC11745998/)

<a id="topic-2.2.1.3-11"></a>

###### Long-term survival in BCG-unresponsive NMIBC, single-center registry

> “In total, 114 patients with a median follow-up of 71.2 mo (interquartile range: 32.6–132.2) were analyzed.”
> “There were no significant differences in OS (hazard ratio [HR]: 1.40, 95% confidence interval [CI]: 0.68–2.89, p = 0.4) or CSS (HR: 0.88, 95% CI: 0.22–3.55, p = 0.9) between patients undergoing early RC”
> “At 60 mo, BST patients had a high-grade recurrence-free rate, muscle-invasive disease/metastasis progression-free rate, and avoidance of RC rate of 37%, 83%, and 58%, respectively.”

Source: [Tan et al. (2023)](https://pmc.ncbi.nlm.nih.gov/articles/PMC10334230/)

<a id="topic-2.2.1.3-12"></a>

###### Recurrence, progression, and cystectomy after BCG, US electronic health record and claims cohort

> “Among patients with recurrence, those who were BCG exposed accounted for 83.0% (366 of 441) of disease progression and 87.8% (337 of 384) of cystectomy cases.”

Source: [Giatsoglou et al. (2026)](https://pmc.ncbi.nlm.nih.gov/articles/PMC13087816/)

<a id="topic-2.2.1.3-13"></a>

###### Outcomes in BCG-exposed high-grade NMIBC not meeting the unresponsive definition, single-center cohort

> “In the BCG-E group, 50.2% experienced recurrence and 15.5% experienced progression; median recurrence-free survival (RFS) was 27.2 mo.”
> “The 5-yr survival rate estimates were 32.25% for RFS, 79.3% for progression-free survival (PFS), 84.5% for metastasis-free survival (MFS), and 65.0% for overall survival (OS).”

Source: [Jazayeri et al. (2026)](https://pubmed.ncbi.nlm.nih.gov/41421932/)

<a id="topic-2.2.1.3-14"></a>

###### Clinical outcomes within 12 months of high-grade recurrence after BCG, prospective CISTO cohort

> “Of 570 participants (mean age 71.4 years; 21% female), 371 selected BST and 199 selected RC.”
> “Cancer-specific survival was 99% for BST versus 96% for RC (wRR, 0.99; 95% CI, 0.97 to 1.01). RC was associated with a higher risk of adverse events and serious adverse events, including a 90-day mortality rate of 2.5%.”
> “Within 12 months, 27 (8.1%) participants in the BST arm underwent an eventual RC, including 21 (6.3%) for recurrent high-grade NMIBC and four (1.2%) for progression to MIBC”
> “Because 22% of patients undergoing RC had pathology demonstrating MIBC, 12-month progression-free survival (PFS) was lower for RC (73% v 92% for BST; wRR, 0.81 [95% CI, 0.74 to 0.88];”

Source: [Gore et al. (2026)](https://pmc.ncbi.nlm.nih.gov/articles/PMC12707586/)

<a id="topic-2.2.1.3-15"></a>

###### Survival after radical cystectomy for BCG failure

> “We retrospectively analyzed the records of 117 patients who underwent radical cystectomy for recurrent nonmuscle invasive bladder cancer at our institution from 1990 to 2012.”
> “Five-year overall and cancer specific survival was similar in groups 1 and 2 at 80% and 85%, respectively, at approximately equivalent followups.”

Source: [Haas et al. (2016)](https://pubmed.ncbi.nlm.nih.gov/26807928/)

> “Among 93 patients, 64 (68.8%) had clinical NMIBC, and 29 (31.2%) showed clinical progression to muscle-invasive bladder cancer (MIBC) prior to RC.”
> “Patients with pNMIBC had significantly better 5-year CSS (95.5%) and OS (77.6%) compared to those with clinical (CSS 70.4%, OS 50.2%) or subclinical progression (CSS 64.1%, OS 43.8%).”

Source: [Farré et al. (2025)](https://pubmed.ncbi.nlm.nih.gov/40947056/)

<a id="topic-2.2.1.3-16"></a>

###### Salvage radical cystectomy compared with BCG rechallenge in BCG-unresponsive NMIBC, Japanese multicenter databases

> “In the adjusted BCG-unresponsive NMIBC cohort, no differences in MFS or OS were detected (p = 0.76 and p = 0.35, respectively), although long-term survival outcomes appeared better in the salvage RC group than in the BCG rechallenge group.”

Source: [Miyake et al. (2026)](https://pubmed.ncbi.nlm.nih.gov/41386721/)

<a id="topic-2.2.1.3-17"></a>

###### Early mortality after radical cystectomy

> “The 30-d mortality rate was 1.5%.”

Source: [Shabsigh et al. (2009)](https://pubmed.ncbi.nlm.nih.gov/18675501/)

<a id="topic-2.2.1.3-18"></a>

###### Early mortality after radical cystectomy for muscle-invasive disease, National Cancer Database

> “Among 7922 patients, 90-day mortality was 7.6% (8.0% for lower and 6.7% for higher volume hospitals).”

Source: [Marqueen et al. (2018)](https://pmc.ncbi.nlm.nih.gov/articles/PMC6349610/)

<a id="heading-2.2.1.4"></a>

##### 2.2.1.4 Pathophysiology

<a id="topic-2.2.1.4-1"></a>

###### Urothelial carcinogen exposure and detoxification

> “The aromatic amines and polycyclic aromatic hydrocarbons within the tobacco smoke, which undergo renal excretion, are linked to the development of BC.”

Source: [European Association of Urology NMIBC Guidelines (2026)](https://d56bochluxqnz.cloudfront.net/documents/full-guideline/EAU-Guidelines-on-Non-muscle-invasive-Bladder-Cancer-2026.pdf)

> “Smokers with less functional polymorphisms of N-acetyltransferase-2 (known as slow acetylators) have a higher risk of bladder cancer than other smokers, presumably because of their reduced ability to detoxify carcinogens.”
> “Chronic inflammation is thought to play a key role in carcinogenesis in these settings.”

Source: [National Cancer Institute PDQ Bladder Cancer Treatment (2025)](https://www.cancer.gov/types/bladder/hp/bladder-treatment-pdq)

<a id="topic-2.2.1.4-2"></a>

###### Field defect and multifocal disease

> “Urothelial carcinomas are thought to reflect a so-called field defect, whereby the cancer emerges because of genetic variants that are widely present in the patient's bladder or entire urothelium.”
> “Thus, people who have had a bladder tumor resected often subsequently have recurrent tumors in the bladder, often in different locations from the site of the initial tumor.”
> “An alternative explanation for these patterns of recurrence is that cancer cells that are disrupted when a tumor is resected may reimplant elsewhere in the urothelium.”

Source: [National Cancer Institute PDQ Bladder Cancer Treatment (2025)](https://www.cancer.gov/types/bladder/hp/bladder-treatment-pdq)

> “Carcinoma in situ is often multifocal and can occur in the bladder, but also in the upper urinary tract, prostatic ducts and urethra”

Source: [European Association of Urology NMIBC Guidelines (2026)](https://d56bochluxqnz.cloudfront.net/documents/full-guideline/EAU-Guidelines-on-Non-muscle-invasive-Bladder-Cancer-2026.pdf)

<a id="topic-2.2.1.4-3"></a>

###### Molecular drivers and transcriptomic classes of NMIBC

> “Activating mutations in FGFR3 and PIK3CA and chromosome 9 deletions have been identified as early disease drivers”
> “Transcriptomic analysis identifies four classes (1, 2a, 2b and 3) reflecting tumor biology and disease aggressiveness.”
> “High chromosomal instability, p53-pathway disruption and APOBEC-related mutations are significantly associated with transcriptomic class 2a and poor outcome.”
> “RNA-derived immune cell infiltration is associated with chromosomally unstable tumors and enriched in class 2b.”

Source: [Lindskrog et al. (2021)](https://pmc.ncbi.nlm.nih.gov/articles/PMC8052448/)

<a id="topic-2.2.1.4-4"></a>

###### Molecular subtypes associated with response and failure after BCG

> “Here we conducted molecular profiling of 132 patients with BCG-naïve HR-NMIBC and 44 patients with recurrences after BCG (34 matched), which uncovered three distinct BCG response subtypes (BRS1–3).”
> “Patients with BRS3 tumors had reduced recurrence and progression-free survival compared to BRS1/2.”
> “BRS3 tumors expressed high EMT-basal markers and had an immunosuppresive profile, which was confirmed with spatial proteomics.”
> “BRS3-predicted tumors were enriched in post-BCG 28/44 (64%) recurrences vs pre-BCG tumors 82/283 (28%)”
> “From the 34 matched tumors, 26/34 patients had BRS1/ 2 tumors pre-BCG of which 14/26 tumors switched to BRS3 post-BCG.”

Source: [de Jong et al. (2023)](https://pmc.ncbi.nlm.nih.gov/articles/PMC10572776/)

<a id="topic-2.2.1.4-5"></a>

###### Adaptive immune resistance as a mechanism of BCG failure

> “The final cohort contained 63 pretreatment NMIBC cases, including 31 BCG responders and 32 BCG nonresponders.”
> “Baseline PD-L1 expression (22C3 and SP-142) was observed in 25% to 28% of nonresponders and 0% to 4% of responders (P < 0.01).”
> “PD-L1+ cells in BCG nonresponders colocalized with CD8+ T cells.”
> “One mechanism of BCG failure may be adaptive immune resistance.”

Source: [Kates et al. (2020)](https://pubmed.ncbi.nlm.nih.gov/31712383/)

<a id="topic-2.2.1.4-6"></a>

###### Biological differences between papillary-only and CIS-containing disease after BCG

> “A contemporary systematic review assessing 42 prospective trials on bladder-preserving treatments after BCG showed that patients with papillary-only recurrences appeared more effectively treated”
> “highlighting potential biological differences between these two tumour entities which should be analysed separately when reporting results of clinical trials”

Source: [European Association of Urology NMIBC Guidelines (2026)](https://d56bochluxqnz.cloudfront.net/documents/full-guideline/EAU-Guidelines-on-Non-muscle-invasive-Bladder-Cancer-2026.pdf)

> “a prolonged versus a short disease-free interval may reflect different underlying biology.”

Source: [FDA BCG-unresponsive NMIBC draft guidance (2024)](https://www.fda.gov/media/101468/download)

<a id="heading-2.2.1.5"></a>

##### 2.2.1.5 Diagnosis

<a id="topic-2.2.1.5-1"></a>

###### Cystoscopy and histological confirmation

> “The diagnosis of papillary BC ultimately depends on cystoscopic examination of the bladder and histological evaluation of sampled tissue by either cold-cup biopsy or resection.”
> “Carcinoma in situ can be suspected based on cystoscopy and urine cytology and confirmed by histological evaluation of multiple bladder biopsies”
> “Perform cystoscopy with or without biopsy confirmation in patients with symptoms suggestive of BC. It cannot be replaced by cytology or by any other non-invasive test.”

Source: [European Association of Urology NMIBC Guidelines (2026)](https://d56bochluxqnz.cloudfront.net/documents/full-guideline/EAU-Guidelines-on-Non-muscle-invasive-Bladder-Cancer-2026.pdf)

> “When bladder cancer is suspected, the most useful diagnostic test is cystoscopy.”
> “Radiological studies such as CT scans or ultrasound do not have sufficient sensitivity to detect bladder cancers.”

Source: [National Cancer Institute PDQ Bladder Cancer Treatment (2025)](https://www.cancer.gov/types/bladder/hp/bladder-treatment-pdq)

<a id="topic-2.2.1.5-2"></a>

###### Urine cytology

> “The examination of voided urine or bladder-washing specimens for exfoliated cancer cells has high sensitivity in HG/G3 tumours (84%), but low sensitivity in LG/G1 tumours (16%)”
> “The sensitivity in CIS detection is 28-100%”
> “Positive voided urinary cytology can indicate an UC anywhere in the urinary tract; however, negative cytology does not exclude its presence.”
> “Use voided urine cytology as an adjunct to cystoscopy to detect high-grade tumour.”
> “Use the Paris System 2nd Edn., for cytology reporting.”

Source: [European Association of Urology NMIBC Guidelines (2026)](https://d56bochluxqnz.cloudfront.net/documents/full-guideline/EAU-Guidelines-on-Non-muscle-invasive-Bladder-Cancer-2026.pdf)

<a id="topic-2.2.1.5-3"></a>

###### Transurethral resection and bladder and prostatic urethral biopsies

> “Perform a transurethral resection of the bladder tumour (TURBT) followed by pathology investigation of the obtained specimen(s) as a diagnostic procedure and initial treatment step in patients suspected of having bladder cancer (BC).”
> “The absence of detrusor muscle in the specimen is associated with a significantly higher risk of residual disease and tumour under-staging (with the exception of Ta LG/G1 tumours).”
> “In patients with positive cytology but negative cystoscopy, exclude an upper tract urothelial carcinoma, CIS in the bladder (by mapping biopsies or PDD-guided biopsies) and tumour in the prostatic urethra (by prostatic urethra biopsy).”
> “Photodynamic diagnosis has been shown to improve the detection of BC, especially CIS.”

Source: [European Association of Urology NMIBC Guidelines (2026)](https://d56bochluxqnz.cloudfront.net/documents/full-guideline/EAU-Guidelines-on-Non-muscle-invasive-Bladder-Cancer-2026.pdf)

<a id="topic-2.2.1.5-4"></a>

###### Imaging and evaluation of the upper urinary tract

> “A diagnosis of CIS cannot be made using imaging methods alone (CT urography, IVU, US), including mpMRI”
> “Once a bladder tumour has been detected, perform a CT urography in selected cases (e.g. tumours located in the trigone, or multiple- or high-risk tumours).”
> “Voided urine cytology, cystoscopy and CT urography are key investigations for early detection of extravesical recurrence.”

Source: [European Association of Urology NMIBC Guidelines (2026)](https://d56bochluxqnz.cloudfront.net/documents/full-guideline/EAU-Guidelines-on-Non-muscle-invasive-Bladder-Cancer-2026.pdf)

> “If a high-grade cancer (including carcinoma in situ) or invasive cancer is seen, the patient is staged with a CT scan of the abdomen and pelvis (or CT urogram) and either a chest x-ray or chest CT scan.”

Source: [National Cancer Institute PDQ Bladder Cancer Treatment (2025)](https://www.cancer.gov/types/bladder/hp/bladder-treatment-pdq)

<a id="topic-2.2.1.5-5"></a>

###### Urinary molecular markers after BCG

> “Benign conditions and previous Bacillus Calmette-Guérin (BCG) instillations may influence the results of many urinary marker tests”
> “none of these markers have been accepted in routine practice by any clinical guidelines for diagnosis”

Source: [European Association of Urology NMIBC Guidelines (2026)](https://d56bochluxqnz.cloudfront.net/documents/full-guideline/EAU-Guidelines-on-Non-muscle-invasive-Bladder-Cancer-2026.pdf)

<a id="topic-2.2.1.5-6"></a>

###### Detection of recurrence during follow-up of high-risk disease

> “The first cystoscopy after TURBT at three months is an important prognostic indicator for recurrence and progression”
> “Therefore, the best surveillance strategy for these patients will continue to include frequent cystoscopy and voided urine cytology.”

Source: [European Association of Urology NMIBC Guidelines (2026)](https://d56bochluxqnz.cloudfront.net/documents/full-guideline/EAU-Guidelines-on-Non-muscle-invasive-Bladder-Cancer-2026.pdf)

<a id="topic-2.2.1.5-7"></a>

###### Establishing BCG-unresponsive status: documentation of prior BCG

> “Type of BCG schedule administered before failure (including induction and maintenance: instillations per course, schedule of instillations and duration)”
> “The timing of recurrence and type of BCG schedule administered before failure should also be documented.”

Source: [Kamat et al. (2016)](https://pmc.ncbi.nlm.nih.gov/articles/PMC5321095/)

> “If a patient has met criteria for”
> “BCG-unresponsive disease at any time during their treatment course, sponsors can consider that”
> “patient to have BCG-unresponsive NMIBC regardless of whether BCG was the most recent”

Source: [FDA BCG-unresponsive NMIBC draft guidance (2024)](https://www.fda.gov/media/101468/download)

<a id="topic-2.2.1.5-8"></a>

###### Characterization of disease extent in BCG-unresponsive trials

> “Investigators should fully characterize a”
> “patient’s disease status at or before trial entry, for example through mandatory templated”
> “biopsies in patients with CIS. Sponsors should also obtain urine cytology.”
> “base of the lesion (the biopsy should contain muscle fibers) before trial entry to ensure the”
> “Sponsors should use imaging by”
> “computerized tomography or magnetic resonance to further evaluate patients for the presence of”
> “The 2004 World Health Organization/International Society of”
> “Urologic Pathology classification system is the preferred system for tumor grading.”

Source: [FDA BCG-unresponsive NMIBC draft guidance (2024)](https://www.fda.gov/media/101468/download)

<a id="heading-2.2.1.6"></a>

##### 2.2.1.6 Clinical Presentation - Signs and Symptoms

<a id="topic-2.2.1.6-1"></a>

###### Urinary bleeding: visible or nonvisible haematuria

> “Haematuria is the most common finding in NMIBC. Visible haematuria was found to be associated with higher stage at diagnosis disease compared to nonvisible haematuria”

Source: [European Association of Urology NMIBC Guidelines (2026)](https://d56bochluxqnz.cloudfront.net/documents/full-guideline/EAU-Guidelines-on-Non-muscle-invasive-Bladder-Cancer-2026.pdf)

> “Bladder cancer typically presents with gross or microscopic hematuria.”

Source: [National Cancer Institute PDQ Bladder Cancer Treatment (2025)](https://www.cancer.gov/types/bladder/hp/bladder-treatment-pdq)

> “Bladder tumors can present with gross or microscopic hematuria, which is evaluated with cystoscopy and upper tract imaging depending on the degree of hematuria and risk of malignancy.”

Source: [Lenis et al. (2020)](https://pubmed.ncbi.nlm.nih.gov/33201207/)

<a id="topic-2.2.1.6-2"></a>

###### Lower urinary tract symptoms: irritative voiding symptoms with carcinoma in situ

> “Carcinoma in situ might be suspected in patients with lower urinary tract symptoms, especially irritative voiding symptoms.”

Source: [European Association of Urology NMIBC Guidelines (2026)](https://d56bochluxqnz.cloudfront.net/documents/full-guideline/EAU-Guidelines-on-Non-muscle-invasive-Bladder-Cancer-2026.pdf)

> “Less commonly, patients may complain of urinary frequency, nocturia, and dysuria, symptoms that are more common in patients with carcinoma in situ.”

Source: [National Cancer Institute PDQ Bladder Cancer Treatment (2025)](https://www.cancer.gov/types/bladder/hp/bladder-treatment-pdq)

<a id="topic-2.2.1.6-3"></a>

###### Physical signs: no findings on examination

> “A focused urological examination is mandatory, although it does not reveal NMIBC.”

Source: [European Association of Urology NMIBC Guidelines (2026)](https://d56bochluxqnz.cloudfront.net/documents/full-guideline/EAU-Guidelines-on-Non-muscle-invasive-Bladder-Cancer-2026.pdf)

<a id="topic-2.2.1.6-4"></a>

###### Cystoscopic signs: flat reddish or nonvisible carcinoma in situ

> “Carcinoma in situ can present as a velvet-like, reddish area indistinguishable from inflammation, or it may not be visible at all.”
> “It can be missed or misinterpreted as an inflammatory lesion during cystoscopy if not biopsied.”

Source: [European Association of Urology NMIBC Guidelines (2026)](https://d56bochluxqnz.cloudfront.net/documents/full-guideline/EAU-Guidelines-on-Non-muscle-invasive-Bladder-Cancer-2026.pdf)

<a id="topic-2.2.1.6-5"></a>

###### Laboratory signs: malignant urine cytology with normal-looking mucosa

> “In patients with positive urine cytology (see Section 5.5) and normal-looking mucosa at cystoscopy, mapping biopsies are recommended”

Source: [European Association of Urology NMIBC Guidelines (2026)](https://d56bochluxqnz.cloudfront.net/documents/full-guideline/EAU-Guidelines-on-Non-muscle-invasive-Bladder-Cancer-2026.pdf)

<a id="topic-2.2.1.6-6"></a>

###### Extravesical disease: upper urinary tract and prostatic urethral involvement

> “This risk becomes significant for both sites in high-risk tumours”
> “In a population-based study, 3.6% of patients with high-risk tumours (Ta G3 and CIS) developed upper urinary tract disease within ten years of diagnosis”
> “The incidence of CIS in the prostatic urethra was shown to be 11.7% in 128 males with T1 G3 UC”

Source: [European Association of Urology NMIBC Guidelines (2026)](https://d56bochluxqnz.cloudfront.net/documents/full-guideline/EAU-Guidelines-on-Non-muscle-invasive-Bladder-Cancer-2026.pdf)

> “Patients with upper urinary tract urothelial carcinomas may present with pain resulting from obstruction by the tumor.”

Source: [National Cancer Institute PDQ Bladder Cancer Treatment (2025)](https://www.cancer.gov/types/bladder/hp/bladder-treatment-pdq)

<a id="heading-2.2.1.7"></a>

##### 2.2.1.7 Long-term Morbidity

<a id="topic-2.2.1.7-1"></a>

###### Burden of repeated recurrence and surveillance with the bladder in place

> “Even though most patients do not die of bladder cancer, the vast majority endures the morbidity of recurrence and progression of their cancer.”

Source: [Chamie et al. (2013)](https://pmc.ncbi.nlm.nih.gov/articles/PMC3773281/)

> “Timely follow-up care after treatment is extremely important for people who still have their bladder because of the high likelihood of cancer recurrence or a subsequent bladder cancer.”

Source: [American Cancer Society Cancer Facts and Figures (2026)](https://www.cancer.org/content/dam/cancer-org/research/cancer-facts-and-statistics/annual-cancer-facts-and-figures/2026/2026-cancer-facts-and-figures.pdf)

<a id="topic-2.2.1.7-2"></a>

###### Lifestyle effects of radical cystectomy and patient reluctance

> “but radical surgery comes with substantial risk”
> “and dramatic lifestyle changes. Further, many patients are unwilling to accept major surgery until all other possibilities are exhausted.”

Source: [Steinberg et al. (2016)](https://pmc.ncbi.nlm.nih.gov/articles/PMC4927860/)

<a id="topic-2.2.1.7-3"></a>

###### Complications within 90 days of radical cystectomy

> “Sixty-four percent (735/1142) of patients experienced a complication within 90 d of surgery.”
> “Overall, the highest grade of complication was grade 0 in 36% (n=407), grade 1-2 in 51% (n=582), and grade 3-5 in 13% (n=153).”
> “Gastrointestinal complications were most common (29%), followed by infectious complications (25%) and wound-related complications (15%).”

Source: [Shabsigh et al. (2009)](https://pubmed.ncbi.nlm.nih.gov/18675501/)

<a id="topic-2.2.1.7-4"></a>

###### Adverse events and readmission after radical cystectomy compared with bladder-sparing therapy, CISTO cohort

> “Participants who selected RC were significantly more likely to experience AEs (62% v 38% for BST; wRR, 1.61 [95% CI, 1.35 to 1.91],”
> “including gastrointestinal, infectious, wound, thromboembolic, and bleeding complications.”
> “Among participants who selected RC, 15 (8.0%) experienced prolonged hospitalization after their RC, 57 (30%) were readmitted within 90 days, and five (2.5%) died within 90 days”
> “while BST was associated with better bowel and sexual health.”

Source: [Gore et al. (2026)](https://pmc.ncbi.nlm.nih.gov/articles/PMC12707586/)

<a id="topic-2.2.1.7-5"></a>

###### Long-term complications of conduit urinary diversion

> “There were 643 (60.8%) patients with 1,453 complications directly attributable to the urinary diversion performed with a mean of 2.3 complications per patient.”
> “Bowel complications were the most common, occurring in 215 patients (20.3%), followed by renal complications in 213 (20.2%), infectious complications in 174 (16.5%), stomal complications in 163 (15.4%) and urolithiasis in 162 (15.3%).”
> “Long-term followup of these patients is necessary to closely monitor for potential complications from the urinary diversion that can occur decades later.”

Source: [Shimko et al. (2011)](https://pubmed.ncbi.nlm.nih.gov/21168867/)

<a id="topic-2.2.1.7-6"></a>

###### Kidney function decline after cystectomy with urinary diversion

> “Among 563 patients who underwent cystectomy with urinary diversion, a NB was used for 72 (12.8%) individuals.”
> “Both NB and IC patients had decreased kidney function over time, with mean GFR losses at 5 years of 17% and 14% of baseline values, respectively.”

Source: [Faraj et al. (2020)](https://pubmed.ncbi.nlm.nih.gov/32482512/)

<a id="topic-2.2.1.7-7"></a>

###### Late complications after robot-assisted radical cystectomy with intracorporeal urinary diversion

> “The mean follow-up was 30 ± 22 months.”
> “The stenosis rate of uretero-ileal anastomosis was 14%, while a reduction in eGFR (≥ 20%) was observed in about half of the cases.”
> “UTIs occurred in 37% of the patients, especially in the first 12 months.”

Source: [Presicce et al. (2021)](https://pmc.ncbi.nlm.nih.gov/articles/PMC8217047/)

<a id="heading-2.2.1.8"></a>

##### 2.2.1.8 Burden of BCG-unresponsive high-risk non-muscle-invasive bladder cancer

<a id="heading-2.2.1.8.1"></a>

###### 2.2.1.8.1 Humanistic Burden and Health-related Quality of Life

<a id="topic-2.2.1.8.1-1"></a>

###### Radical cystectomy versus bladder-sparing therapy: 12-month patient-reported outcomes in recurrent high-grade NMIBC after BCG

> “Eligible adults were candidates for both RC or BST, had previous induction Bacillus Calmette-Guérin (BCG), and received their last treatment within 12 months. The primary outcome was the EORTC-QLQ-C30 physical function scale at 12 months.”
> “Of 570 participants (mean age 71.4 years; 21% female), 371 selected BST and 199 selected RC. Physical function was significantly worse in the RC arm at 3 months; by 9 months, there was no difference between arms, and at 12 months, physical function did not differ (ATE, 0.9; 95% CI, –0.6 to 2.4; P = .22). RC was associated with better emotional function, generic health-related QOL, and financial burden, and lower depression and anxiety, while BST was associated with better bowel and sexual health.”
> “At 12 months, the primary outcome of EORTC QLQ-C30 physical function did not differ between the BST arm and the RC arm (mean 85.4 [SD, 17.7] v 86.2 [17.6], respectively; ATE, 0.9 [95% CI, –0.6 to 2.4]; P = .22; Fig 2, Data Supplement, Table S10).”
> “Emotional function, cognitive function, global health, anxiety, and depression were significantly better in the RC arm 12 months after enrollment (Fig 2). There were no significant differences between treatment arms in role function and social function.”
> “Participants in the RC arm had significantly worse 12-month bowel and sexual summary scores than those in the BST arm.”
> “EORTC QLQ-C30 physical and role function were significantly worse in the RC arm at 3 months compared with the BST arm, but no significant treatment effects were observed by 9 months, including for physical function among participants age 75 years and older. Emotional function and anxiety were better in the RC arm at all follow-up time points. Urinary and bowel health were significantly worse in the RC arm at 3 months. By 12 months, there were no significant differences between the two treatments with respect to urinary health, but bowel health remained worse in the RC arm.”

Source: [Gore et al. (2026)](https://pmc.ncbi.nlm.nih.gov/articles/PMC12707586/)

<a id="topic-2.2.1.8.1-2"></a>

###### Health-state utilities elicited for BCG-unresponsive NMIBC and progression to cystectomy

> “The purpose of this study was to elicit the general public’s perspective on quality of life, measured as utility scores associated with treatment for Bacillus Calmette-Guerin (BCG)-unresponsive NMIBC and disease progression, for supporting economic evaluation of newly developed treatments for NMIBC.”
> “Time trade-off (TTO) interviews were conducted with members of the UK general public.”
> “In total, 202 members of the general public participated.”
> “Mean utilities were 0.781 for No High-Grade Recurrence, 0.586 for High-Grade Recurrence, 0.572 for > 1-Year Post-cystectomy and 0.283 for metastatic disease. The First Year Post-cystectomy path health state had a mean utility of 0.288. Pairwise comparisons found statistically significant differences between utilities (p < 0.001), except between High-Grade Recurrence and > 1-Year Post-cystectomy (p = 0.524).”

Source: [Cooper et al. (2023)](https://pmc.ncbi.nlm.nih.gov/articles/PMC9897878/)

<a id="topic-2.2.1.8.1-3"></a>

###### Utility values used in a U.S. cost-effectiveness model of BCG-unresponsive carcinoma in situ

> “We derived quality-adjusted life years (QALYs) from literature-reported utility values for bladder cancer health states (Table 3), adjusting for the health state's utility toll and duration.”

Source: [Myers et al. (2026)](https://pmc.ncbi.nlm.nih.gov/articles/PMC13454959/)

| Health state | Utility value | Range | Toll |
| --- | --- | --- | --- |
| Bladder cancer | “0.95” | “0.93–0.97” | “Lifetime” |
| Radical cystectomy with ileal conduit | “0.8” | “0.7–0.9” | “3 months” |
| Neoadjuvant chemotherapy, radical cystectomy, and ileal conduit | “0.694” | “0.6–0.9” | “3 months” |
| Post-cystectomy state | “0.9” | “0.8–0.95” | “Lifetime” |
| Metastatic disease | “0.62” | “0.5–0.7” | “Lifetime” |
| Recurrence | “0.8” | “0.75–0.95” | “3 months” |
| Disutility: acute minor toxicity (urinary tract infection) | “−0.15” | “0–0.3” | “2 weeks” |
| Disutility: acute major toxicity (hospitalization) | “−0.2” | “0–0.3” | “1 month” |
| Disutility: recurrence (TURBT, restaging) | “−0.15” | “0–0.3” | “1 month” |
| Disutility: radical cystectomy, major complications | “−0.07” | “0–0.1” | “1 month” |
| Disutility: radical cystectomy, minor complications | “−0.03” | “0–0.1” | “1 month” |
| Disutility: metastasis, initial | “−0.28” | “0.1–0.4” | “1.5 month” |

Source: [Myers et al. (2026)](https://pmc.ncbi.nlm.nih.gov/articles/PMC13454959/)

<a id="topic-2.2.1.8.1-4"></a>

###### Patient preferences for bladder-sparing treatment versus radical cystectomy

> “Patients with self-reported NMIBC completed an online discrete-choice experiment survey evaluating their preferences for efficacy-, safety-, and administration-related treatment attributes.”
> “A total of 206 respondents completed the survey. Reduced risks of progression to MIBC and NMIBC recurrence were the most important of the attributes evaluated, followed by, in order, chance of immune-related side effects requiring steroids, mode and frequency of administration, treatment-related fatigue, and urinary symptoms or infection. In fixed direct-elicitation questions, most patients (>70%) preferred bladder-sparing treatments over RC except when comparing repeated Bacillus Calmette-Guérin treatment to RC.”
> “Over 25% of respondents disagreed with the statement "My doctor asked me which treatment option I prefer" when reflecting on their shared decision-making experiences.”

Source: [Smith et al. (2026)](https://pubmed.ncbi.nlm.nih.gov/41687978/)

<a id="topic-2.2.1.8.1-5"></a>

###### Treatment burden of intravesical therapy: travel, caregiver support, and daily activities

> “Two hundred thirty-three patients responded to the survey with median age of 70 years (range 33-88 years). Two-thirds of respondents (66%, 151/232) had received greater than 12 bladder instillations.”
> “Sixty-one respondents (26%) felt the process of receiving bladder instillations adversely affected their ability to perform regular daily activities. Among those surveyed, 72% (168/232) reported openness to receiving in-home intravesical instillations and 54% (122/228) answered that in-home instillations would make the treatment process less disruptive to their lives.”

Source: [Myers et al. (2024)](https://pubmed.ncbi.nlm.nih.gov/37993341/)

<a id="topic-2.2.1.8.1-6"></a>

###### Quality of life with frequent intravesical instillations: systematic review

> “A total of 17 studies were selected, comprising 6 qualitative, 8 quantitative, and 3 mixed-methods designs, totaling 20,045 patients. Frequent instillations were associated with increased urinary symptoms (e.g., urgency and dysuria), fatigue, and emotional distress. Withdrawal rates were high (up to 90%) in intensive schedules, particularly during the first year, due to treatment burden and side effects.”
> “Frequent intravesical instillations can significantly impair QoL, particularly among older patients.”

Source: [Griebsch et al. (2025)](https://pmc.ncbi.nlm.nih.gov/articles/PMC12647504/)

<a id="topic-2.2.1.8.1-7"></a>

###### Quality of life during cystoscopic surveillance: systematic review

> “NMIBC survivors had significantly lower QoL compared to the general population, Surveillance strategies involving repeated intravesical therapies and cystoscopies have a negative impact on QoL with impaired physical function and mental health.”
> “Surveillance is also tailored according to the risk strata. The frequency of surveillance increases with the increase in risk accordingly impacting the QoL”
> “most guidelines advocate 3-month cystoscopy for 2 years, then every 6 months for 5 years and then annually (39), provided there is no recurrence.”

Source: [Nayak et al. (2021)](https://pmc.ncbi.nlm.nih.gov/articles/PMC8261437/)

<a id="topic-2.2.1.8.1-8"></a>

###### Quality of life of NMIBC survivors compared with the general population

> “Non-muscle-invasive bladder cancer survivors had significantly lower QOL compared with the general population, especially in fatigue, physical and role functioning, and mental health. Repeated transurethral resections and intravesical treatments were associated with impaired physical function and mental health. Most NMIBC survivors had concerns of urinary and bowel problems and sexual function.”

Source: [Jung et al. (2019)](https://pubmed.ncbi.nlm.nih.gov/29863576/)

<a id="topic-2.2.1.8.1-9"></a>

###### Patient-reported outcomes during bladder-sparing therapy in BCG-unresponsive NMIBC: N-803 plus BCG

> “Both cohort A patients with carcinoma in situ with or without Ta/T1 disease and cohort B patients with high-grade Ta/T1 papillary disease who received N-803 plus BCG therapy completed the EORTC (European Organization for Research and Treatment of Cancer) Core 30 and Quality of Life NMIBC-Specific 24 questionnaires at baseline and months 6, 12, 18, and 24 on study.”
> “On study, mean physical function (PF) and global health (GH) scores remained relatively stable from baseline for cohorts A (n = 86) and B (n = 78).”
> “NMIBC-Specific 24 summary scores also remained stable on study for both cohorts.”

Source: [Chamie et al. (2024)](https://pubmed.ncbi.nlm.nih.gov/38226931/)

<a id="topic-2.2.1.8.1-10"></a>

###### Patient-reported outcomes during bladder-sparing therapy in BCG-unresponsive NMIBC: gemcitabine and docetaxel

> “PRO assessments were performed using the validated European Organisation for Research and Treatment of Cancer Quality of Life Questionnaire (EORTC QLQ-C30) and NMIBC24 questionnaires.”
> “Sixty-three patients were included.”
> “Urinary symptom burden, global function, and functional outcomes remained stable during treatment.”

Source: [Tan et al. (2026)](https://pubmed.ncbi.nlm.nih.gov/42869744/)

Additional sources: [Mohamed et al. (2021)](https://pubmed.ncbi.nlm.nih.gov/33423864/)

<a id="heading-2.2.1.8.2"></a>

###### 2.2.1.8.2 Economic Burden and Healthcare Resource Utilization

<a id="topic-2.2.1.8.2-1"></a>

###### Healthcare resource utilization and costs after BCG in high-grade NMIBC, by progression status

> “Patients aged ≥ 65 years diagnosed with HG-NMIBC between 2008 and 2015 who received adequate BCG induction and were identified in the SEER-Medicare database.”
> “Of 986 patients diagnosed with HG-NMIBC who met the inclusion criteria, 257 (26.1%) progressed; the mean ages were similar between patients who did and did not progress (77.6 vs. 77.0 years). The overall population had a mean of 0.96 [standard deviation (SD): 1.18] inpatient admissions, 6.47 (11.40) hospitalization days, 1.38 (2.19) emergency department (ED) visits, and 48.03 (44.97) outpatient visits per patient-year during the study period; total annualized costs per patient post-BCG were $39,102 ($44,244).”
> “Patients experiencing progression had significantly higher mean numbers of inpatient admissions [1.61 (SD 1.40) vs. 0.72 (0.99)], hospitalization days [11.77 (14.96) vs. 4.59 (9.29)], ED visits [2.34 (2.92) vs. 1.03 (1.76)], and outpatient visits [65.97 (44.72) vs. 41.63 (43.09)] per patient-year compared with patients without progression (all p < 0.05). Total mean annualized costs per patient after BCG among those who progressed [$65,668 (SD $53,943)] were more than double compared with patients who did not [$29,780 ($36,425)].”

Source: [Yang et al. (2021)](https://pubmed.ncbi.nlm.nih.gov/33543424/)

<a id="topic-2.2.1.8.2-2"></a>

###### Costs of high-risk NMIBC after BCG in the Veterans Affairs Health System, by progression status

> “This retrospective cohort study identified 412 patients with high-risk NMIBC from 63 139 patients diagnosed with bladder cancer who received at least 1 dose of BCG within Department of Veterans Affairs (VA) centers across the US from January 1, 2000, to December 31, 2015.”
> “All-cause expenditures were summarized as medians with corresponding interquartile ranges (IQRs) and adjusted to 2019 USD.”
> “Total median costs at 1 year were $29 459 (IQR, $14 991-$52 060); at 2 years, $55 267 (IQR, $28 667-$99 846); and at 5 years, $117 361 (IQR, $59 680-$211 298). Patients with progressive disease had significantly higher median 5-year costs ($232 729 [IQR, $151 321-$341 195] vs $94 879 [IQR, $52 498-$172 631]; P < .001), with outpatient care, pharmacy, and surgery-related costs contributing.”

Source: [Williams et al. (2021)](https://pmc.ncbi.nlm.nih.gov/articles/PMC8013821/)

<a id="topic-2.2.1.8.2-3"></a>

###### Costs and resource use of radical cystectomy and trimodal therapy in the United States

> “Of 1323 patients, 839 underwent RC (median age 71 years; 26.2% female), and 484 received trimodal therapy (median age 75; 26.2% female). Median [IQR] per-patient costs were $70,671 [$55,878-$106,812] for the RC cohort at 90-days follow-up and rose to $211,671 [$138,597-$346,389] by 5-years post-index. For trimodal therapy, total costs were $34,612 [$16,705-$64,263] at 90-days and increased to $274,462 [$186,337-$421,534] by 5-years. At 90-days, median overall visits (inpatient, outpatient, emergency room, or other) were 26 [16-39] for RC and 19 [12-33] for trimodal therapy; overall visits were 163 [119-218] and 186 [144-238] by 5-years, respectively.”
> “This analysis reveals that RC costs were primarily driven by inpatient services, particularly inpatient facility costs.”

Source: [Williams et al. (2025)](https://pubmed.ncbi.nlm.nih.gov/40122296/)

<a id="topic-2.2.1.8.2-4"></a>

###### Medicare costs of bladder cancer care by phase of care

| Phase of care | Annualized cancer-attributable medical services cost, bladder cancer (2019 US thousand dollars) |
| --- | --- |
| Initial (first 12 months after diagnosis) | “$25.4” |
| Continuing | “$6.1” |
| End of life, cancer death | “$92.2” |
| End of life, non-cancer death | “$21.8” |

Source: [Mariotto et al. (2020)](https://pmc.ncbi.nlm.nih.gov/articles/PMC9514601/)

<a id="topic-2.2.1.8.2-5"></a>

###### National costs of bladder cancer care in the United States, 2015 and projected to 2030

> “Cancer sites for which population changes will increase costs more than the average (39%) from 2015 through 2030 are bladder (45%), kidney (54%), leukemia (51%), melanoma (51%), Non-Hodgkin (45%), prostate (46%) and thyroid (55%) cancers (Table 5).”

Source: [Mariotto et al. (2020)](https://pmc.ncbi.nlm.nih.gov/articles/PMC9514601/)

| Year | National cost of bladder cancer care, Medicare Parts A, B, and D (2019 US billion dollars) |
| --- | --- |
| 2015 | “$8.0” |
| 2020 | “$9.0” |
| 2025 | “$10.2” |
| 2030 | “$11.6” |

Source: [Mariotto et al. (2020)](https://pmc.ncbi.nlm.nih.gov/articles/PMC9514601/)

<a id="topic-2.2.1.8.2-6"></a>

###### Costs of high-risk NMIBC progressing after BCG: systematic review

> “Non-muscle-invasive BCa (NMIBC) incurs significant costs for surveillance and treatment, with costs exceeding $200 000 after 5 yr for high-risk NMIBC patients progressing after bacillus Calmette-Guerin (BCG) treatment (including inpatient, outpatient, and physician service expenses). Muscle-invasive BCa generates substantial costs from radical cystectomy (RC) and neoadjuvant chemotherapy, averaging $30 000-40 000 from surgical costs of RC, with additional expenses in case of complications.”

Source: [Scilipoti et al. (2025)](https://pubmed.ncbi.nlm.nih.gov/39730299/)

<a id="topic-2.2.1.8.2-7"></a>

###### Per-patient and lifetime cost of bladder cancer

> “Collectively, this results in bladder cancer having the highest cost of any malignancy when stratified on a per-patient basis [7]. A patient diagnosed with localized bladder cancer from the years 1998-2013 contributed to a lifetime cumulative expenditure of roughly $124,000 to Medicare, which is likely higher today given new treatment regimens and higher costs [8].”

Source: [Kurnot and Kaye (2024)](https://pmc.ncbi.nlm.nih.gov/articles/PMC11560494/)

> “Due to high recurrence rates, intensive surveillance strategies, and expensive treatment costs, the management of bladder cancer contributes significantly to medical costs.”

Source: [Svatek et al. (2014)](https://pubmed.ncbi.nlm.nih.gov/24472711/)

<a id="heading-2.2.1.8.3"></a>

###### 2.2.1.8.3 Economic Impact of BCG-unresponsive high-risk non-muscle-invasive bladder cancer on Families

<a id="topic-2.2.1.8.3-1"></a>

###### Caregiver attendance, missed work, and travel for intravesical therapy

> “A travel time of >30 minutes to an intravesical treatment facility was reported by 55% (126/231) of respondents. Fifty-six percent (128/232) brought caregivers to their appointments, and 36% (82/230) missed work to receive treatment.”
> “Bladder cancer patients reported considerable travel distances, time requirements, and need for caregiver support when receiving intravesical therapy.”

Source: [Myers et al. (2024)](https://pubmed.ncbi.nlm.nih.gov/37993341/)

<a id="topic-2.2.1.8.3-2"></a>

###### Financial toxicity after radical cystectomy versus bladder-sparing therapy

> “Financial toxicity was measured with the Comprehensive Score for Financial Toxicity (COST),”
> “which includes questions about concern with covering the costs of treatment, out-of-pocket expenses, ability to work, and impact and worry about finances. COST scores range from 0 to 44, with lower scores indicating greater financial distress.”
> “Participants in the BST arm reported significantly higher financial toxicity and financial difficulties 12 months after enrollment than participants in the RC arm.”
> “Participants in the BST and RC arms endorsed similar financial burden at enrollment. However, by 12 months, participants in the RC arm experienced lower financial difficulties and lower financial toxicity. Although RC is a morbid surgery with a high initial burden, after recovery, those patients mostly experience low health care utilization. Conversely, patients undergoing BST have several induction and maintenance treatments in the year after their recurrence coupled with quarterly surveillance cystoscopies. The financial burden of BST may increase going forward, given recent US Food and Drug Administration approvals of nadofaragene and nogapendekin for BCG-unresponsive NMIBC, which are substantially more expensive than currently available BSTs.”

Source: [Gore et al. (2026)](https://pmc.ncbi.nlm.nih.gov/articles/PMC12707586/)

<a id="topic-2.2.1.8.3-3"></a>

###### Financial toxicity among patients with NMIBC in a diverse urban population

> “Hundred patients with NMIBC were surveyed. The median age was 74 years (IQR, 66-79).”
> “The median COST score was 23 (IQR,15-33). 61% of patients reported at least mild FT (COST score 25-14). A total of 21% reported moderate FT (COST score < 14). Black patients were more likely to experience FT than Caucasians (73% vs 37%, P < .05).”
> “Overall median household income was $30,000 (IQR, $18,250-$60,750), and increasing income had a significant positive correlation with COST score (Spearman ρ = 0.502, P < .001).”

Source: [Nadelmann et al. (2026)](https://pubmed.ncbi.nlm.nih.gov/42143549/)

<a id="topic-2.2.1.8.3-4"></a>

###### Financial toxicity in bladder cancer: definition and associated factors

> “Financial toxicity (FT) refers to the detrimental effects of financial strain caused by a cancer diagnosis on the well-being of patients and their families.”
> “Of 629 titles identified, 19, ten, and two studies met the inclusion criteria for prostate, bladder, and kidney cancer, respectively, and were included (24 unique articles).”
> “Factors commonly associated with FT included younger age at diagnosis, black race, low socioeconomic status, low education attainment, and rurality. FT was commonly associated with lower quality of life and nonadherence.”

Source: [Bhanvadia et al. (2021)](https://pubmed.ncbi.nlm.nih.gov/33820747/)

<a id="topic-2.2.1.8.3-5"></a>

###### Indirect costs: lost productivity, retirement, and unemployment

> “Lost productivity for example, contributed to 44% of total cancer care costs in a study of Italian BC patients, and 67% of costs in a recent Iranian study [11-12]. Additionally, this effect may be permanent for many as bladder cancer patients face a roughly 60% retirement rate following diagnosis and 22% unemployment rate for previously full-time workers [13].”
> “Those who are younger, without a college degree, and are black all experience worse financial toxicity [15].”

Source: [Kurnot and Kaye (2024)](https://pmc.ncbi.nlm.nih.gov/articles/PMC11560494/)

<a id="topic-2.2.1.8.3-6"></a>

###### Caregiver financial strain after radical cystectomy with urinary diversion

> “Financial strains, including medical costs and potential work interruptions, further complicate their role.”
> “Financial worries were also evident, as a study involving 123 caregivers, 17% of whom were attending to bladder cancer patients with urostomy, revealed heightened economic concerns. The findings suggested pronounced financial strain among caregivers with young children (34%) and those who were older (mean age=56.10 years; SD=10.56).”

Source: [Zhang and Qi (2024)](https://pmc.ncbi.nlm.nih.gov/articles/PMC11317044/)

<a id="topic-2.2.1.8.3-7"></a>

###### Financial toxicity across bladder cancer stages: systematic review

> “FT is particularly prevalent among younger, less educated, and minority populations.”

Source: [Scilipoti et al. (2025)](https://pubmed.ncbi.nlm.nih.gov/39730299/)

<a id="heading-2.2.1.8.4"></a>

###### 2.2.1.8.4 Economic Impact of Diagnostic Testing

<a id="topic-2.2.1.8.4-1"></a>

###### Share of bladder cancer costs attributable to surveillance

> “Bladder cancer surveillance, including cystoscopy and recurrent imaging, contribute to more than half of the costs of the disease [17].”

Source: [Kurnot and Kaye (2024)](https://pmc.ncbi.nlm.nih.gov/articles/PMC11560494/)

> “Another potential important target for decreasing variation and cost lies in risk-modified surveillance strategies after initial bladder tumor removal to reduce the cost associated with frequent cystoscopic and radiographic procedures.”
> “Two scenarios where economic and comparative-effectiveness research is limited but would be most beneficial are (1) the management of NMIBC patients where excessive costs are due to vigilant surveillance strategies and (2) in patients with metastatic disease due to the enormous cost associated with late-stage and end-of-life care.”

Source: [Svatek et al. (2014)](https://pubmed.ncbi.nlm.nih.gov/24472711/)

<a id="topic-2.2.1.8.4-2"></a>

###### Medicare cost of surveillance testing during bladder-sparing therapy and after radical cystectomy

| Surveillance regimen | Cost | Range | CPT codes |
| --- | --- | --- | --- |
| Bladder-sparing therapy (CT urogram annually, cystoscopy and cytology every 3 months) | “3638 per year” | “3384–7284” | “74178, 88112, 52000” |
| After radical cystectomy for NMIBC (annual CT urogram, cytology, laboratory tests, office visit) | “687 per year” | “597–897” | “74178, 85027, 80053, 82607, 88112” |

Source: [Myers et al. (2026)](https://pmc.ncbi.nlm.nih.gov/articles/PMC13454959/)

<a id="topic-2.2.1.8.4-3"></a>

###### Five-year cost of NMIBC surveillance by risk category

> “A Markov model was constructed to determine the average 5-year costs for the surveillance of patients with NMIBC.”
> “Cumulative costs of care over a 5-year period were $52,125 for low-risk, $146,250 for intermediate-risk, and $366,143 for high-risk NMIBC. The primary driver of cost was progression to muscle-invasive disease requiring definitive therapy, contributing to 81% and 92% of overall cost for intermediate- and high-risk disease.”
> “Although protracted surveillance cystoscopy contributes to the expenditures associated with NMIBC, progression increases the overall cost of care across all three patient risk groups and most notably for intermediate- and high-risk disease patients.”

Source: [Mossanen et al. (2019)](https://pubmed.ncbi.nlm.nih.gov/30446799/)

<a id="topic-2.2.1.8.4-4"></a>

###### Cost-effectiveness of cystoscopic surveillance intensity in high-risk NMIBC

> “We performed real-world clinical data-driven microsimulations of a hypothetical cohort of 100 000 patients diagnosed with HRNMIBC at age 70 years.”
> “Compared to surveillance intensity de-escalation, higher-intensity regimens incurred an incremental cost of ≥$336 000 per incremental quality-adjusted life year gained, which well exceeded conventional willingness-to-pay thresholds, ≥$686 000 per additional MIBC progression prevented, and ≥$2.2 million per additional cancer-related mortality avoided.”

Source: [Su et al. (2025)](https://pubmed.ncbi.nlm.nih.gov/39210627/)

<a id="heading-2.2.2"></a>

#### 2.2.2 Approaches to Treatment

<a id="heading-2.2.2.1"></a>

##### 2.2.2.1 Current Treatment Options and Standard of Care

<a id="heading-2.2.2.1.1"></a>

###### 2.2.2.1.1 Radical Cystectomy

<a id="topic-2.2.2.1.1-1"></a>

###### Guideline recommendation: radical cystectomy as the standard option for BCG-unresponsive disease

> “Patients with BCG-unresponsive disease are unlikely to respond to further BCG therapy; RC is therefore the standard and preferred option.”
> “Offer an RC to patients with BCG-unresponsive tumours.”
> “Early RC is recommended in patients with BCG-unresponsive tumours and should be considered in BCG-relapsing HG tumours, as discussed in Section 7.8 and Table 7.5.”
> “A delay in RC may lead to decreased disease-specific survival”
> “Treatments other than RC must be considered oncologically inferior in patients with BCG-unresponsive tumours.”
> “However, the potential benefit of RC must be weighed against its risks, morbidity, and impact on quality of life (QoL) and discussed with patients in a shared decision-making process.”
> “Offer patients with BCG-unresponsive tumours, who are not candidates for RC due to comorbidities, or who decline RC, preservation strategies (intravesical chemotherapy, chemotherapy and microwave-induced hyperthermia, electromotive administration of chemotherapy, intravesical- or systemic immunotherapy; preferably within clinical trials).”

Source: [European Association of Urology NMIBC Guidelines (2026)](https://d56bochluxqnz.cloudfront.net/documents/full-guideline/EAU-Guidelines-on-Non-muscle-invasive-Bladder-Cancer-2026.pdf)

<a id="topic-2.2.2.1.1-2"></a>

###### Standard of care, morbidity, and deferral of surgery

> “Standard treatment for patients with BCG-unresponsive NMIBC is radical cystectomy, which carries substantial morbidity and mortality; the incidence of complications is 35% to 40% and the 90-day mortality rate is 4.7%”

Source: [Colbert et al. (2025)](https://pmc.ncbi.nlm.nih.gov/articles/PMC11961324/)

> “Major guidelines recommend radical cystectomy (RC) with urinary diversion as the standard‐of‐care for BCG‐unresponsive NMIBC due to higher propensity for disease recurrence and progression”
> “Cancer‐specific survival (CSS) is >80% after RC is performed for NMIBC”
> “However, many patients defer RC due to concerns about perioperative morbidity and its impact on quality of life (QoL).”

Source: [Taylor et al. (2025a)](https://pmc.ncbi.nlm.nih.gov/articles/PMC11745998/)

> “Although radical cystectomy is the preferred treatment for BCG-unresponsive disease”
> “surgery is associated with considerable morbidity and mortality risks, which are particularly germane for patients with this disease, who are often older and have comorbid conditions”

Source: [Moyer et al. (2026a)](https://pmc.ncbi.nlm.nih.gov/articles/PMC12721500/)

<a id="topic-2.2.2.1.1-3"></a>

###### Upfront radical cystectomy compared with bladder-sparing therapy: multicenter retrospective cohort

> “Among 578 patients, 28% underwent upfront RC and 72% received BST. The median (interquartile range) follow‐up was 50 (20–69) months. There were no statistically significant differences in metastasis‐free survival, cancer‐specific survival, or overall survival between treatment groups.”
> “RC was performed in 31.7% in the BST group and nodal disease was found in 13% compared with 4% in upfront RC (P = 0.030).”
> “There were no significant differences in MFS (HR 0.88, 95% CI 0.53–1.46; P = 0.62), CSS (HR 0.91, 95% CI 0.54–1.53; P = 0.73), or OS (HR 1.31, 95% CI 0.91–1.90; P = 0.15) between patients who received upfront RC compared to those receiving BST at time of diagnosis of BCG‐unresponsive NMIBC (Fig. 1).”
> “Although adverse oncological outcomes began to rise 12 months after diagnosis, the rate of dying from bladder cancer were similar at 14% in both the upfront RC and BST groups at 5 years.”
> “The low rates of metastasis and death for patients who underwent BST are reassuring, but comparison with RC is impacted by selection bias.”

Source: [Taylor et al. (2025a)](https://pmc.ncbi.nlm.nih.gov/articles/PMC11745998/)

<a id="topic-2.2.2.1.1-4"></a>

###### Radical cystectomy compared with bladder-sparing therapy: prospective CISTO cohort, 12-month results

> “Of 570 participants (mean age 71.4 years; 21% female), 371 selected BST and 199 selected RC. Physical function was significantly worse in the RC arm at 3 months; by 9 months, there was no difference between arms, and at 12 months, physical function did not differ (ATE, 0.9; 95% CI, –0.6 to 2.4; P = .22).”
> “Cancer-specific survival was 99% for BST versus 96% for RC (wRR, 0.99; 95% CI, 0.97 to 1.01). RC was associated with a higher risk of adverse events and serious adverse events, including a 90-day mortality rate of 2.5%.”
> “Among participants who selected RC, 15 (8.0%) experienced prolonged hospitalization after their RC, 57 (30%) were readmitted within 90 days, and five (2.5%) died within 90 days”
> “Upstaging occurred among 22% of patients undergoing RC, reflective of the higher cancer severity in the RC arm and well-established understaging of bladder cancer with imaging and endoscopy.”

Source: [Gore et al. (2026)](https://pmc.ncbi.nlm.nih.gov/articles/PMC12707586/)

<a id="topic-2.2.2.1.1-5"></a>

###### Timing of radical cystectomy after BCG failure

> “Five-year overall and cancer specific survival was similar in groups 1 and 2 at 80% and 85%, respectively, at approximately equivalent followups. Median bladder retention was 1.7 years longer in group 2 (p <0.001).”
> “On multivariate Cox regression analysis delayed cystectomy in group 2 did not convey a significant hazard for all cause mortality after cystectomy (HR 1.08, p = 0.808).”

Source: [Haas et al. (2016)](https://pubmed.ncbi.nlm.nih.gov/26807928/)

> “In the historical cohort the 85 patients with documented T1 recurrence were initially treated with repeat transurethral resection and intravesical bacillus Calmette-Guerin.”
> “At 5 years after T1 recurrence, the cumulative incidence of progression to T2 disease was 71% (95% CI 61%, 81%) and the cumulative incidence of death from disease was 48% (95% CI 39%, 60%).”
> “In this cohort 65 of the 129 patients with recurrent T1 underwent immediate radical cystectomy. At 5 years after T1 recurrence, the cumulative incidence of progression to muscle invasive disease was 28% (95% CI 20%, 38%) and the cumulative incidence of death from disease was 31% (95% CI 22%, 42%).”

Source: [Raj et al. (2007)](https://pubmed.ncbi.nlm.nih.gov/17382713/)

<a id="topic-2.2.2.1.1-6"></a>

###### Early complications of radical cystectomy: standardized reporting in 1,142 procedures

> “Sixty-four percent (735/1142) of patients experienced a complication within 90 d of surgery.”
> “Overall, the highest grade of complication was grade 0 in 36% (n=407), grade 1-2 in 51% (n=582), and grade 3-5 in 13% (n=153). Gastrointestinal complications were most common (29%), followed by infectious complications (25%) and wound-related complications (15%). The 30-d mortality rate was 1.5%.”

Source: [Shabsigh et al. (2009)](https://pubmed.ncbi.nlm.nih.gov/18675501/)

<a id="topic-2.2.2.1.1-7"></a>

###### Ninety-day mortality after radical cystectomy: muscle-invasive disease, National Cancer Database

> “Among 7922 patients, 90-day mortality was 7.6% (8.0% for lower and 6.7% for higher volume hospitals).”
> “The model predicted 25% of patients had a 90-day mortality risk higher than 10%, and observed 90-day mortality in this group was 14.0% (95% CI = 12.5% to 15.6%).”

Source: [Marqueen et al. (2018)](https://pmc.ncbi.nlm.nih.gov/articles/PMC6349610/)

<a id="heading-2.2.2.1.2"></a>

###### 2.2.2.1.2 Intravesical Chemotherapy

<a id="topic-2.2.2.1.2-1"></a>

###### Guideline description: intravesical chemotherapy and chemotherapy combinations

> “Valrubicin, an anthracycline topoisomerase inhibitor that interferes with deoxyribonucleic acid (DNA) synthesis and metabolism by inhibiting the activity of DNA topoisomerase II, leading to cell cycle arrest in the G2 phase, was approved by the FDA in 1998, but its use has been limited due to the availability of more effective options”
> “have been assessed in a small series of BCG-recurrent NMIBC patients usually not fulfilling the definition of BCG-unresponsive, with inconsistent results.”
> “sequential intravesical administration of gemcitabine and docetaxel is an emerging treatment option in patients failing BCG.”
> “In a retrospective series of 102 patients with BCG-unresponsive NMIBC, with or without CIS, 6-, 12-, and 24-month HG RFS was 78%, 65% and 49%, respectively.”
> “Fifty-seven percent of patients experienced mild/moderate adverse effects, the most common being represented by urinary frequency/urgency (41%) and dysuria (21%) and leading to treatment delay in only 7% of cases”
> “Notably, published data on this combination are currently predominantly retrospective, with only one small prospective series reported in Table 7.4”

Source: [European Association of Urology NMIBC Guidelines (2026)](https://d56bochluxqnz.cloudfront.net/documents/full-guideline/EAU-Guidelines-on-Non-muscle-invasive-Bladder-Cancer-2026.pdf)

<a id="topic-2.2.2.1.2-2"></a>

###### Guideline description: device-assisted chemotherapy

> “In a phase III RCT including predominantly high-risk NMIBC patients failing at least a previous induction course of BCG, MMC combined with microwave-induced hyperthermia (RITE) provided 35% overall DFS at two years as compared to 41% in the control arm (treated with either BCG, MMC or MMC and EDMA at the discretion of the investigator).”
> “A prospective phase II single-arm study evaluating the efficacy and safety of the EMDA-MMC treatment in 26 consecutive patients with BCG-refractory HG NMIBC at three years follow-up, demonstrated DFSs of 75%, 71.4%, 50% and 25%, for Ta G3, T1 G3, CIS, Ta/T1 G3 + CIS, respectively”

Source: [European Association of Urology NMIBC Guidelines (2026)](https://d56bochluxqnz.cloudfront.net/documents/full-guideline/EAU-Guidelines-on-Non-muscle-invasive-Bladder-Cancer-2026.pdf)

<a id="topic-2.2.2.1.2-3"></a>

###### Approval status: valrubicin approved, other intravesical chemotherapy used off-label

> “Other intravesical chemotherapies commonly used off-label include gemcitabine, mitomycin C, and the doublet of gemcitabine and docetaxel.”

Source: [Colbert et al. (2025)](https://pmc.ncbi.nlm.nih.gov/articles/PMC11961324/)

> “For over two decades, valrubicin was the only United States Food and Drug Administration (FDA) approved intravesical treatment for patients with BCG‐unresponsive carcinoma in situ (CIS) despite disease‐free rates of only 10% at 1 year following treatment”
> “Other options include non‐FDA approved therapies such as sequential intravesical gemcitabine and docetaxel”
> “which is supported by retrospective evidence only and no prospective clinical trials.”

Source: [Taylor et al. (2025a)](https://pmc.ncbi.nlm.nih.gov/articles/PMC11745998/)

<a id="topic-2.2.2.1.2-4"></a>

###### Valrubicin: labeled indication, dosing, and administration

> “VALSTAR is an anthracycline topoisomerase inhibitor indicated for intravesical therapy of BCG-refractory carcinoma in situ (CIS) of the urinary bladder in patients for whom immediate cystectomy would be associated with unacceptable morbidity or mortality.”
> “VALSTAR is recommended at a dose of 800 mg administered intravesically once a week for six weeks.”
> “Insert a urethral catheter into the patient's bladder under aseptic conditions, drain the bladder, and instill the diluted 75 mL VALSTAR solution slowly via gravity flow over a period of several minutes.”
> “Withdraw the catheter and retain VALSTAR in the bladder for two hours before voiding.”

Source: [Valstar prescribing information (2016)](https://www.accessdata.fda.gov/drugsatfda_docs/label/2016/020892s019lbl.pdf)

<a id="topic-2.2.2.1.2-5"></a>

###### Valrubicin: efficacy in BCG-refractory carcinoma in situ

> “In the 90 study patients with BCG-refractory carcinoma in situ (CIS), 70% had received at least 2 courses of BCG and 30% had received one course of BCG and at least one additional course of treatment with another agent(s) - e.g., mitomycin, thiotepa, or interferon.”
> “After intravesical administration of VALSTAR, 16 patients (18%) had a complete response documented by bladder biopsies and cytology at 6 months following initiation of therapy.”
> “Median duration of response from start of treatment varied according to the method of analysis (13.5 months if measured to last bladder biopsy without tumor and 21 months if measured until time of documented recurrence).”

Source: [Valstar prescribing information (2016)](https://www.accessdata.fda.gov/drugsatfda_docs/label/2016/020892s019lbl.pdf)

<a id="topic-2.2.2.1.2-6"></a>

###### Valrubicin: safety and the risk of delayed cystectomy

> “Approximately 84% of patients who received intravesical VALSTAR in clinical studies experienced local adverse reactions.”
> “The local adverse reactions associated with VALSTAR usually occur during or shortly after instillation and resolve within 1 to 7 days after the instillate is removed from the bladder.”
> “Delaying cystectomy can lead to development of metastatic bladder cancer, which is lethal.”
> “If there is not a complete response of CIS to treatment after 3 months or if CIS recurs, reconsider cystectomy.”

Source: [Valstar prescribing information (2016)](https://www.accessdata.fda.gov/drugsatfda_docs/label/2016/020892s019lbl.pdf)

<a id="topic-2.2.2.1.2-7"></a>

###### Sequential gemcitabine and docetaxel: multi-institution retrospective cohort after BCG

> “Overall 276 patients (median age 73 years, median followup 22.9 months) received treatment. Nine patients were unable to tolerate a full induction course. One and 2-year recurrence-free survival rates were 60% and 46%, and high grade recurrence-free survival rates were 65% and 52%, respectively.”
> “Forty-three patients (15.6%) went on to cystectomy (median 11.3 months from induction), of whom 11 (4.0%) had progression to muscle invasion.”

Source: [Steinberg et al. (2020)](https://pubmed.ncbi.nlm.nih.gov/31821066/)

<a id="topic-2.2.2.1.2-8"></a>

###### Sequential gemcitabine and docetaxel: long-term single-institution follow-up after BCG failure

> “Median follow-up was 49 months. Median age was 73 years, and 71% of the cohort had CIS containing disease. Thirty five percent of the cohort had BCG-unresponsive disease. Complete response at 3-month surveillance was 74% and median duration of response was 25 months. At 1, 2, and 5 years, HG-RFS was 60%, 50%, and 30%, respectively. HG-RFS was similar among BCG-unresponsive patients and the overall cohort.”
> “Five-year PFS, CFS, CSS, and OS were 82%, 75%, 91%, and 64%, respectively.”

Source: [Chevuru et al. (2023)](https://pubmed.ncbi.nlm.nih.gov/36456454/)

<a id="topic-2.2.2.1.2-9"></a>

###### Sequential gemcitabine and docetaxel compared with additional BCG in BCG-unresponsive disease

> “Of 299 total patients, 204 underwent additional BCG treatment at the time of BCG unresponsiveness and 95 underwent gem/doce treatment. Rates of PFS (HR 2.6, 95% confidence interval [CI] 1.1-5.0, p = 0.03), CFS (HR 2.0, 95% CI 1.2-3.4, p = 0.01), and CSS (HR 3.7, 95% CI 1.1-12.3, p=0.03) were higher in patients receiving gem/doce. HGRFS, MFS, and OS were similar between both groups.”

Source: [Taylor et al. (2025b)](https://pubmed.ncbi.nlm.nih.gov/39694798/)

<a id="topic-2.2.2.1.2-10"></a>

###### Sequential gemcitabine and docetaxel: prospective two-institution cohort in BCG-unresponsive disease

> “Sixty-three patients were included. The median follow-up was 14 mo (interquartile range = 8-27). HGRFS rates at 3 and 12 mo were 88.8% (95% confidence interval [CI] = 81.3-97.0) and 68.1% (95% CI = 56.6-81.8), respectively.”
> “Eight patients (12.7%) underwent radical cystectomy and six patients (9.5%) experienced disease progression. Twenty patients (31.7%) experienced mild irritative symptoms and no grade 3 or 4 adverse events were reported.”

Source: [Tan et al. (2026)](https://pubmed.ncbi.nlm.nih.gov/42869744/)

<a id="topic-2.2.2.1.2-11"></a>

###### Gemcitabine alone compared with sequential gemcitabine and docetaxel: regimens and outcomes

> “Patients received 2 g of gemcitabine in 100 mL of saline, instilled into the bladder via a catheter for a minimum of 60 minutes once weekly for 6 weeks.”
> “Patients received 1 g of gemcitabine in 50 mL of saline, instilled via catheter for 60 to 90 minutes. The bladder was then drained, and 37.5 mg of docetaxel in 50 mL of saline was instilled via a catheter for 60 to 120 minutes. This treatment sequence was administered weekly for 6 weeks.”
> “Median HGRFS was similar between groups (gemcitabine: 22.6 months; Gem/Doce: 19.5 months [P=.25]). Among patients with BCG-unresponsive carcinoma in situ (n=49), median HGRFS was comparable (gemcitabine: 12.2 months; Gem/Doce: 7.6 months [P=.12]).”
> “Low-grade adverse events were common (gemcitabine: 63%; Gem/Doce: 55% [P=.19]), but grade ≥3 adverse events were rare (2.3% vs 2.4%).”
> “Sequential Gem/Doce also poses logistical barriers, including extended chair time, sequential instillation, staffing demands, and reimbursement issues, which may limit its adoption, especially in community settings.”

Source: [Moyer et al. (2026b)](https://pmc.ncbi.nlm.nih.gov/articles/PMC13360992/)

<a id="heading-2.2.2.1.3"></a>

###### 2.2.2.1.3 Intravesical Gene Therapy

<a id="topic-2.2.2.1.3-1"></a>

###### Guideline description: nadofaragene firadenovec

> “Nadofaragene firadenovec (rAd-IFNα/Syn3) consists of rAd-IFNα, a non-replicating recombinant adenovirus vector-based gene therapy that delivers a copy of the human interferon alfa-2b gene to urothelial cells, and Syn3, a polyamide surfactant that enhances the viral transduction of the urothelium, leading to production of IFN-α2b protein.”
> “Cystectomy-free survival at month 60 was 49% (43% in the CIS cohort and 59% in the Ta/T1 cohort)”

Source: [European Association of Urology NMIBC Guidelines (2026)](https://d56bochluxqnz.cloudfront.net/documents/full-guideline/EAU-Guidelines-on-Non-muscle-invasive-Bladder-Cancer-2026.pdf)

<a id="topic-2.2.2.1.3-2"></a>

###### Nadofaragene firadenovec: labeled indication

> “ADSTILADRIN is a non-replicating adenoviral vector-based gene therapy indicated for the treatment of adult patients with high-risk Bacillus Calmette-Guérin (BCG)-unresponsive non-muscle invasive bladder cancer (NMIBC) with carcinoma in situ (CIS) with or without papillary tumors.”

Source: [Adstiladrin prescribing information (2026)](https://www.fda.gov/media/164029/download)

<a id="topic-2.2.2.1.3-3"></a>

###### Nadofaragene firadenovec: dosing and administration

> “Premedication with an anticholinergic is recommended before each instillation of ADSTILADRIN.”
> “After the instillation, ADSTILADRIN should be retained in the bladder for 1 hour. During the 1-hour dwell time, the patient should reposition approximately every 15 minutes from left to right, back and abdomen to maximize bladder surface exposure.”
> “Voided urine should be disinfected for 15 minutes with an equal volume of virucidal agent before flushing of the toilet.”
> “ADSTILADRIN is provided in a carton containing four (4) vials.”
> “ADSTILADRIN is shipped frozen at ≤ -60°C (≤ -76°F) in an insulated shipping box that will maintain the required temperature for a minimum of 72 hours after being sealed.”

Source: [Adstiladrin prescribing information (2026)](https://www.fda.gov/media/164029/download)

<a id="topic-2.2.2.1.3-4"></a>

###### Nadofaragene firadenovec: efficacy in the pivotal trial (label)

> “The efficacy of ADSTILADRIN was evaluated in CS-003 (NCT02773849), an open-label, multicenter, single-arm trial in 103 adults with BCG-unresponsive, high-risk, non-muscle invasive bladder cancer with carcinoma in situ (CIS) with or without papillary tumors following transurethral resection, of whom 98 were considered evaluable for response.”
> “The major efficacy outcome measures were complete response (CR) at any time (as defined by negative results for cystoscopy [with TURBT/biopsies as applicable] and urine cytology) and duration of response.”

Source: [Adstiladrin prescribing information (2026)](https://www.fda.gov/media/164029/download)

| Efficacy outcome measure (Study CS-003) | Adstiladrin (n=98) |
| --- | --- |
| Complete response rate | “51%” |
| 95% CI | “(41%, 61%)” |
| Median duration of response in months (range) | “9.7 (3, 52+)” |
| Duration of response ≥ 12 months | “46%” |

Source: [Adstiladrin prescribing information (2026)](https://www.fda.gov/media/164029/download)

<a id="topic-2.2.2.1.3-5"></a>

###### Nadofaragene firadenovec: phase 3 trial results by cohort

> “55 (53·4%) of 103 patients with carcinoma in situ (with or without a high-grade Ta or T1 tumour) had a complete response within 3 months of the first dose and this response was maintained in 25 (45·5%) of 55 patients at 12 months. Micturition urgency was the most common grade 3–4 study drug-related adverse event (two [1%] of 157 patients, both grade 3), and there were no treatment-related deaths.”
> “In the high-grade Ta or T1 cohort, 35 of 48 patients (72·9%; 95% CI 58·2 to 84·7) were high-grade recurrence-free at month 3, and 21 patients (43·8%; 29·5 to 58·8) were recurrence-free at month 12.”

Source: [Boorjian et al. (2021)](https://pmc.ncbi.nlm.nih.gov/articles/PMC7988888/)

<a id="topic-2.2.2.1.3-6"></a>

###### Nadofaragene firadenovec: 5-year follow-up of the phase 3 trial

> “Median follow-up was 50.8 months (interquartile range 39.1-60.0), with 27% receiving ≥ 5 instillations and 7.6% receiving treatment for ≥ 57 months.”
> “Kaplan-Meier–estimated HGRF survival at 57 months was 13% (95% CI 6.9-21.5) and 33% (95% CI 19.5-46.6) in the CIS and Ta/T1 cohorts, respectively. Cystectomy-free survival at month 60 was 49% (95% CI 40.0-57.1): 43% (95% CI 32.2-53.7) in the CIS cohort and 59% (95% CI 43.1-71.4) in the Ta/T1 cohort. Overall survival at 60 months was 80% (71.0, 86.0): 76% (64.6-84.5) and 86% (70.9-93.5) in the CIS and Ta/T1 cohorts, respectively.”
> “Most adverse events were grades 1 or 2 (66%), with 3.8% of patients reporting grade 3 events and no patients experiencing grades 4 or 5 study-drug related adverse events.”

Source: [Narayan et al. (2024)](https://pmc.ncbi.nlm.nih.gov/articles/PMC12721637/)

<a id="topic-2.2.2.1.3-7"></a>

###### Nadofaragene firadenovec: FDA approval summary

> “On December 16, 2022, the FDA approved the adenoviral vector-based gene therapy nadofaragene firadenovec-vncg (brand name Adstiladrin) for the treatment of adult patients with high-risk bacillus Calmette-Guérin (BCG)-unresponsive non-muscle invasive bladder cancer (NMIBC) with carcinoma in situ (CIS).”
> “Fifty subjects experienced CR 3 months after initial treatment (CR=51%; 95% CI: 40.7; 61.3%), of whom 46% remained in response for ≥12 months. The median DoR was 9.7 months (range: 3 to 52+).”

Source: [Colbert et al. (2025)](https://pmc.ncbi.nlm.nih.gov/articles/PMC11961324/)

<a id="topic-2.2.2.1.3-8"></a>

###### Nadofaragene firadenovec: adverse reactions in the pivotal trial

> “Serious adverse reactions occurred in 11% of patients who received ADSTILADRIN.”
> “Permanent discontinuation of ADSTILADRIN due to an adverse reaction occurred in 3 (1.9%) patients.”
> “Dosage interruptions of ADSTILADRIN due to an adverse reaction occurred in 54 (34%) patients.”
> “The most common (>10%) adverse reactions, including laboratory abnormalities (>15%), were glucose increased, instillation site discharge, triglycerides increased, fatigue, bladder spasm, micturition (urination) urgency, creatinine increased, hematuria (blood in urine), phosphate decreased, chills, dysuria, and pyrexia (fever).”

Source: [Adstiladrin prescribing information (2026)](https://www.fda.gov/media/164029/download)

<a id="topic-2.2.2.1.3-9"></a>

###### Nadofaragene firadenovec: warnings on delayed cystectomy and disseminated adenovirus infection

> “Of the patients with CIS treated with ADSTILADRIN on Study CS-003 who underwent subsequent radical cystectomy and for whom pathologic data were available, 14% (n = 6) had muscle-invasive (T2 or greater) disease at cystectomy.”
> “If patients with CIS do not have a complete response to treatment after 3 months or if CIS recurs, consider cystectomy.”
> “Immunocompromised persons, including those receiving immunosuppressant therapy, may be at risk for disseminated adenovirus infection because of the possible presence of low levels of replication-competent adenovirus in ADSTILADRIN.”

Source: [Adstiladrin prescribing information (2026)](https://www.fda.gov/media/164029/download)

<a id="topic-2.2.2.1.3-10"></a>

###### Nadofaragene firadenovec: real-world outcomes at a multisite academic center

> “Of 24 evaluable patients with carcinoma in situ with/without papillary disease, 79% had a CR at 3 months. The median response duration was not reached; 68% (13/19) of responders still had CRs with median follow-up of 9.3 months. Of 19 patients with papillary-only disease (median follow-up of 7.6 months), HGRFS at 3, 6, and 12 months was 68%, 53%, and 26%, respectively.”
> “The most common adverse events were grade 1–2 bladder spasms (61%) and failure to fully retain the instillation (33%).”

Source: [Moyer et al. (2026a)](https://pmc.ncbi.nlm.nih.gov/articles/PMC12721500/)

<a id="topic-2.2.2.1.3-11"></a>

###### Detalimogene voraplasmid: investigational non-viral gene therapy, LEGEND pivotal Cohort 1

> “Detalimogene is a novel, investigational, non-viral gene therapy for patients with high-risk, non-muscle invasive bladder cancer (NMIBC), including Bacillus Calmette-Guérin (BCG)-unresponsive disease.”
> “The following efficacy data are based on 120 efficacy-evaluable patients enrolled in Cohort 1 as of the data cutoff date, October 29, 2026.”
> “CR at any time of 56% (CI:47%, 65%) (n=120)”
> “Landmark 12-month CR rate is 24% (CI: 16%, 33%) (n=110)”
> “Median duration of complete response is 10.1 months (CI: 7.5, Not Estimable)”
> “Of the 125 patients assessed for safety in Cohort 1, 59% experienced at least one TRAE, which were mainly Grade 1/2 in severity.”
> “Only 4% of patients experienced Grade 3 TRAE, with just 2% of patients experiencing a serious TRAE. No Grade 4 or Grade 5 TRAEs were reported.”
> “The Company expects to initiate the submission by year-end 2026 and plans to complete the BLA submission in the first half of 2027, with potential FDA approval in 2027.”

Source: [enGene LEGEND Cohort 1 and BLA plan press release (2026)](https://investors.engene.com/English/investor/press-releases/news-details/2026/enGene-to-Initiate-a-BLA-Submission-for-Detalimogene-by-Year-End-and-Reports-New-Data-from-LEGEND-Trial-Pivotal-Cohort-1-in-BCG-Unresponsive-NMIBC/default.aspx)

<a id="topic-2.2.2.1.3-12"></a>

###### Detalimogene voraplasmid: LEGEND phase 2 dosing regimen

> “Under the Treatment Period, patients will receive 4 instillations per cycle for up to 4 cycles, of EG-70 at the RP2D defined in Phase 1, administered as a bladder instillation of a 50 mL volume of study drug via catheter with a targeted retention time of 60 minutes. One cycle lasts approximately 12 weeks. For Maintenance treatment 2 doses of EG-70 will be administered as a bladder instillation per 12-week cycle.”

Source: [ClinicalTrials.gov NCT04752722](https://clinicaltrials.gov/study/NCT04752722)

<a id="heading-2.2.2.1.4"></a>

###### 2.2.2.1.4 Interleukin-15 Receptor Agonists

<a id="topic-2.2.2.1.4-1"></a>

###### FDA-approved indication and mechanism: nogapendekin alfa inbakicept-pmln with BCG

> “ANKTIVA, in combination with Bacillus Calmette-Guérin (BCG) is indicated for the treatment of adult patients with BCG-unresponsive nonmuscle invasive bladder cancer (NMIBC).”
> “Nogapendekin alfa inbakicept-pmln is an interleukin-15 (IL-15) receptor agonist.”
> “Binding of nogapendekin alfa inbakicept-pmln to its receptor results in proliferation and activation of NK, CD8+, and memory T cells without proliferation of immuno-suppressive Treg cells.”

Source: [Anktiva prescribing information (2026)](https://www.accessdata.fda.gov/drugsatfda_docs/label/2026/761336s002lbl.pdf)

<a id="topic-2.2.2.1.4-2"></a>

###### Dosage and administration with BCG

> “For induction: ANKTIVA is recommended at a dose of 400 mcg administered intravesically with BCG once a week for 6 weeks.”
> “For maintenance: After BCG and ANKTIVA induction therapy, ANKTIVA is recommended at a dose of 400 mcg administered intravesically with BCG once a week for 3 weeks at months 4, 7, 10, 13 and 19 (for a total of 15 doses).”
> “The recommended duration of treatment is until disease persistence after second induction, disease recurrence or progression, unacceptable toxicity, or a maximum of 37 months.”
> “The ANKTIVA in combination with BCG admixture is retained in the bladder for 2 hours and then voided.”

Source: [Anktiva prescribing information (2026)](https://www.accessdata.fda.gov/drugsatfda_docs/label/2026/761336s002lbl.pdf)

<a id="topic-2.2.2.1.4-3"></a>

###### Expanded indication to papillary-only disease by extrapolation, October 2026

> “On October 14, 2026, the Food and Drug Administration (FDA) approved nogapendekin alfa inbakicept-pmln (Anktiva, Altor BioScience, LLC, an indirect wholly-owned subsidiary of ImmunityBio, Inc.) with Bacillus Calmette-Guérin (BCG) for adults with BCG-unresponsive non-muscle invasive bladder cancer.”
> “The current approval expands the indication to include patients with BCG-unresponsive high-grade NMIBC with papillary-only tumors based on review of available scientific information.”
> “Based on the overlapping clinical and non-clinical features of these two histologic types, the FDA concluded that the prior demonstration of efficacy in patients with BCG-unresponsive NMIBC containing CIS could be extrapolated to patients with BCG-unresponsive high-grade papillary disease.”
> “FDA is working toward finalizing the Guidance for Industry, 'Bacillus Calmette-Guérin-Unresponsive Nonmuscle Invasive Bladder Cancer: Developing Drugs and Biological Products for Treatment' to address this approach.”

Source: [FDA nogapendekin alfa inbakicept-pmln expanded indication notice (2026)](https://www.fda.gov/drugs/resources-information-approved-drugs/fda-approves-expanded-indication-nogapendekin-alfa-inbakicept-pmln-bcg-unresponsive-non-muscle)

<a id="topic-2.2.2.1.4-4"></a>

###### QUILT-3.032 Cohort A: design and population

> “The efficacy of ANKTIVA in combination with TICE BCG was evaluated in QUILT-3.032 (NCT03022825), a single-arm, multicenter trial in 77 adults with BCG-unresponsive, high-risk, NMIBC with CIS with or without Ta/T1 papillary disease following transurethral resection.”
> “Clinical studies evaluating the efficacy of ANKTIVA in combination with other BCG products have not been conducted.”
> “The major efficacy outcome measures were CR at any time (as defined by negative results for cystoscopy [with TURBT/biopsies as applicable] and urine cytology) and duration of response.”
> “Baseline high-risk NMIBC disease status was 43% refractory and 57% relapsed.”
> “Thirty-one percent (n=24) of patients received a second induction course.”

Source: [Anktiva prescribing information (2026)](https://www.accessdata.fda.gov/drugsatfda_docs/label/2026/761336s002lbl.pdf)

<a id="topic-2.2.2.1.4-5"></a>

###### QUILT-3.032 Cohort A: efficacy in the prescribing information

| Endpoint | Nogapendekin alfa inbakicept-pmln with TICE BCG |
| --- | --- |
| Participants | “n=77” |
| Complete response rate (95% CI) | “62% (51, 73)” |
| Duration of response, range in months | “0.0, 47.0+” |
| Duration of response ≥12 months, % (n) | “58% (28)” |
| Duration of response ≥24 months, % (n) | “40% (19)” |
| Basis of duration of response | “Based on 48 patients that achieved a complete response at any time” |

Source: [Anktiva prescribing information (2026)](https://www.accessdata.fda.gov/drugsatfda_docs/label/2026/761336s002lbl.pdf)

<a id="topic-2.2.2.1.4-6"></a>

###### QUILT-3.032 Cohort A: long-term follow-up in 100 participants

> “Participants received 400 mcg NAI in combination with 50 mg BCG through intravesical instillation weekly for 6 weeks, with optional reinduction if complete response (CR) was not achieved at month 3.”
> “The CR rate (n = 100) was 71% (95% CI 61.1-79.6) with a median duration of CR of 26.6 months (range 0.03-53.62).”
> “This included 56 participants who responded to the initial induction treatment and 15 participants receiving reinduction treatment.”
> “The Kaplan-Meier estimated cystectomy-free rate in the 71 responders at 24 and 36 months was 90.3% (95% CI 79.7-95.6) and 84.2% (95% CI 69.6-92.1), respectively.”

Source: [Chang et al. (2026b)](https://pmc.ncbi.nlm.nih.gov/articles/PMC13657391/)

<a id="topic-2.2.2.1.4-7"></a>

###### QUILT-3.032 Cohort B: papillary-only disease

> “NCT03022825 is an open-label, multicenter study of patients with BCG-unresponsive high-grade Ta/T1 papillary nonmuscle-invasive bladder cancer who received 400 μg NAI plus 50 mg BCG intravesically weekly for 6 consecutive weeks.”
> “The primary end point is disease-free survival (DFS) at 12 months.”
> “At July 15, 2024, data cutoff, the DFS rates at 12, 24, and 36 months were 58.2% (95% CI: 46.6, 68.2), 52.1% (95% CI: 40.3, 62.7), and 38.2% (95% CI: 25.6, 50.6), respectively.”
> “Cystectomy avoidance rates at 12 and 36 months were 92.2% (95% CI: 83.4, 96.4) and 81.8% (95% CI: 68.1, 90.1), with median time to cystectomy not reached.”

Source: [Chang et al. (2026a)](https://pmc.ncbi.nlm.nih.gov/articles/PMC12708036/)

<a id="topic-2.2.2.1.4-8"></a>

###### European guideline summary of QUILT-3.032

> “The QUILT 3.032 trial has evaluated the potential of the IL-15 superagonist nagopendekin alfa-inbakicept (NAI), administered intravesically in combination with BCG, in BCG-unresponsive HG NMIBC, demonstrating 3-, 6- and 12-month CRR of 55%, 56% and 45%, respectively, in patients with CIS (n = 82), with a median duration of 26.6 months.”
> “Among patients with Ta/T1 disease (n = 72), the 12-month estimated DFS rate was 55.4%, with median DFS of 19.3 months.”

Source: [European Association of Urology NMIBC Guidelines (2026)](https://d56bochluxqnz.cloudfront.net/documents/full-guideline/EAU-Guidelines-on-Non-muscle-invasive-Bladder-Cancer-2026.pdf)

<a id="topic-2.2.2.1.4-9"></a>

###### FDA review: contribution of each component of the combination

> “Cohort C (N-803 as a single agent) was closed early due to futility based on 10 patients; CRR was 20% [95% CI: 3, 56] with only 1 patient with a durable CR ≥ 6 months.”
> “The CRR with BCG was 14% [95% CI: 2, 43], indicating that the response rate observed with the combination of N-803 and BCG did not appear to be due solely to the activity of BCG.”
> “TICE BCG was the only strain studied in QUILT-3.032 and is currently the only approved BCG strain marketed in the U.S.”

Source: [Heiss et al. (2025)](https://pmc.ncbi.nlm.nih.gov/articles/PMC12363661/)

<a id="topic-2.2.2.1.4-10"></a>

###### Safety in QUILT-3.032 Cohort A

> “Serious adverse reactions occurred in 16% of patients receiving ANKTIVA with TICE BCG.”
> “A fatal adverse reaction of cardiac arrest occurred in 1 (1.1%) patient receiving ANKTIVA with TICE BCG.”
> “Permanent discontinuation of ANKTIVA with TICE BCG due to adverse reactions occurred in 7% of patients.”
> “The most common (≥15%) adverse reactions, including laboratory test abnormalities, were increased creatinine, dysuria, hematuria, urinary frequency, micturition urgency, urinary tract infection, increased potassium, musculoskeletal pain, chills and pyrexia.”

Source: [Anktiva prescribing information (2026)](https://www.accessdata.fda.gov/drugsatfda_docs/label/2026/761336s002lbl.pdf)

<a id="topic-2.2.2.1.4-11"></a>

###### Progression to muscle-invasive disease and delayed cystectomy

> “Delaying cystectomy in patients with BCG-unresponsive NMIBC could lead to development of muscle invasive or metastatic bladder cancer, which can be lethal.”
> “10% (n = 8) progressed to muscle invasive (T2 or greater) bladder cancer, including 7 during the treatment period.”
> “The median time between determination of persistent or recurrent CIS and progression to muscle-invasive disease was 107 days (range: 0 – 210).”
> “If patients with BCG-unresponsive NMIBC have evidence of high-grade disease after a second induction course of ANKTIVA with BCG, reconsider cystectomy.”

Source: [Anktiva prescribing information (2026)](https://www.accessdata.fda.gov/drugsatfda_docs/label/2026/761336s002lbl.pdf)

<a id="heading-2.2.2.1.5"></a>

###### 2.2.2.1.5 Intravesical Drug-releasing Systems

<a id="topic-2.2.2.1.5-1"></a>

###### FDA-approved indication and mechanism: gemcitabine intravesical system

> “INLEXZO is indicated for the treatment of adult patients with Bacillus Calmette-Guérin (BCG)-unresponsive, non-muscle invasive bladder cancer (NMIBC) with carcinoma in situ (CIS), with or without papillary tumors.”
> “INLEXZO is a nucleoside metabolic inhibitor-containing intravesical system”
> “Gemcitabine kills cells undergoing DNA synthesis and blocks the progression of cells through the G1/S-phase boundary.”

Source: [Inlexzo prescribing information (2025)](https://www.accessdata.fda.gov/drugsatfda_docs/label/2025/219683s000lbl.pdf)

<a id="topic-2.2.2.1.5-2"></a>

###### European guideline description of TAR-200

> “TAR-200 is an intravesical system for the continuous release of gemcitabine, providing a sustained dose to increase the therapeutic window of intravesical exposure and enhance targeted treatment within the bladder.”

Source: [European Association of Urology NMIBC Guidelines (2026)](https://d56bochluxqnz.cloudfront.net/documents/full-guideline/EAU-Guidelines-on-Non-muscle-invasive-Bladder-Cancer-2026.pdf)

<a id="topic-2.2.2.1.5-3"></a>

###### Dosage and administration

> “Insert INLEXZO (225 mg of gemcitabine) into the bladder once every 3 weeks for up to 6 months (8 doses), followed by once every 12 weeks for up to 18 months (6 doses), or until persistent or recurrent NMIBC, disease progression, or unacceptable toxicity.”
> “Remove INLEXZO after each 3-week indwelling period.”
> “INLEXZO is co-packaged with a urinary catheter and stylet used to insert INLEXZO through the urinary catheter into the bladder.”
> “INLEXZO is a hazardous drug.”

Source: [Inlexzo prescribing information (2025)](https://www.accessdata.fda.gov/drugsatfda_docs/label/2025/219683s000lbl.pdf)

<a id="topic-2.2.2.1.5-4"></a>

###### SunRISe-1 Cohort 2: design and population

> “The efficacy of INLEXZO was evaluated in Cohort 2 of SunRISe-1 (NCT04640623), a single-arm, multi-center trial in 83 adults with BCG-unresponsive, NMIBC with CIS, with or without papillary tumors (T1, or high-grade Ta) following transurethral resection.”
> “The trial included patients who were ineligible for or who had elected not to undergo radical cystectomy and excluded patients with extra-vesical (i.e., urethra, ureter, or renal pelvis), muscle invasive (T2-T4), locally advanced, or metastatic urothelial carcinoma.”
> “Mandatory biopsies were performed 24 and 48 weeks after treatment initiation.”
> “The major efficacy outcome measures were complete response rate at any time”
> “Tumor pattern at study entry was CIS only (67%), CIS with high-grade Ta only (22%), and CIS with T1 (11%).”
> “The median number of prior instillations of BCG was 12 (range: 7 to 42).”

Source: [Inlexzo prescribing information (2025)](https://www.accessdata.fda.gov/drugsatfda_docs/label/2025/219683s000lbl.pdf)

<a id="topic-2.2.2.1.5-5"></a>

###### SunRISe-1 Cohort 2: efficacy in the prescribing information

| Endpoint | Gemcitabine intravesical system |
| --- | --- |
| Participants | “N=83” |
| Complete response rate (95% CI) | “82% (72, 90)” |
| Duration of response, range in months | “0+, 44+” |
| Duration of response ≥12 months, % (n) | “51% (35)” |
| Basis of duration of response | “Based on patients (n=68) with a complete response at any time” |

Source: [Inlexzo prescribing information (2025)](https://www.accessdata.fda.gov/drugsatfda_docs/label/2025/219683s000lbl.pdf)

<a id="topic-2.2.2.1.5-6"></a>

###### SunRISe-1 Cohort 2: published complete response and duration of response

> “The centrally confirmed CR rate in Cohort 2 was 82.4% (95% CI, 72.6 to 89.8), with 70 of 85 patients achieving CR”
> “After a median follow-up in responders of 20.2 months (range, 5-48), median DOR was 25.8 months (95% CI, 8.3 to not estimable”
> “Among 70 responders, 37 (52.9%) had a DOR of ≥12 months.”

Source: [Daneshmand et al. (2025)](https://pmc.ncbi.nlm.nih.gov/articles/PMC12622271/)

<a id="topic-2.2.2.1.5-7"></a>

###### SunRISe-1 Cohort 4: papillary-only disease

> “Fifty-two patients with BCG-unresponsive high-risk papillary disease–only NMIBC received TAR-200 monotherapy”
> “The Cohort 4 primary end point was disease-free survival (DFS).”
> “After a median follow-up of 12.8 months (range, 4-17), the median DFS was not estimable.”
> “At 6, 9, and 12 months, DFS rates were 85.3% (95% CI, 71.6 to 92.7), 81.1% (95% CI, 66.7 to 89.7), and 70.2 (95% CI, 51.6 to 82.8), respectively”

Source: [Daneshmand et al. (2025)](https://pmc.ncbi.nlm.nih.gov/articles/PMC12622271/)

<a id="topic-2.2.2.1.5-8"></a>

###### Safety in SunRISe-1 Cohort 2

> “Serious adverse reactions occurred in 24% of patients receiving INLEXZO.”
> “Fatal adverse reactions occurred in 1.2% of patients who received INLEXZO, including cognitive disorder.”
> “Permanent discontinuation of INLEXZO due to an adverse reaction occurred in 7% of patients.”
> “Dosage interruptions of INLEXZO due to an adverse reaction occurred in 41% of patients.”
> “The most common (>15%) adverse reactions, including laboratory abnormalities, were urinary frequency, urinary tract infection, dysuria, micturition urgency, decreased hemoglobin, increased lipase, urinary tract pain, decreased lymphocytes, hematuria, increased creatinine, increased potassium, increased AST, decreased sodium, bladder irritation, and increased ALT.”

Source: [Inlexzo prescribing information (2025)](https://www.accessdata.fda.gov/drugsatfda_docs/label/2025/219683s000lbl.pdf)

<a id="topic-2.2.2.1.5-9"></a>

###### Progression to muscle-invasive disease and MRI conditions

> “Of the 83 evaluable patients with BCG-unresponsive CIS treated with INLEXZO in Cohort 2 of SunRISe-1, seven patients (8%) progressed to muscle invasive (T2 or greater) bladder cancer.”
> “The median time between determination of persistent or recurrent CIS or T1 and progression to muscle invasive disease was 94 days.”
> “INLEXZO may be used with MRI only under the specific predefined conditions provided below to avoid potential safety hazards or severe adverse reactions.”

Source: [Inlexzo prescribing information (2025)](https://www.accessdata.fda.gov/drugsatfda_docs/label/2025/219683s000lbl.pdf)

<a id="topic-2.2.2.1.5-10"></a>

###### Randomized phase 3 trial in papillary-only disease: SunRISe-5

> “The purpose of this study is to compare disease free survival (DFS) in participants with recurrence of papillary-only high-risk non-muscle-invasive bladder cancer (HR-NMIBC) within 1 year of last dose of”
> “who refused or are unfit for Radical Cystectomy (RC), receiving TAR-200 versus investigator's choice of single agent intravesical chemotherapy.”

Source: [ClinicalTrials.gov NCT06211764](https://clinicaltrials.gov/study/NCT06211764)

<a id="heading-2.2.2.1.6"></a>

###### 2.2.2.1.6 Immune Checkpoint Inhibitors

<a id="topic-2.2.2.1.6-1"></a>

###### FDA-approved indication: pembrolizumab as a single agent

> “KEYTRUDA, as a single agent, is indicated for the treatment of patients with Bacillus Calmette-Guerin (BCG)-unresponsive, high-risk, non-muscle invasive bladder cancer (NMIBC) with carcinoma in situ (CIS) with or without papillary tumors who are ineligible for or have elected not to undergo cystectomy.”

Source: [Merck KEYTRUDA prescribing information (2026)](https://www.accessdata.fda.gov/drugsatfda_docs/label/2026/125514s191lblCorrected.pdf)

<a id="topic-2.2.2.1.6-2"></a>

###### Recommended dosage in BCG-unresponsive high-risk NMIBC

| Item | Pembrolizumab |
| --- | --- |
| Dose | “200 mg every 3 weeks or 400 mg every 6 weeks” |
| Duration | “Until persistent or recurrent high-risk NMIBC, disease progression, unacceptable toxicity, or up to 24 months” |

Source: [Merck KEYTRUDA prescribing information (2026)](https://www.accessdata.fda.gov/drugsatfda_docs/label/2026/125514s191lblCorrected.pdf)

<a id="topic-2.2.2.1.6-3"></a>

###### KEYNOTE-057 Cohort A: design and population

> “The safety of KEYTRUDA was investigated in KEYNOTE-057, a multicenter, open-label, single-arm trial that enrolled 148 patients with high-risk non-muscle invasive bladder cancer (NMIBC), 96 of whom had BCG-unresponsive carcinoma in situ (CIS) with or without papillary tumors.”
> “Patients received KEYTRUDA 200 mg every 3 weeks until unacceptable toxicity, persistent or recurrent high-risk NMIBC, or progressive disease.”
> “The major efficacy outcome measures were complete response (as defined by negative results for cystoscopy [with TURBT/biopsies as applicable], urine cytology, and computed tomography urography [CTU] imaging) and duration of response.”
> “The study population characteristics were: median age of 73 years (range: 44 to 92); 44% age ≥75; 84% male; 67% White; and 73% and 27% with an ECOG performance status of 0 or 1, respectively.”
> “Tumor pattern at study entry was CIS with T1 (13%), CIS with high grade TA (25%), and CIS (63%).”
> “The median follow-up time was 28.0 months (range: 4.6 to 40.5 months).”

Source: [Merck KEYTRUDA prescribing information (2026)](https://www.accessdata.fda.gov/drugsatfda_docs/label/2026/125514s191lblCorrected.pdf)

<a id="topic-2.2.2.1.6-4"></a>

###### KEYNOTE-057 Cohort A: efficacy in the prescribing information

| Endpoint | Pembrolizumab 200 mg every 3 weeks |
| --- | --- |
| Participants | “n=96” |
| Complete response rate (95% CI) | “41% (31, 51)” |
| Median duration of response, months (range) | “16.2 (0.0+, 30.4+)” |
| Duration of response ≥12 months, % (n) | “46% (18)” |
| Basis of duration of response | “Based on patients (n=39) that achieved a complete response” |

Source: [Merck KEYTRUDA prescribing information (2026)](https://www.accessdata.fda.gov/drugsatfda_docs/label/2026/125514s191lblCorrected.pdf)

<a id="topic-2.2.2.1.6-5"></a>

###### KEYNOTE-057 Cohort A: primary publication

> “In cohort A of the trial, adults aged 18 years or older with histologically confirmed BCG-unresponsive carcinoma in situ of the bladder, with or without papillary tumours, with an Eastern Cooperative Oncology Group performance status of 0-2, and who were ineligible for or declined radical cystectomy were enrolled.”
> “The primary endpoint was clinical complete response rate (absence of high-risk non-muscle-invasive bladder cancer or progressive disease), assessed by cystoscopy and urine cytology approximately 3 months after the first dose of study drug.”
> “Median follow-up was 36·4 months (IQR 32·0-40·7).”
> “39 (41%; 95% CI 30·7-51·1) of 96 patients with BCG-unresponsive carcinoma in situ of the bladder with or without papillary tumours had a complete response at 3 months.”
> “Grade 3 or 4 treatment-related adverse events occurred in 13 (13%) patients; the most common were arthralgia (in two [2%] patients) and hyponatraemia (in three [3%] patients).”

Source: [Balar et al. (2021)](https://pubmed.ncbi.nlm.nih.gov/34051177/)

<a id="topic-2.2.2.1.6-6"></a>

###### KEYNOTE-057 Cohort B: papillary-only disease

> “Cohort B eligible patients were aged 18 years and older, had an Eastern Cooperative Oncology Group performance status of 0-2, and had BCG-unresponsive high-risk non-muscle-invasive bladder cancer with papillary tumours (high-grade Ta or any-grade T1) without carcinoma in situ.”
> “Primary endpoint was 12-month disease-free survival of high-risk non-muscle-invasive bladder cancer or progressive disease as assessed by cystoscopy, cytology, and central pathology and radiology review.”
> “The 12-month disease-free survival was 43·5% (95% CI 34·9-51·9).”
> “Treatment-related adverse events occurred in 97 (73%) of 132 patients; 19 (14%) had a grade 3 or 4 treatment-related adverse event; the most common grade 3 or 4 treatment-related adverse events were colitis (in three [2%] patients) and diarrhoea (in two [2%]).”
> “Findings will need to be confirmed in a randomised controlled trial.”

Source: [Necchi et al. (2024)](https://pubmed.ncbi.nlm.nih.gov/38740030/)

<a id="topic-2.2.2.1.6-7"></a>

###### Safety in KEYNOTE-057

> “The median duration of exposure to KEYTRUDA was 4.3 months (range: 1 day to 25.6 months).”
> “KEYTRUDA was discontinued due to adverse reactions in 11% of patients.”
> “Serious adverse reactions occurred in 28% of KEYTRUDA-treated patients.”
> “The most frequent serious adverse reactions (≥2%) in KEYTRUDA-treated patients were pneumonia (3%), cardiac ischemia (2%), colitis (2%), pulmonary embolism (2%), sepsis (2%), and urinary tract infection (2%).”

Source: [Merck KEYTRUDA prescribing information (2026)](https://www.accessdata.fda.gov/drugsatfda_docs/label/2026/125514s191lblCorrected.pdf)

<a id="topic-2.2.2.1.6-8"></a>

###### FDA advisory committee review of KEYNOTE-057

> “In KEYNOTE-057, the CRR at first disease assessment was 41% (95% CI: 31%, 51%) and median DOR was 16.2 months; 46% of responders remaining in response for at least 1 year.”
> “The committee voted 9–4 in favor of a favorable benefit-risk profile for these patients.”

Source: [Heiss et al. (2025)](https://pmc.ncbi.nlm.nih.gov/articles/PMC12363661/)

<a id="topic-2.2.2.1.6-9"></a>

###### Other checkpoint inhibitors: atezolizumab in SWOG S1605

> “Notably, 3-month CR rates of 41% and 43% have been reported for pembrolizumab and atezolizumab, respectively, as monotherapy in patients with BCG-unresponsive CIS.”

Source: [Daneshmand et al. (2025)](https://pmc.ncbi.nlm.nih.gov/articles/PMC12622271/)

> “In the SWOG S1605 phase II trial, atezolizumab only achieved a 27% CRR at six months in a cohort of 74 patients with CIS, with a median duration of response of 17 months not reaching the prespecified efficacy threshold.”

Source: [European Association of Urology NMIBC Guidelines (2026)](https://d56bochluxqnz.cloudfront.net/documents/full-guideline/EAU-Guidelines-on-Non-muscle-invasive-Bladder-Cancer-2026.pdf)

<a id="heading-2.2.2.1.7"></a>

###### 2.2.2.1.7 Limitations of Current Therapies

<a id="topic-2.2.2.1.7-1"></a>

###### Summary: limitations of cystectomy and of approved bladder-sparing therapies

The EAU guideline states that radical cystectomy is the standard and preferred option for BCG-unresponsive disease and that other treatments must be considered oncologically inferior; it recommends bladder-preserving strategies, preferably within clinical trials, for patients who are not candidates for cystectomy or who decline it. Up to 80% of patients decline or are ineligible for cystectomy. Reported risks of the procedure include morbidity of 50% to 70% and 90-day mortality of approximately 5% (up to 15% in elderly patients), and a manufacturer-funded cost model states that up to one-quarter of patients die and approximately 70% to 80% experience complications within the first year after surgery.

Pembrolizumab, nogapendekin alfa inbakicept-pmln with BCG, and the gemcitabine intravesical system were each approved on the basis of single-arm trials. Their labeled complete response rates were 41% (96 participants), 62% (77 participants), and 82% (83 participants), and no randomized trial compares these agents with each other or with cystectomy. FDA draft guidance states that a randomized controlled trial is preferable and can provide stronger evidence of effectiveness, that time-to-event endpoints are uninterpretable in a single-arm trial, and that a single-arm study cannot assess the contribution of each drug in a combination. For papillary-only disease resected at or before trial entry, the FDA recommends a randomized controlled trial with a time-to-event endpoint. In October 2026, the FDA extended the nogapendekin alfa inbakicept-pmln indication to papillary-only disease by extrapolation from efficacy in disease containing CIS. Labeling for pembrolizumab and the gemcitabine intravesical system is limited to disease with CIS, and pembrolizumab is further limited to patients ineligible for or electing not to undergo cystectomy. Of 31 BCG-unresponsive trials registered on ClinicalTrials.gov, 15 (48%) had enrollment criteria fully consistent with the FDA definition, which the authors state hinders comparisons across agents.

In a meta-analysis of bladder-sparing trials after BCG failure cited by the EAU guideline, pooled 12-month response rates were 24% for trials with more than 2 prior BCG courses and 36% for those with more than 1, and initial response did not predict durable response. Among responders, 46% (pembrolizumab), 58% (nogapendekin alfa inbakicept-pmln with BCG), and 51% (gemcitabine intravesical system) had a duration of response of at least 12 months in the labels. In QUILT-3.032 Cohort A, complete response rates at the 12-, 24-, and 36-month assessments were 47%, 30%, and 16% of 100 participants; in SunRISe-1 Cohort 2, the complete response rate 12 months after treatment initiation was 45.9%. The QUILT-3.032 median duration of response was considered an unreliable estimate because of the limited sample size, small number of events, and substantial censoring. Progression to muscle-invasive disease occurred in 10% (8 participants) in QUILT-3.032 and 8% (7 of 83 evaluable participants) in SunRISe-1 Cohort 2, and each label warns that delaying cystectomy can lead to muscle-invasive or metastatic disease.

Nogapendekin alfa inbakicept-pmln is given with BCG, and TICE BCG is the only approved BCG strain marketed in the U.S. Merck, its sole U.S. manufacturer since 2012, allocates supply to wholesalers and distributors by historical purchasing patterns; in its 2026 letter to health care professionals it reported delays to full startup of a new facility and stated that it will provide an update on timing in the first quarter of 2027. In Medicare claims, BCG use for initial induction therapy decreased from 38.9% before the shortage to 33.0% during it.

Source: [European Association of Urology NMIBC Guidelines (2026)](https://d56bochluxqnz.cloudfront.net/documents/full-guideline/EAU-Guidelines-on-Non-muscle-invasive-Bladder-Cancer-2026.pdf); [Yang et al. (2026)](https://www.tandfonline.com/doi/full/10.1080/13696998.2026.2630599); [Daneshmand et al. (2025)](https://pmc.ncbi.nlm.nih.gov/articles/PMC12622271/); [Williams et al. (2026)](https://www.tandfonline.com/doi/full/10.1080/13696998.2026.2651037); [FDA BCG-unresponsive NMIBC draft guidance (2024)](https://www.fda.gov/media/101468/download); [Merck KEYTRUDA prescribing information (2026)](https://www.accessdata.fda.gov/drugsatfda_docs/label/2026/125514s191lblCorrected.pdf); [Anktiva prescribing information (2026)](https://www.accessdata.fda.gov/drugsatfda_docs/label/2026/761336s002lbl.pdf); [Inlexzo prescribing information (2025)](https://www.accessdata.fda.gov/drugsatfda_docs/label/2025/219683s000lbl.pdf); [FDA nogapendekin alfa inbakicept-pmln expanded indication notice (2026)](https://www.fda.gov/drugs/resources-information-approved-drugs/fda-approves-expanded-indication-nogapendekin-alfa-inbakicept-pmln-bcg-unresponsive-non-muscle); [Chandra et al. (2023)](https://pubmed.ncbi.nlm.nih.gov/37061453/); [Chang et al. (2026b)](https://pmc.ncbi.nlm.nih.gov/articles/PMC13657391/); [Heiss et al. (2025)](https://pmc.ncbi.nlm.nih.gov/articles/PMC12363661/); [Merck TICE BCG HCP letter (2026)](https://www.auanet.org/documents/about/Annual%20HCP%20Letter%20TICE%20BCG%20September%202026%20%28AUA%29.pdf); [Chun et al. (2023)](https://pmc.ncbi.nlm.nih.gov/articles/PMC11221414/)

<a id="topic-2.2.2.1.7-2"></a>

###### Guideline position on radical cystectomy and bladder-sparing therapy

> “Patients with BCG-unresponsive disease are unlikely to respond to further BCG therapy; RC is therefore the standard and preferred option.”
> “Treatments other than RC must be considered oncologically inferior in patients with BCG-unresponsive tumours.”
> “Offer patients with BCG-unresponsive tumours, who are not candidates for RC due to comorbidities, or who decline RC, preservation strategies (intravesical chemotherapy, chemotherapy and microwave-induced hyperthermia, electromotive administration of chemotherapy, intravesical- or systemic immunotherapy; preferably within clinical trials).”

Source: [European Association of Urology NMIBC Guidelines (2026)](https://d56bochluxqnz.cloudfront.net/documents/full-guideline/EAU-Guidelines-on-Non-muscle-invasive-Bladder-Cancer-2026.pdf)

<a id="topic-2.2.2.1.7-3"></a>

###### Cystectomy refusal, ineligibility, and perioperative risk

> “Treatment options for BCG-unresponsive patients with NMIBC are currently limited.”
> “up to 80% of patients decline or are ineligible for the procedure due to associated morbidity, mortality, or quality of life concerns”

Source: [Yang et al. (2026)](https://www.tandfonline.com/doi/full/10.1080/13696998.2026.2630599)

> “The current standard of care for BCG-unresponsive high-risk NMIBC is radical cystectomy,”
> “which is a life-changing surgery associated with considerable morbidity (50%-70%) and significant impact on quality of life.”
> “Radical cystectomy is also associated with substantial 90-day mortality risk (approximately 5%), particularly in elderly patients (≤15%).”
> “Therefore, many patients are unable or unwilling to undergo this procedure, and real-world rates of radical cystectomy for NMIBC are low (<20%).”

Source: [Daneshmand et al. (2025)](https://pmc.ncbi.nlm.nih.gov/articles/PMC12622271/)

> “In patients with BCG-unresponsive NMIBC with CIS, radical cystectomy (RC) is the standard of care”
> “However, up to one-quarter of patients die and approximately 70%-80% experience complications within the first year following surgery”

Source: [Williams et al. (2026)](https://www.tandfonline.com/doi/full/10.1080/13696998.2026.2651037)

<a id="topic-2.2.2.1.7-4"></a>

###### Limitations of approved bladder-sparing therapies stated by trial investigators

> “However, these treatments are associated with limited complete response (CR) rates and response durability, systemic or immune-related toxicities, frequent urethral catheterizations, reliance on BCG as combination therapy, and limited physician adoption.”

Source: [Daneshmand et al. (2025)](https://pmc.ncbi.nlm.nih.gov/articles/PMC12622271/)

> “However, outcomes with these treatments continue to be suboptimal, with the respective clinical trial data reporting overall CR rates of less than 55% and a 12-month duration of response (DOR) of less than 49%”

Source: [Williams et al. (2026)](https://www.tandfonline.com/doi/full/10.1080/13696998.2026.2651037)

<a id="topic-2.2.2.1.7-5"></a>

###### Single-arm trial evidence and FDA trial design recommendations

> “An RCT is preferrable and can”
> “provide stronger evidence of effectiveness, allow for evaluation of both CIS and”
> “papillary disease, and generate comparative safety data.”
> “Time-to-event endpoints are uninterpretable in a single-arm trial.”
> “When the investigational therapy consists of more than one drug, assessing the”
> “contribution of effect of each drug to the combination therapy is not possible in a”
> “single-arm study.”
> “For patients with papillary-only disease that was resected at or before trial entry, FDA”
> “recommends a randomized, controlled trial design using a time-to-event endpoint such as”
> “recurrence-free survival.”

Source: [FDA BCG-unresponsive NMIBC draft guidance (2024)](https://www.fda.gov/media/101468/download)

> “However, the review of QUILT-3.032 highlighted several challenges in interpreting single-arm data in this disease setting.”
> “One key consideration is that both the primary endpoint of CRR and the key secondary endpoint of DoR may be impacted by heterogeneity across investigators in disease assessment.”
> “However, a randomized trial with a time-to-event endpoint would be required to demonstrate benefit in patients with papillary-only disease due to the lack of an available response endpoint for resected tumors and variability in the natural history of resected papillary disease, which challenges the interpretation of uncontrolled time-to-event endpoints.”

Source: [Heiss et al. (2025)](https://pmc.ncbi.nlm.nih.gov/articles/PMC12363661/)

> “A limitation was the noncomparative cohort design.”
> “The duration of follow-up in the present analysis (median, 20.2 months in Cohort 2 responders) limits the ability to draw firm conclusions regarding long-term efficacy and safety of TAR-200 treatment”

Source: [Daneshmand et al. (2025)](https://pmc.ncbi.nlm.nih.gov/articles/PMC12622271/)

<a id="topic-2.2.2.1.7-6"></a>

###### Heterogeneity of trial enrollment criteria

> “Of 31 trials, 15 (48%) had inclusion/exclusion criteria that were fully consistent with (inclusive of patients that met) the BCG unresponsive bladder cancer definition.”
> “The most common disease specific exclusion for patients with BCG unresponsive bladder cancer was a requirement for stage Tis (carcinoma in situ, CIS), which pertained to 7 (23%) of trials.”
> “For bladder cancer treating physicians and regulatory bodies, this also hinders comparisons across agents.”

Source: [Chandra et al. (2023)](https://pubmed.ncbi.nlm.nih.gov/37061453/)

<a id="topic-2.2.2.1.7-7"></a>

###### Durability of complete response

> “The significant heterogeneity of both trial designs and patient characteristics included in these studies, the different definitions of BCG failures used, and missing information on prior BCG courses may account for the variability in efficacy for the different compounds assessed across different trials.”
> “The pooled 12-month response rates were 24% for trials with > 2 prior BCG courses and 36% for those with > 1 BCG courses.”
> “Initial response rate did not predict durable responses highlighting the need for longer-term follow-up.”

Source: [European Association of Urology NMIBC Guidelines (2026)](https://d56bochluxqnz.cloudfront.net/documents/full-guideline/EAU-Guidelines-on-Non-muscle-invasive-Bladder-Cancer-2026.pdf)

> “At the 12-, 24-, and 36-month response assessments, CR rates were 47% (47 of 100; 95% CI 36.9%-57.2%), 30% (30 of 100; 95% CI 21.2%-40.0%), and 16% (16 of 100; 95% CI 9.4%-24.7%), respectively.”

Source: [Chang et al. (2026b)](https://pmc.ncbi.nlm.nih.gov/articles/PMC13657391/)

> “At 3, 6, and 12 months after treatment initiation, CR rates were 78.8% (95% CI, 68.6 to 86.9), 58.8% (95% CI, 47.6 to 69.4), and 45.9% (95% CI, 35.0 to 57.0), respectively.”
> “For context, among patients treated with pembrolizumab, nadofaragene firadenovec, or NAI plus BCG, 46%-58% had a DOR of ≥12 months, with CIs overlapping.”

Source: [Daneshmand et al. (2025)](https://pmc.ncbi.nlm.nih.gov/articles/PMC12622271/)

> “However, given the limited sample size, small number of events, and substantial censoring from approximately 12–15 months, the median DOR in QUILT-3.032 was considered an unreliable estimate.”
> “A post-marketing commitment to better characterize the response duration and risk for progression in all patients was agreed upon with the Applicant.”

Source: [Heiss et al. (2025)](https://pmc.ncbi.nlm.nih.gov/articles/PMC12363661/)

<a id="topic-2.2.2.1.7-8"></a>

###### BCG supply constraints

> “Since 2012, Merck has been the sole US manufacturer and primary global supplier of TICE BCG.”
> “Increasing global demand for TICE BCG has exceeded our manufacturing capabilities.”
> “While work is underway to address these issues, the cumulative additional time will delay full startup, filing, and approval of the facility.”
> “We will provide an update on the expected timing of our new facility’s opening in the first quarter of 2027.”
> “As a reminder, Merck continues to allocate available supply of TICE BCG to wholesalers and distributors, based on their historical purchasing patterns.”

Source: [Merck TICE BCG HCP letter (2026)](https://www.auanet.org/documents/about/Annual%20HCP%20Letter%20TICE%20BCG%20September%202026%20%28AUA%29.pdf)

> “Among eligible patients, BCG utilization rates for initial induction therapy decreased 5.9%, from 38.9% (1030 of 2648 patients) in the pre-shortage period, to 33.0% (1756 of 5323 patients) in the shortage period”

Source: [Chun et al. (2023)](https://pmc.ncbi.nlm.nih.gov/articles/PMC11221414/)

> “Ten (13%) patients in Cohort A received prior partial dose BCG, which was allowed due to the BCG supply issues during the conduct of the study.”

Source: [Heiss et al. (2025)](https://pmc.ncbi.nlm.nih.gov/articles/PMC12363661/)

> “Furthermore, ongoing national BCG shortages since 2012 have constrained access to adequate BCG therapy, limiting treatment options for patients with NMIBC in the US and underscoring the need for additional effective therapies”

Source: [Williams et al. (2026)](https://www.tandfonline.com/doi/full/10.1080/13696998.2026.2651037)

<a id="heading-2.2.2.2"></a>

##### 2.2.2.2 Place in Treatment, Anticipated Use, and Care Setting

<a id="topic-2.2.2.2-1"></a>

###### Summary: anticipated place in treatment and care setting

Radical cystectomy is the guideline standard for BCG-unresponsive disease; the EAU 2026 guideline recommends offering it and recommends bladder preservation strategies, preferably within clinical trials, for patients who are not candidates for cystectomy or who decline it. BOND-003 enrolled participants who were medically unfit for cystectomy or who refused it, and the FDA draft guidance states that patients with BCG-unresponsive NMIBC “are unlikely to benefit from further therapy with BCG”. CG Oncology states that only approximately 6% of patients with NMIBC elect cystectomy, and another publication reports real-world rates of radical cystectomy for NMIBC below 20%.

The anticipated first use is in BCG-unresponsive high-risk NMIBC with carcinoma in situ, with or without papillary tumors. In its PIVOT-006 topline release, CG Oncology stated that, based on FDA feedback, the initial BLA will be broadened to include both carcinoma in situ and high-grade papillary-only disease, with completion anticipated in March 2027. Cretostimogene would enter a setting in which the FDA has approved pembrolizumab, nadofaragene firadenovec, nogapendekin alfa inbakicept-pmln with BCG, and TAR-200 for high-risk, BCG-unresponsive NMIBC with CIS ± Ta/T1.

The expected care setting is the urology office. BOND-003 Cohort C was run at 41 community and academic centres. Cretostimogene is instilled through a soft catheter without anesthesia or operating room time, and the company states that a medical assistant or nurse can prepare and administer it. The product is handled under biosafety level 2 precautions, described as “BSL-2 like BCG”, with protective equipment during preparation and administration. CG Oncology describes a field organization directed at community and academic urology networks.

Source: [European Association of Urology NMIBC Guidelines (2026)](https://d56bochluxqnz.cloudfront.net/documents/full-guideline/EAU-Guidelines-on-Non-muscle-invasive-Bladder-Cancer-2026.pdf); [ClinicalTrials.gov NCT04452591](https://clinicaltrials.gov/study/NCT04452591); [FDA BCG-unresponsive NMIBC draft guidance (2024)](https://www.fda.gov/media/101468/download); [CG Oncology Form 10-K (2026)](https://www.sec.gov/Archives/edgar/data/1991792/000119312526079498/ck0001991792-20251231.htm); [CG Oncology PIVOT-006 topline press release (2026)](https://ir.cgoncology.com/news-releases/news-release-details/pivot-006-phase-3-registrational-trial-demonstrates); [Daneshmand et al. (2025)](https://pmc.ncbi.nlm.nih.gov/articles/PMC12622271/); [Tyson et al. (2026)](https://pubmed.ncbi.nlm.nih.gov/42508433/); [CG Oncology investor presentation (2026)](https://ir.cgoncology.com/static-files/16380a7a-42d9-40fc-a2a5-03e0b5235ed3); [Donahue et al. (2025)](https://cgoncology.com/wp-content/uploads/2025/11/SUNA_Cretostimogene-Nursing-Logisitics_Final-1.pdf); [Yang et al. (2026)](https://www.tandfonline.com/doi/full/10.1080/13696998.2026.2630599)

<a id="topic-2.2.2.2-2"></a>

###### Guideline position of radical cystectomy and bladder preservation

> “Patients with BCG-unresponsive disease are unlikely to respond to further BCG therapy; RC is therefore the standard and preferred option.”
> “Offer an RC to patients with BCG-unresponsive tumours.”
> “Offer patients with BCG-unresponsive tumours, who are not candidates for RC due to comorbidities, or who decline RC, preservation strategies (intravesical chemotherapy, chemotherapy and microwave-induced hyperthermia, electromotive administration of chemotherapy, intravesical- or systemic immunotherapy; preferably within clinical trials).”
> “Treatments other than RC must be considered oncologically inferior in patients with BCG-unresponsive tumours.”

Source: [European Association of Urology NMIBC Guidelines (2026)](https://d56bochluxqnz.cloudfront.net/documents/full-guideline/EAU-Guidelines-on-Non-muscle-invasive-Bladder-Cancer-2026.pdf)

<a id="topic-2.2.2.2-3"></a>

###### Guideline description of cretostimogene evidence

> “In an interim analysis of 45 patients with Ta/T1, with or without CIS, the six-month CRR was 47% (32%-62%) with predominantly mild bladder toxicity”

Source: [European Association of Urology NMIBC Guidelines (2026)](https://d56bochluxqnz.cloudfront.net/documents/full-guideline/EAU-Guidelines-on-Non-muscle-invasive-Bladder-Cancer-2026.pdf)

<a id="topic-2.2.2.2-4"></a>

###### Population that declines or is unfit for cystectomy

> “Patients with BCG-unresponsive NMIBC are unlikely to benefit from further therapy with BCG”

Source: [FDA BCG-unresponsive NMIBC draft guidance (2024)](https://www.fda.gov/media/101468/download)

> “Ineligible to receive radical cystectomy (medically unfit) or refusal of radical cystectomy according to Investigator assessment.”

Source: [ClinicalTrials.gov NCT04452591](https://clinicaltrials.gov/study/NCT04452591)

> “Therefore, many patients are unable or unwilling to undergo this procedure, and real-world rates of radical cystectomy for NMIBC are low (<20%).”

Source: [Daneshmand et al. (2025)](https://pmc.ncbi.nlm.nih.gov/articles/PMC12622271/)

<a id="topic-2.2.2.2-5"></a>

###### Company positioning as a bladder-sparing therapy after BCG

> “Given the limitations of currently approved therapies, the next course of treatment for these patients with BCG-unresponsive tumors is radical cystectomy, which is the complete removal of the bladder.”
> “As such, there is a significant unmet need for effective bladder-sparing treatments.”
> “While radical cystectomy is the current guideline recommended treatment for BCG-unresponsive NMIBC, only approximately 6% of patients with NMIBC elect to undergo cystectomy considering the significant social, functional and emotional burden associated with this procedure.”

Source: [CG Oncology Form 10-K (2026)](https://www.sec.gov/Archives/edgar/data/1991792/000119312526079498/ck0001991792-20251231.htm)

> “Cretostimogene shows promise as an innovative bladder-sparing treatment for high-risk, BCG-unresponsive, non-muscle-invasive bladder cancer with carcinoma in situ.”

Source: [Tyson et al. (2026)](https://pubmed.ncbi.nlm.nih.gov/42508433/)

<a id="topic-2.2.2.2-6"></a>

###### Anticipated initial indication including papillary-only disease

> “Based on FDA feedback, initial BLA submission in BCG-unresponsive NMIBC to be broadened to include both CIS and high-grade papillary-only disease; completion anticipated in March 2027”

Source: [CG Oncology PIVOT-006 topline press release (2026)](https://ir.cgoncology.com/news-releases/news-release-details/pivot-006-phase-3-registrational-trial-demonstrates)

<a id="topic-2.2.2.2-7"></a>

###### Care setting: in-office intravesical instillation without anesthesia

> “BOND-003 Cohort C is a single-arm, international, phase 3 study done in 41 centres (community practices and academic centres) located in North America, Asia, and Australia.”

Source: [Tyson et al. (2026)](https://pubmed.ncbi.nlm.nih.gov/42508433/)

> “Importantly, urology practices are already deeply familiar with IVE delivery of BCG in NMIBC.”
> “Cretostimogene is similarly administered via IVE in the clinic setting by a nurse or medical assistant and therefore does not require urologists nor anesthesia.”
> “This administration process does not require operating room time nor placement of the patient under anesthesia.”

Source: [CG Oncology Form 10-K (2026)](https://www.sec.gov/Archives/edgar/data/1991792/000119312526079498/ck0001991792-20251231.htm)

> “Procedure Can Be Prepared and Administered By:”
> “Medical Assistant, Nurse, Nurse Practitioner, Physician Assistant, or Urologist”
> “Administered via soft catheter by medical assistant, a urologist or MD does not have to be involved in process”

Source: [CG Oncology investor presentation (2026)](https://ir.cgoncology.com/static-files/16380a7a-42d9-40fc-a2a5-03e0b5235ed3)

<a id="topic-2.2.2.2-8"></a>

###### Care setting: biosafety handling in the urology office

> “Follow universal biosafety protocols- cretostimogene is BSL-2 like BCG”
> “Use appropriate protective equipment (e.g., gloves, gown, eye protection) during preparation and administration”
> “Convenient in-office instillation with familiar treatment schedule”
> “Aligned with joint AUA/SUNA policy & position statement on IVE therapy”

Source: [Donahue et al. (2025)](https://cgoncology.com/wp-content/uploads/2025/11/SUNA_Cretostimogene-Nursing-Logisitics_Final-1.pdf)

<a id="topic-2.2.2.2-9"></a>

###### Prescriber network targeted for launch

> “Physicians in top key accounts treat >70% of NMIBC patients by volume”
> “Community (LUGPA, Independent)”
> “Academic (Health Systems, Federal, Comprehensive Care)”
> “Leading urology center network represent >70% of the market opportunity by volume”

Source: [CG Oncology investor presentation (2026)](https://ir.cgoncology.com/static-files/16380a7a-42d9-40fc-a2a5-03e0b5235ed3)

> “In preparation for potential FDA regulatory approval for cretostimogene, we are in the process of building a capital-efficient, in-house commercial organization including field sales, marketing and market access capabilities to successfully commercialize cretostimogene in the United States.”

Source: [CG Oncology Form 10-K (2026)](https://www.sec.gov/Archives/edgar/data/1991792/000119312526079498/ck0001991792-20251231.htm)

<a id="heading-2.2.2.3"></a>

##### 2.2.2.3 Heterogeneity of Treatment Effect

<a id="topic-2.2.2.3-1"></a>

###### BOND-003 Cohort C: tumor pattern and prior therapy at study entry

| Baseline characteristic | n | % |
| --- | --- | --- |
| CIS with high-grade Ta/T1 | “22” | “19.6” |
| CIS alone | “90” | “80.4” |
| At least one prior therapy other than BCG | “53” | “47.3” |
| Serial adjuvant chemotherapy | “34” | “30.4” |
| Systemic immunotherapy | “7” | “6.3” |

Source: [Kassouf et al. (2026)](https://cgoncology.com/wp-content/uploads/2026/06/CUA_2026-BOND%E2%80%91003_Cohort_C_Podium.pdf)

<a id="topic-2.2.2.3-2"></a>

###### BOND-003 Cohort C: complete response in second-line and chemotherapy-pretreated subgroups

> “Median follow-up: 25.8 months; CR rate at any time: 75.5% (83/110)”
> “23/110 (21%) patients: Second-Line BCG-UR”
> “CR rate at any time: 69.6% (16/23)”
> “34/110 (31%) patients Prior Intervening Chemotherapy, with”
> “CR rate at any time: 64.7% (22/34)”
> “Second-Line: patients diagnosed with BCG-UR who received an additional therapy after adequate BCG.”
> “Prior Intervening Chemotherapy: adjuvant IVE chemotherapy before or after adequate BCG.”

Source: [Clinton et al. (2026a)](https://cgoncology.com/wp-content/uploads/2026/09/NSAUA_2026_BOND-003_CohortC_Second_Line_Poster.pdf)

<a id="topic-2.2.2.3-3"></a>

###### BOND-003 Cohort C: subgroup consistency and response after re-induction

> “High CR Rate Consistent Across Patient Subgroups, Including Patients Treated with Prior Chemotherapy”
> “50.0% of patients reinduced with oncolytic immunotherapy converted to CR”
> “64.3% remain in durable response after conversion to CR”

Source: [Tyson (2025a)](https://cgoncology.com/wp-content/uploads/2025/11/AUA_2025_BOND-003_Cohort_C_Late-Breaking_Plenary.pdf)

<a id="topic-2.2.2.3-4"></a>

###### BOND-003 Cohort C: cystectomy-free survival across subgroups

> “Median CFS not reached in the efficacy analysis set or any subgroups”

Source: [Kassouf et al. (2026)](https://cgoncology.com/wp-content/uploads/2026/06/CUA_2026-BOND%E2%80%91003_Cohort_C_Podium.pdf)

<a id="topic-2.2.2.3-5"></a>

###### Comparator trial: TAR-200 by presence of papillary disease and T stage

> “Subgroup analyses showed consistently high CR rates across all clinically relevant subgroups, including patients with and without concurrent papillary disease (82.1% and 82.5%, respectively; Data Supplement, Fig S2).”
> “Twelve-month DFS rates were consistent in patients with high-grade Ta and T1 disease (70.0% [95% CI, 44.8 to 85.4] and 72.2% [95% CI, 44.8 to 87.6], respectively).”

Source: [Daneshmand et al. (2025)](https://pmc.ncbi.nlm.nih.gov/articles/PMC12622271/)

<a id="topic-2.2.2.3-6"></a>

###### Comparator trials: carcinoma in situ cohorts and papillary-only cohorts

> “Five-year follow-up data from this trial found an estimated HG RFS at 57 months of 13% in the CIS cohort, and 33% in the Ta/T1 cohort.”
> “Cystectomy-free survival at month 60 was 49% (43% in the CIS cohort and 59% in the Ta/T1 cohort)”
> “In cohort A (patients with CIS with or without Ta/T1 papillary disease), pembrolizumab monotherapy achieved a 41% CRR at three months”
> “In cohort B (patients with Ta/T1 papillary disease without CIS), the 12-month DFS was 43.5%”

Source: [European Association of Urology NMIBC Guidelines (2026)](https://d56bochluxqnz.cloudfront.net/documents/full-guideline/EAU-Guidelines-on-Non-muscle-invasive-Bladder-Cancer-2026.pdf)

<a id="topic-2.2.2.3-7"></a>

###### Systematic reviews: predictors of response after BCG failure

> “A higher number of previous BCG courses, BCG refractory/unresponsive or CIS predicted lower response rates.”
> “The pooled 12-month response rates were 24% for trials with > 2 prior BCG courses and 36% for those with > 1 BCG courses.”
> “Initial response rate did not predict durable responses highlighting the need for longer-term follow-up.”
> “showed that patients with papillary-only recurrences appeared more effectively treated (median recurrence free rate of 44% at one year, median progression-free rate of 89% at a median follow-up of 19 months)”
> “(median CRR of 17% at one year with a median progression-free rate of 95% at a median follow-up of 12 months), highlighting potential biological differences between these two tumour entities which should be analysed separately when reporting results of clinical trials”

Source: [European Association of Urology NMIBC Guidelines (2026)](https://d56bochluxqnz.cloudfront.net/documents/full-guideline/EAU-Guidelines-on-Non-muscle-invasive-Bladder-Cancer-2026.pdf)

<a id="topic-2.2.2.3-8"></a>

###### Regulatory guidance on stratification by tumor pattern

> “Sponsors should stratify the randomization and analysis of trials that include patients”
> “with CIS based on the type of disease (CIS alone or CIS with resected papillary disease)”

Source: [FDA BCG-unresponsive NMIBC draft guidance (2024)](https://www.fda.gov/media/101468/download)

<a id="topic-2.2.2.3-9"></a>

###### Variable enrollment criteria across BCG-unresponsive trials

> “Of 31 trials, 15 (48%) had inclusion/exclusion criteria that were fully consistent with (inclusive of patients that met) the BCG unresponsive bladder cancer definition.”
> “The most common disease specific exclusion for patients with BCG unresponsive bladder cancer was a requirement for stage Tis (carcinoma in situ, CIS), which pertained to 7 (23%) of trials.”
> “For bladder cancer treating physicians and regulatory bodies, this also hinders comparisons across agents.”

Source: [Chandra et al. (2023)](https://pubmed.ncbi.nlm.nih.gov/37061453/)

<a id="heading-2.2.2.4"></a>

##### 2.2.2.4 Care Management Intervention Strategies

<a id="topic-2.2.2.4-1"></a>

###### Nursing considerations before and during instillation

> “Review patient history (difficult catheterizations, UTI, etc)”
> “Ensure bladder is emptied prior to instillation”
> “Administered with foley (indwelling with balloon)”
> “Administration allows patient throughput and comfort”

Source: [Donahue et al. (2025)](https://cgoncology.com/wp-content/uploads/2025/11/SUNA_Cretostimogene-Nursing-Logisitics_Final-1.pdf)

<a id="topic-2.2.2.4-2"></a>

###### Patient education and follow-up after instillation

> “Provide instructions and resources for post treatment care”
> “Close contact with loved ones is acceptable if patient is free from cold- or flu-like symptoms”
> “Counsel on the importance of open communication with the care team regarding potential side effects”
> “Reinforce importance of ongoing NMIBC surveillance and adherence to the treatment plan”
> “Nurses and APPs play a vital role integrating novel bladder cancer therapies and enhancing patient experience”

Source: [Donahue et al. (2025)](https://cgoncology.com/wp-content/uploads/2025/11/SUNA_Cretostimogene-Nursing-Logisitics_Final-1.pdf)

<a id="topic-2.2.2.4-3"></a>

###### Response surveillance schedule in BOND-003

> “Response assessments: cystoscopy (± biopsy) & cytology q3mo × 2yrs, then q6mo starting Yr 3; all responses centrally confirmed”

Source: [Donahue et al. (2025)](https://cgoncology.com/wp-content/uploads/2025/11/SUNA_Cretostimogene-Nursing-Logisitics_Final-1.pdf)

> “All patients required to undergo mandatory, systematic bladder mapping of 5 locations, biopsy of the prostatic urethra, and upper tract imaging to confirm CR.”

Source: [CG Oncology investor presentation (2026)](https://ir.cgoncology.com/static-files/16380a7a-42d9-40fc-a2a5-03e0b5235ed3)

<a id="topic-2.2.2.4-4"></a>

###### Re-induction for persistent disease at 3 months

> “Patients received intravesical cretostimogene (1 × 1012 viral particles per 0·8 mL per week) as 6-week induction followed by maintenance; re-induction was permitted for persistent disease at 3 months.”

Source: [Tyson et al. (2026)](https://pubmed.ncbi.nlm.nih.gov/42508433/)

<a id="topic-2.2.2.4-5"></a>

###### Treatment adherence and resolution of treatment-related adverse events

> “Most AES were Grade 1-2; 1-day median time to TRAE resolution”
> “High Tx Compliance- no tx-related discontinuations; few missed (1.8%) or delayed (7.1%) doses”

Source: [Tyson et al. (2025d)](https://cgoncology.com/wp-content/uploads/2025/12/SUO_2025_Final_Results_BOND_003_Cohort_C_ePoster.pdf)

<a id="topic-2.2.2.4-6"></a>

###### Cystectomy decisions with comparator bladder-sparing therapies

> “If patients with CIS do not have a complete response to treatment after 3 months or if CIS recurs, consider cystectomy.”

Source: [Adstiladrin prescribing information (2026)](https://www.fda.gov/media/164029/download)

> “Delaying cystectomy can lead to the development of metastatic bladder cancer, which can be lethal.”

Source: [Anktiva prescribing information (2026)](https://www.accessdata.fda.gov/drugsatfda_docs/label/2026/761336s002lbl.pdf)

<a id="topic-2.2.2.4-7"></a>

###### Multidisciplinary tumour board review

> “Discuss high-risk and very high-risk patients within a multidisciplinary board, when possible.”

Source: [European Association of Urology NMIBC Guidelines (2026)](https://d56bochluxqnz.cloudfront.net/documents/full-guideline/EAU-Guidelines-on-Non-muscle-invasive-Bladder-Cancer-2026.pdf)

<a id="heading-2.2.2.5"></a>

##### 2.2.2.5 Other Product Development or Post-marketing Obligations Required by the FDA

Not applicable.

<a id="heading-2.2.2.6"></a>

##### 2.2.2.6 Ongoing Post-approval Monitoring

Not applicable.

<a id="heading-2.2.2.7"></a>

##### 2.2.2.7 Expected Outcomes of Therapy

<a id="topic-2.2.2.7-1"></a>

###### Complete response at any time in BOND-003 Cohort C

> “As of June 23, 2025, after a median follow-up of 25·8 months (IQR 22·1-33·1), complete response at any time was observed in 83 (75% [95% CI 66·3-83·2]) of 110 patients.”
> “Cretostimogene showed clinically meaningful anti-tumour response, with an adverse event profile characterised predominantly by low-grade, transient events.”

Source: [Tyson et al. (2026)](https://pubmed.ncbi.nlm.nih.gov/42508433/)

<a id="topic-2.2.2.7-2"></a>

###### Durability of response, progression, and cystectomy avoidance at 24 months

> “High landmark CR at 24 mo in ITT population of 41.8% (46/110)”
> “Median DOR is 27.9 months (95% CI 14.3-NE%) and is on-going”
> “83.6% (92/110) did not undergo RC post recurrence or progression”

Source: [Tyson et al. (2025d)](https://cgoncology.com/wp-content/uploads/2025/12/SUO_2025_Final_Results_BOND_003_Cohort_C_ePoster.pdf)

> “This topline data shows that 90% of 12-month responders remain disease free at two years, as of June 23, 2025 cutoff in our Phase 3 BOND-003 Cohort C trial.”
> “The estimated 12- and 24-month duration of response (DOR) rates are 64.1% and 58.3%, respectively.”

Source: [CG Oncology Form 10-K (2026)](https://www.sec.gov/Archives/edgar/data/1991792/000119312526079498/ck0001991792-20251231.htm)

<a id="topic-2.2.2.7-3"></a>

###### Cystectomy-free survival at 12 and 24 months

> “12-month: 89.2% (95% CI 81.3-93.9)”
> “24-month: 81.3% (95% CI 71.8-87.8)”

Source: [Kassouf et al. (2026)](https://cgoncology.com/wp-content/uploads/2026/06/CUA_2026-BOND%E2%80%91003_Cohort_C_Podium.pdf)

<a id="topic-2.2.2.7-4"></a>

###### Expected outcomes with cretostimogene plus pembrolizumab

> “Of the participants, 83% with BCG unresponsive CIS containing NMIBC achieved a complete response at three months, and 57% achieved a complete response at 12 months post treatment.”

Source: [European Association of Urology NMIBC Guidelines (2026)](https://d56bochluxqnz.cloudfront.net/documents/full-guideline/EAU-Guidelines-on-Non-muscle-invasive-Bladder-Cancer-2026.pdf)

<a id="topic-2.2.2.7-5"></a>

###### Pooled outcomes of bladder-sparing therapies after BCG failure

> “Another systematic review, including 57 studies, with 68 unique study arms totalling 2,589 patients, reported estimated three-month overall response rate (ORR) across all studies, CRR in concomitant CIS or CIS only disease, and recurrence-free rate in papillary disease of 52.4%, 52.8%, and 26.4%, respectively”
> “The 12-month ORR, CRR, and recurrence-free rate were estimated to be 78%, 27.8%, and 25.4%, respectively.”

Source: [European Association of Urology NMIBC Guidelines (2026)](https://d56bochluxqnz.cloudfront.net/documents/full-guideline/EAU-Guidelines-on-Non-muscle-invasive-Bladder-Cancer-2026.pdf)

## Related pages
- [Cretostimogene grenadenorepvec (CG0070): BCG-unresponsive high-risk non-muscle-invasive bladder cancer](https://www.evicenter.com/drugs/cretostimogene-grenadenorepvec--bcg-unresponsive-high-risk-non-muscle-invasive-bladder-cancer) · [Markdown](https://www.evicenter.com/drugs/cretostimogene-grenadenorepvec--bcg-unresponsive-high-risk-non-muscle-invasive-bladder-cancer.md)
- [Cretostimogene grenadenorepvec (CG0070) in BCG-unresponsive high-risk non-muscle-invasive bladder cancer: Terms and abbreviations](https://www.evicenter.com/drugs/cretostimogene-grenadenorepvec--bcg-unresponsive-high-risk-non-muscle-invasive-bladder-cancer/terms-and-abbreviations) · [Markdown](https://www.evicenter.com/drugs/cretostimogene-grenadenorepvec--bcg-unresponsive-high-risk-non-muscle-invasive-bladder-cancer/terms-and-abbreviations.md)
- [Cretostimogene grenadenorepvec (CG0070): BCG-unresponsive high-risk non-muscle-invasive bladder cancer](https://www.evicenter.com/drugs/cretostimogene-grenadenorepvec--bcg-unresponsive-high-risk-non-muscle-invasive-bladder-cancer/executive-summary) · [Markdown](https://www.evicenter.com/drugs/cretostimogene-grenadenorepvec--bcg-unresponsive-high-risk-non-muscle-invasive-bladder-cancer/executive-summary.md)
- [Cretostimogene grenadenorepvec (CG0070) in BCG-unresponsive high-risk non-muscle-invasive bladder cancer: Clinical evidence](https://www.evicenter.com/drugs/cretostimogene-grenadenorepvec--bcg-unresponsive-high-risk-non-muscle-invasive-bladder-cancer/clinical-evidence) · [Markdown](https://www.evicenter.com/drugs/cretostimogene-grenadenorepvec--bcg-unresponsive-high-risk-non-muscle-invasive-bladder-cancer/clinical-evidence.md)
- [Cretostimogene grenadenorepvec (CG0070) in BCG-unresponsive high-risk non-muscle-invasive bladder cancer: Economic information and modeling report](https://www.evicenter.com/drugs/cretostimogene-grenadenorepvec--bcg-unresponsive-high-risk-non-muscle-invasive-bladder-cancer/economics) · [Markdown](https://www.evicenter.com/drugs/cretostimogene-grenadenorepvec--bcg-unresponsive-high-risk-non-muscle-invasive-bladder-cancer/economics.md)
- [Cretostimogene grenadenorepvec (CG0070) in BCG-unresponsive high-risk non-muscle-invasive bladder cancer: References](https://www.evicenter.com/drugs/cretostimogene-grenadenorepvec--bcg-unresponsive-high-risk-non-muscle-invasive-bladder-cancer/references) · [Markdown](https://www.evicenter.com/drugs/cretostimogene-grenadenorepvec--bcg-unresponsive-high-risk-non-muscle-invasive-bladder-cancer/references.md)
